Conflict of interest register:  
Clinical Practice Guidelines for the Diagnosis and Management of Melanoma

Management Committee members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Relevant financial activities</th>
<th>Relevant professional and organisational experience</th>
<th>Other relationships or activities</th>
</tr>
</thead>
</table>
| Professor John Thompson | Executive Director, Melanoma Institute Australia | Consultancy fees/ honorarium  
Honoraria received from GlaxoSmithKline, Bristol Myers Squibb and Provectus  
Support for travel or accommodation  
Travel support received from GlaxoSmithKline, Bristol Myers Squibb and Provectus | Publications  
See attachment A1.  
Speeches/lectures  
See attachment A1.  
Development of related materials, including guidelines, standards, educational materials or fact sheets  
Chairman of previous Working Party for Clinical Practise Guidelines for the Management of Cutaneous Melanoma in Australia and New Zealand  
Honorary Roles  
See attachment A1. | None. |
| Professor Michael Henderson | Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre | None. | None. | None. |
| Professor John Kelly | Dermatologist, Victorian Melanoma Service, Alfred Health, Melbourne | Ownership interests  
Superannuation fund owns shares in MoleMap Australia PL. Personal shares in MoleMap Australia since 2005. | Publications  
See attachment A2.  
Speeches/lectures  
See attachment A2.  
Expert Testimony  
Medicolegal opinions provided.  
Development of related materials, including guidelines, standards, educational materials or fact sheets  
<table>
<thead>
<tr>
<th>Name</th>
<th>Profession and Affiliation</th>
<th>Other</th>
<th>Publications</th>
<th>Speeches/lectures</th>
<th>Development of related materials, including guidelines, standards, educational materials or fact sheets</th>
<th>Unpaid advisory roles</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Professor Georgina Long</strong></td>
<td>Medical oncologist, Melanoma Institute Australia; Professor of Melanoma Medical Oncology and Translational Research (MIA, University of Sydney, Mater and Royal North Shore Hospitals), NSW</td>
<td>Consultancy fees/ honorarium</td>
<td>BMS, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array</td>
<td>Support for travel or accommodation</td>
<td>BMS, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array</td>
<td>None.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Support for travel or accommodation</td>
<td>Previous Guideline meetings</td>
<td>Meals and beverages</td>
<td>Previous Guideline meetings</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other (e.g. registration fees for conferences, institutional interests, etc – see policy)</td>
<td>BMS, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array</td>
<td>Other (e.g. registration fees for conferences, institutional interests, etc – see policy)</td>
<td>BMS, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>See attachment A3.</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>See attachment A3.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>None.</td>
<td></td>
<td>Unpaid advisory roles</td>
<td>RACS Examiner</td>
<td></td>
</tr>
<tr>
<td><strong>A/Professor Susan Neuhaus</strong></td>
<td>General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide, SA</td>
<td>Support for travel or accommodation</td>
<td>None.</td>
<td>Speeches/lectures</td>
<td>See attachment A4.</td>
<td>None.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Meals and beverages</td>
<td>Previous Guideline meetings</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>See attachment A4.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Publications</td>
<td>See attachment A4.</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>See attachment A4.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>None.</td>
<td></td>
<td>Unpaid advisory roles</td>
<td>RACS Examiner</td>
<td></td>
</tr>
<tr>
<td><strong>Dr Annette Pflugfelder</strong></td>
<td>PhD Student, Dermatology Research Centre, School of Medicine, The University of Queensland</td>
<td>None.</td>
<td></td>
<td>Publications</td>
<td>See attachment A5.</td>
<td>None.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speeches/lectures</td>
<td>Related to German Melanoma Guideline.</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>See attachment A5.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>Development of German Guideline for melanoma patients.</td>
<td></td>
</tr>
<tr>
<td><strong>Professor Richard Scolyer</strong></td>
<td>Clinical Professor, Pathology, Central Clinical School</td>
<td>None.</td>
<td></td>
<td>Publications</td>
<td>See attachment A6.</td>
<td>None.</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Relevant financial activities</td>
<td>Relevant professional and organisational experience</td>
<td>Other relationships or activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>----------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor Graham Stevens</td>
<td>Director of Radiation Oncology; Professor Radiation Oncology</td>
<td>None.</td>
<td>None.</td>
<td>None.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Publications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oxford Textbook of Melanoma.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of related materials, including guidelines, standards,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>educational materials or fact sheets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Previous Melanoma Guideline.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Australia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ms Laura Wuellner</td>
<td>Acting Head, Clinical Guidelines Network (until November 2016)</td>
<td><strong>Employment</strong></td>
<td>Acting Head, Clinical Guidelines Network, Cancer</td>
<td>None.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Council Australia</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Section Leaders**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Relevant financial activities</th>
<th>Relevant professional and organisational experience</th>
<th>Other relationships or activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Professor Andrew Barbour</td>
<td>General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD</td>
<td>None.</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Dr Matteo Carlino</td>
<td>Medical Oncologist Westmead and Blacktown Hospitals, Melanoma institute Australia Clinical Senior lecturer University of Sydney</td>
<td><strong>Consultancy fees/honorarium:</strong> Board member Bristol Myers Squibb, MSD, Novartis <strong>Travel support and registration fees</strong> from Bristol Myers Squibb &amp; MSD</td>
<td>Publications; speeches and lecture See attachment A7.</td>
<td>None.</td>
</tr>
<tr>
<td>Dr David Gyorki</td>
<td>Consultant Surgeon, Peter MacCallum Centre</td>
<td>None.</td>
<td><strong>Publications</strong></td>
<td>See attachment A8.</td>
</tr>
<tr>
<td>A/Professor Angela Hong</td>
<td>Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney</td>
<td><strong>Consultancy fees/ honorarium</strong></td>
<td><strong>Publications</strong></td>
<td>Not specified.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Speeches/lectures</strong></td>
<td>Not specified.</td>
</tr>
</tbody>
</table>

*Last updated: June 2018. Page 3*
<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Institution</th>
<th>Employment/Ownership</th>
<th>Publications</th>
<th>Speeches/Lectures</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dr Julie Howle</strong></td>
<td>Clinical Senior Lecturer, Surgery, The University of Sydney; Surgeon, Westmead Hospital</td>
<td>None.</td>
<td>Publications</td>
<td>Speeches/Lectures</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Not specified.</td>
<td>Not specified.</td>
<td></td>
</tr>
<tr>
<td>A/Professor T Michael Hughes</td>
<td>Associate Professor in Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital</td>
<td>Employment Surgical oncologist. Ownership Interests Owns a surgical oncology practise.</td>
<td>Publications Not specified.</td>
<td>Speeches/Lectures Not specified.</td>
<td>Relationships Associate of M.I.A.</td>
</tr>
<tr>
<td>Professor Richard Kefford AM</td>
<td>Professor of Cancer Medicine, Macquarie University</td>
<td>Support for travel or accommodation Support for conference attendance; Bristol Myers Squibb, Merck Registration fees for conferences Bristol Myers Squibb, Merck</td>
<td>Paid advisory boards Bristol Myers Squibb, Merck, Amgem, Novartis, Tera</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td>Professor Graham Mann</td>
<td>Chair, University of Sydney Cancer Research Network and Cancer MDI Co-Director, Centre for Cancer Research, Westmead Institute of Medical Research Chair, Research Committee, Melanoma Institute Australia, University of Sydney.</td>
<td>Employment University of Sydney. Grants Benefits received or expected: NHMRC, NSW Govt (OHMR), CINSW, Cancer Council NSW, ARC, ACRF, University of Sydney Consultancy fees/ honorarium NHMRC Support for travel or accommodation, Meals and/or beverages NHMRC</td>
<td>Publications See Attachment A9.</td>
<td>Speeches/Lectures Reviews of evidence, including outcomes of own and collaborative research, multiple forums Expert testimony Australian Parliamentary Enquiry into Skin Cancer 2014 Development of related materials, including guidelines, standards, educational materials or fact sheets 2010 NHMRC Guidelines on Melanoma; Information guides – e.g. CV ref 65 (attachment A9)</td>
<td>None.</td>
</tr>
<tr>
<td>Dr Victoria Mar</td>
<td>Dermatologist and Director, Victorian Melanoma Service, Alfred Health, Melbourne</td>
<td>None.</td>
<td>Publications See Attachment A10.</td>
<td>Speeches/Lectures See Attachment A10.</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
</tr>
<tr>
<td>Professor Scott Menzies</td>
<td>The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney</td>
<td>Employment</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------------------------------------------</td>
<td>------------</td>
<td>-------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ownership interests</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Board membership</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grants</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consultancy fees/ honorarium</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Publications</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speeches/lectures</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Expert Testimony</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>See attachment A10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unpaid advisory roles</td>
<td>Not specified.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor Michael Millward</td>
<td>Professor of Clinical Cancer Research, The University of Western Australia; Consultant Medical Oncologist, Sir Charles Gairdner Hospital</td>
<td>Grants</td>
<td>See attachment A12.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Conducted multiple clinical trials in melanoma which has resulted in payments to departments/institutions associated with Professor Michael Millward’s. The entities involved include Bristol-Meyers Squibb, Glaxo-Smith Kline, Novartis, Merck, Sharp &amp; Dohme, Roche. No personal remuneration was received for these activities.</td>
<td>Publications</td>
<td>See attachment A12.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consultancy fees/ honorarium</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Member of pharmaceutical advisory boards relating to the treatment of melanoma. Entities involved include Bristol-Meyers Squibb, Glaxo-Smith Kline, Merck, Sharp &amp; Dohme, Roche, Amgem, Provectus.</td>
<td>Development of education materials, information for the consumers related to the management of melanoma.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Support for travel or accommodation</td>
<td>Unpaid advisory roles</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Received travel and accommodation support for pharmaceutical advisory board roles above.</td>
<td>Provided advice to various bodies related to management of melanoma and the care of melanoma patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Meals and beverages</td>
<td>Not specified.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Received meals and beverages in accordance with Medicines Australia Guidelines for pharmaceutical advisory board roles above.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Registration fees for conferences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Relationships</td>
<td>See Attachment A12.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Grants</td>
<td>Consultancy fees/honorarium</td>
<td>Support for travel or accommodation, Meals and/or beverages</td>
<td>Publications</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dr Rachael Morton</td>
<td>Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney</td>
<td>Benefits received or expected: NHMRC, Cancer Australia, CINSW, Cancer Council NSW, University of Sydney</td>
<td>NHMRC</td>
<td>NHMRC</td>
<td>See attachment A13.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Support for travel or accommodation, Meals and/or beverages</td>
<td>NHMRC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NHMRC</td>
<td></td>
</tr>
<tr>
<td>Dr Robyn Saw</td>
<td>Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred &amp; Mater Hospitals</td>
<td>Consultancy fees/honorarium Amgen and Bristol Myers Squibb</td>
<td>NHMRC</td>
<td>Amgen</td>
<td>See Attachment A14.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Support for travel or accommodation Amgen</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Support for travel or accommodation Amgen</td>
<td></td>
</tr>
<tr>
<td>Dr Brindha Shivalingam</td>
<td>Director of Neurosurgery, The Chris O’Brien Lifehouse; Consultant Neurosurgeon, Royal Prince Alfred Hospital and The Mater Hospital North Sydney</td>
<td>None.</td>
<td>None.</td>
<td>None.</td>
<td>See Attachment A15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Conflict of Interest</td>
<td>Publications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A/Professor Michael Sladden</td>
<td>Dermatologist, Tas Derm</td>
<td>None.</td>
<td>See attachment A16.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cochrane review on melanoma excision margins.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor H. Peter Soyer</td>
<td>Director, School of Medicine, University of Queensland; Director, Dermatology Department, Princess Alexandra Hospital</td>
<td>Board membership: See attachment A38.</td>
<td>See attachment A38.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grants: See attachment A38.</td>
<td>Speeches/lectures: See attachment A38.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consultancy fees/honorarium: Greenslopes Private Hospital (Qld, AUS); Canfield Scientific (SA); Molemap Australia</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets: See attachment A38.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Support for travel or accommodation: Not specified.</td>
<td>Other (e.g. unpaid advisory roles): See attachment A38.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Meals and beverages: Not specified.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Entertainment, gifts or gratuities: Not specified.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other (e.g. registration feeds for conferences, institutional interests, etc – see policy): Not specified.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### A/Professor Andrew Spillane
- **Position:** Associate Professor, Surgical Oncology, The University of Sydney; Surgical oncologist,
- **Support for travel or accommodation:** Invited speaker ABS Breast Cancer Conference 2015 Airfares and Accommodation paid by ABS
- **Publications:**
  - See attachment A17.
- **Speeches/lectures:**
  - See attachment A17.
- **Development of related materials, including guidelines, standards, educational materials or fact sheets:**
  - See attachment A17.
- **None.**

### Dr Alex Varey
- **Position:** Staff Specialist, Department of Plastic and Maxillofacial Surgery, Westmead Hospital, Sydney, Australia
- **Support for travel or accommodation:** None.
- **Publications:**
  - See attachment A34.
- **Speeches/lectures:**
  - See attachment A34.
- **Development of related materials, including guidelines, standards, educational materials or fact sheets:**
  - See attachment A34.
- **Relationships:**
  - See attachment A34.
- **Activities:**
  - See attachment A34.

### Consumers

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Relevant financial activities</th>
<th>Relevant professional and organisational experience</th>
<th>Other relationships or activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms Alison Button-Sloan</td>
<td>Consumer</td>
<td><strong>Employment</strong> Employed as a Registered Nurse and Diabetes Educator in General Practice. Also assist General Practitioners with skin checks and skin excisions/biopsies. <strong>Support for travel or accommodation</strong> All provided by Melanoma Patients Australia (MPA): Attended launch of MPA’s KPMG commissioned report ‘Advanced</td>
<td><strong>Other</strong> Review research proposals from the ANZMTG and other researchers from a consumer perspective forwarded by Project Manager for the Melbourne Melanoma Project (MMP) Write articles of interest for MPA’s National Support Group Facilitators’ Newsletter quarterly.</td>
<td><strong>Relationships</strong> Member/consumer representative of the following organisations: Melanoma Patients Australia (MPA) Cancer Council Victoria (CCV) Melbourne Melanoma Project - Consumer Reference Group</td>
</tr>
<tr>
<td>Mr Clinton Heal</td>
<td>Consumer, CEO and Founder, Melanoma WA; 2011 WA Young Australian of the Year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Employment</strong></td>
<td>CEO of Melanoma WA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Board membership</strong></td>
<td>Board member of WAMAS WA Melanoma Health study and AMCA.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Support for travel or accommodation</strong></td>
<td>Support (flights) to attend Guideline meetings.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Publications** | WA Medical Forum. |
| **Speeches/lectures** | Community forums, Media and Speaking engagements. |
| **Expert Testimony** | National Skin cancer inquiry. |
| **Development of related materials, including guidelines, standards, educational materials or fact sheets** | Previous involvement in ‘Understanding Melanoma’ publication. |
| **Unpaid advisory roles** | Board member of WAMAS WA Melanoma health study. |

**Melanoma – The real cost of Australia’s national cancer’ at Parliament House.** Return economy flights Melbourne to Canberra.

One-night accommodation.

Attended MPA annual gala dinner committee meetings in Brisbane.

Car hire for 3days.

Attended the MPA Annual Gala and Awards Dinner as organiser.

Return economy flights Melbourne to Brisbane.

One-night accommodation.

**Meals and Beverages**

Meals and beverages provided by MPA at events above.

**Other**

Sponsored by MPA to attend Clinical Oncology Society of Australia Annual Scientific Meeting Conference.

(MMP-CRG)

Australian Melanoma Consumer Alliance (AMCA)

**Activities**

Facilitator for monthly MPA Support Group Meetings in Melbourne.
### GP representatives

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Relevant financial activities</th>
<th>Relevant professional and organisational experience</th>
<th>Other relationships or activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Margaret Hardy</td>
<td>General practitioner</td>
<td>MSD's GP Advisory Committee on Insomnia (disclosed because MSD produce a product for melanoma)</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Dr Paul Fishburn</td>
<td>General practitioner</td>
<td>None.</td>
<td>None.</td>
<td>None.</td>
</tr>
</tbody>
</table>

### Cancer Council Australia Staff Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Relevant financial activities</th>
<th>Relevant professional and organisational experience</th>
<th>Other relationships or activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms Laura Wuellner</td>
<td>Project Manager Clinical Guidelines Network (until November 2016); Acting Head, Clinical Guidelines Network (from November 2016)</td>
<td>Employment Project Manager Clinical Guidelines Network, Cancer Council Australia</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Ms Katrina Anderson</td>
<td>Project Manager Clinical Guidelines Network (from November 2016)</td>
<td>Employment Project Manager Clinical Guidelines Network, Cancer Council Australia</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Ms Jackie Buck</td>
<td>Project Officer, Clinical Guidelines Network (until April 2016)</td>
<td>Employment Project Officer Clinical Guidelines Network, Cancer Council Australia</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Ms Lani Teddy</td>
<td>Project Officer, Clinical Guidelines Network (until December 2016)</td>
<td>Employment Project Officer Clinical Guidelines Network, Cancer Council Australia</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Ms Lyndal Alchin</td>
<td>Project Officer, Clinical Guidelines Network (until December 2016)</td>
<td>Employment Project Officer Clinical Guidelines Network, Cancer Council Australia</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Ms Tamsin Parrish</td>
<td>Project Officer, Clinical Guidelines Network (from June 2016 until December 2017)</td>
<td>Employment Project Officer Clinical Guidelines Network, Cancer Council Australia</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Ms Cecilia Taing</td>
<td>Project Officer, Clinical Guidelines Network (from January 2017)</td>
<td>Employment Project Officer Clinical Guidelines Network, Cancer Council Australia</td>
<td>None.</td>
<td>None.</td>
</tr>
</tbody>
</table>
### Subcommittee members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Relevant financial activities</th>
<th>Relevant professional and organisational experience</th>
<th>Other relationships or activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Nikki Adler</td>
<td>Clinical Fellow, The Alfred Hospital</td>
<td>None.</td>
<td>Publications</td>
<td>Activities</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adler NR, Haydon A, McLean C, Kelly JW &amp; Mar VJ.</td>
<td>I am currently employed as a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Metastatic pathways in patients</td>
<td>Clinical Fellow at the Victorian</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with cutaneous melanoma.</td>
<td>Melanoma Service, The Alfred</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pigment Cell Melanoma Res</td>
<td>Hospital, Melbourne, Australia.</td>
</tr>
<tr>
<td>Dr Victoria Atkinson</td>
<td>Senior Medical Oncologist, Princess Alexandra Hospital</td>
<td>Consultancy fees/honorarium</td>
<td>Publications</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advisory boards of MSD,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Novartis, Bristol Myers Squibb,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck Serono, Pierre Fabre</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Support for travel or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>accommodation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bristol Myers Squibb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Trevor Beer</td>
<td>Dermatopathologist, Clinipath Pathology</td>
<td>None.</td>
<td>Publications</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>See Attachment A18</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speeches/lectures</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>See Attachment A19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Development of related materials, including</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>guidelines, standards, educational materials or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>fact sheets</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>See Attachment A19</td>
<td></td>
</tr>
<tr>
<td>Dr Friyana Bhabha</td>
<td></td>
<td>None.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Michael Brown</td>
<td>Medical oncolgost, Royal Adelaide Hospital</td>
<td>Consultancy fees/honorarium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Melanoma Advisory Boards for</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>GSK, BMS, Roche Prostate</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Last updated: June 2018. Page 11
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Conflict of Interest</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Frank Bruscino-Raiola</td>
<td>Director, Plastic, Hand &amp; Faciomaxillary Surgery Unit, The Alfred Hospital</td>
<td>None.</td>
<td>Speeches/lectures&lt;br&gt;See attachment A39.</td>
</tr>
<tr>
<td>Prof Bryan Burmeister</td>
<td>Director of Radiation Oncology, Princess Alexandra Hospital</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Dr Svetlana Cherepanoff</td>
<td>Consultant Pathologist &amp; Leader, Ophthalmic Pathology Research Group, Brain and Mind Centre, The University of Sydney</td>
<td>None.</td>
<td>Speeches/lectures&lt;br&gt;See attachment A20. Development of related materials, including guidelines, standards, educational materials or fact sheets.</td>
</tr>
</tbody>
</table>
### A/Prof Max Conway

**Position:** Associate Professor, Clinical Ophthalmology & Eye Health, Central Clinical School, Save Sight Institute

**Publications**
- None.

**Speeches/lectures**
- Many (not specified)

**Expert testimony**
- One (not specified)

**Development of related materials, including guidelines, standards, educational materials or fact sheets**
- Previous guideline

### Dr Rachel Conyers

**Position:** None.

**Publications**
- None.

**Speeches/lectures**
- Not specified.

**Expert testimony**
- Not specified.

**Development of related materials, including guidelines, standards, educational materials or fact sheets**
- Not specified.

**Other (e.g. unpaid advisory roles)**
- Not specified.

### A/Prof Brendon Coventry

**Position:** Associate Professor, Department of Surgery, The University of Adelaide; Senior Consultant Surgeon, Royal Adelaide Hospital

**Publications**
- None.

**Speeches/lectures**
- Not specified.

**Expert testimony**
- Not specified.

**Development of related materials, including guidelines, standards, educational materials or fact sheets**
- Not specified.

**Other (e.g. unpaid advisory roles)**
- Not specified.

### Dr Anne Cust

**Position:** Senior Research Fellow Public Health, School of Public Health, The University of Sydney

**Grants**
- I have received NHMRC & NIH grants related to melanoma. These were peer reviewed grants.

**Publications**
- None.

**Speeches/lectures**
- None.
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Publications</th>
<th>Other (e.g. unpaid advisory roles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof Diona Damian</td>
<td>Professor of Dermatology, Central Clinical School, The University of Sydney</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Publications</strong> [See Attachment A23]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speeches/lectures</strong> [See Attachment A23]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Development of related materials, including guidelines, standards, educational materials or fact sheets</strong> [See Attachment A23]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Other (e.g. unpaid advisory roles)</strong> [See Attachment A23]</td>
<td></td>
</tr>
<tr>
<td>Dr Gerald Fogarty</td>
<td>Director of Radiation Oncology, Mater Hospital; Clinical Associate Professor of Medicine, The University of Sydney</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Publications</strong> [See Attachment A24]</td>
<td></td>
</tr>
<tr>
<td>Dr Michael Giblin</td>
<td>Clinical Senior Lecturer, Clinical Ophthalmology &amp; Eye Health, Central Clinical School</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td>A/Prof Pascale Guitera</td>
<td>Senior Research Fellow, Dermatology, Central Clinical School, The University of Sydney</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Publications</strong> Not specified.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speeches/lectures</strong> Not specified.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Expert testimony</strong> Not specified.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Development of related materials, including guidelines, standards, educational materials or fact sheets</strong> Not specified.</td>
<td></td>
</tr>
<tr>
<td>A/Prof Alexander Guminski</td>
<td>Associate Professor Medicine, The University of Sydney; Medical Oncologist, Melanoma Institute Australia, North Shore Private Hospital, and Royal North Shore Hospital</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Employment</td>
<td>Publications</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dr Mark Hanikeri</td>
<td>Director, Western Australia Plastic Surgery Centre</td>
<td>Clinical director of Western Australian Kirkbride Melanoma Advisory Service</td>
<td>See Attachment A25</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speeches/lectures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>See Attachment A25</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other (e.g. unpaid advisory roles)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>See Attachment A25</td>
</tr>
<tr>
<td>Dr Andrew Haydon</td>
<td>Medical Oncologist, Alfred Hospital and Cabrini Health</td>
<td>Consultancy fees/honorarium</td>
<td>Publications</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Not specified.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Support for travel or accommodation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Not specified.</td>
</tr>
<tr>
<td>Dr Craig James</td>
<td>Pathologist, Adelaide Pathology Partners</td>
<td>None.</td>
<td>Publications</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>See Attachment A26</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speeches/lectures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>See Attachment A26</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Expert testimony</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Not specified.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Not specified.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other (e.g. unpaid advisory roles)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Not specified.</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Employment</td>
<td>Publications</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Dr Wenyuan Liu</td>
<td>Dermatologist, Alfred Hospital, Peter MacCallum Cancer Centre, Victorian Melanoma Service</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Prof Grant McArthur</td>
<td>Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre</td>
<td>Employment Peter MacCallum Cancer Centre Victorian Comprehensive Cancer Centre University of Melbourne</td>
<td>Publications</td>
</tr>
<tr>
<td>A/Prof Chris McCormack</td>
<td>Lead dermatologist, Peter MacCallum Cancer Institute; Lead dermatologist, Caulfield Dermatology</td>
<td>Consultancy fees/honorarium Merck – advisory/board Takeda – advisory/board</td>
<td>Publications</td>
</tr>
<tr>
<td>Name</td>
<td>Position and Institution</td>
<td>Grants</td>
<td>Consultancy fees/honorarium</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Prof Catriona McLean</td>
<td>Director, Pathology Board, Monash University; Director, Anatomical Pathology, The Alfred Hospital</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>A/Prof Catriona McNeil</td>
<td>Staff Specialist, Medical Oncology, Chris O'Brien Lifehouse and Royal Prince Alfred Hospital, NSW</td>
<td>MSD has provided grant support</td>
<td>MSD: fees directed to my institution</td>
</tr>
<tr>
<td>A/Prof Alexander Menzies</td>
<td>Medical Oncologist, CINSW Senior Research Fellow, Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Dr Bill Murray</td>
<td>Head of anatomical pathology, Peter MacCallum Cancer Centre</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Dr Jonathan Ng</td>
<td>Honorary Research Fellow, Victorian Melanoma Service, The Alfred Hospital, VIC; Dermatologist, Hobart Medical Specialist, TAS</td>
<td>None.</td>
<td>None.</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Involvements</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Prof Omgo Nieweg</td>
<td>Surgeon, Melanoma Institute Australia</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Publications</strong> Not specified</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speeches/lectures</strong> Not specified</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Development of related materials, including guidelines, standards, educational materials or fact sheets</strong> Not specified</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Involvement with this present guidelines.</td>
<td></td>
</tr>
<tr>
<td>Dr Shahneen Sandhu</td>
<td>Medical oncologist and Clinical researcher, Peter MacCallum Cancer Centre</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Publications</strong> See Attachment A32</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speeches/lectures</strong> See Attachment A32</td>
<td></td>
</tr>
<tr>
<td>Dr Mark Shackleton</td>
<td>Group Leader: Cancer Development and Treatment Laboratory; Medical Oncologist, Peter MacCallum Cancer Centre</td>
<td><strong>Grants</strong> Not specified.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Consultancy fees/honorium</strong> Not specified.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Support for travel or accommodation</strong> Not specified.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Meals and beverages</strong> Not specified.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Other (e.g. registration for conferences, institutional interest, etc – see policy)</strong> Not specified</td>
<td></td>
</tr>
<tr>
<td>Dr Saxon Smith</td>
<td>Principal Dermatologist in Private Practice, The</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Publications</strong> See Attachment A40</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speeches/lectures</strong></td>
<td></td>
</tr>
</tbody>
</table>

Last updated: June 2018. Page 18
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Publications</th>
<th>Speeches/lectures</th>
<th>Other (e.g. unpaid advisory roles)</th>
<th>Relationships</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A/Prof Mark (Bernard) Smithers</strong></td>
<td>Surgeon, Upper GI, Soft Tissue Unit, Princess Alexandra Hospital; Associate Professor, Department of Surgery, The University of Queensland</td>
<td>None.</td>
<td><strong>Speeches/lectures</strong> See Attachment A40</td>
<td>Other (e.g. unpaid advisory roles)</td>
<td>Assisting Cancer Council Australia with skin cancer public awareness information and website content. Australian Medical Association (NSW) creation of skin cancer and sun protection awareness campaign.</td>
<td></td>
</tr>
<tr>
<td><strong>Mr John Spillane</strong></td>
<td>General surgeon, Epworth Eastern Consulting</td>
<td>None.</td>
<td><strong>Publications</strong> See Attachment A29</td>
<td><strong>Speeches/lectures</strong> See Attachment A29</td>
<td>I am a surgeon and I work in a Melanoma unit in a public hospital and I run a private practice that is involved in a large number of patients with melanoma.</td>
<td></td>
</tr>
<tr>
<td><strong>A/Prof Jonathan Stretch AM</strong></td>
<td>Plastic surgeon and Deputy Director, Melanoma Institute Australia; Associate Professor of Melanoma and Skin Oncology, The University of Sydney</td>
<td>None.</td>
<td><strong>Publications</strong> See Attachment A30</td>
<td><strong>Speeches/lectures</strong> See Attachment A30</td>
<td>I am actively treating patients with melanoma – see above.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Position and Affiliation</td>
<td>Development of related materials, including guidelines, standards, educational materials or fact sheets</td>
<td>Publications</td>
<td>Relationships</td>
<td>Activities</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>Dr Geoffrey (Geoff) Strutton</td>
<td>Anatomical Pathologist, Princess Alexandra Hospital</td>
<td>None.</td>
<td>None.</td>
<td>None.</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td>Prof David Whiteman</td>
<td>Senior Principal Research Fellow and Head, Cancer Control Group, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute</td>
<td>Support for travel or accommodation Invited speaker to Australian Melanoma Congress 2016 and World Congress of Melanoma 2017 Other (e.g. registration fees for conferences, institutional interests etc – see policy) Invited speaker to Australian Melanoma Congress 2016 and World Congress of Melanoma 2017</td>
<td>Publications Not specified. Speeches/lectures Invited speaker to Australian Melanoma Congress 2016 and World Congress of Melanoma 2017 Development of related materials, including guidelines, standards, educational materials or fact sheets Melanoma guidelines 2018 Other (e.g. unpaid advisory roles) Advice to Cancer Council’s various public health committees</td>
<td>Relationships Employee of QIMR Berghofer Medical Research Institute, which derives philanthropic donations for the purpose of conducting research into melanoma Activities Convenor of the Sunscreen Summit 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Gabrielle Williams</td>
<td>Researcher, University of Sydney, The Children's Hospital at Westmead and Melanoma Institute Australia</td>
<td>None.</td>
<td>None.</td>
<td>None.</td>
<td>None.</td>
<td></td>
</tr>
</tbody>
</table>
1. **Professor John Thompson**

**Publications**

1. Thompson JF, Gee DC, Little JM. The carcinoid tumour.  

2. Thompson JF, Little JM. Liver resection for neoplasm.  


8. French ME, Thompson JF, Hunnisett AGW, Wood RFM, Morris PJ. Impaired function of renal allografts during treatment with Cyclosporin A: nephrotoxicity or rejection?  


10. Thompson JF, Chalmers DHK, Hunnisett AGW, Wood RFM, Morris PJ. Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with Cyclosporin A.


20. Wood RFM, Thompson JF, Allen NH, Ting A, Morris PJ. The consequences of conversion
from cyclosporine to azathioprine and prednisolone in renal allograft recipients.


15


27. Wood RFM, Thompson JF, Allen NH, Ting A, Morris PJ. The consequences of conversion from Cyclosporine to Azathioprine and Prednisolone in renal allograft recipients.

In Cyclosporine - Biological Activity and Clinical Applications Ed. BD Kahan, pp 646-652.


57. Sheil AGR, Thompson JF, Stephen MS, Eyers AA, Bookallil M, McCaughan GW, Dorney
SFA, Bell R, Mears D, Kelly GE, Woodman K. Donor portal vein arterialization during liver transplantation. 


61. Jeremy RW, Fletcher PJ, Thompson JF. Coronary pressure-flow relations in hypertensive left ventricular hypertrophy. comparison of intact autoregulation with physiological and pharmacological vasodilation in the dog. 


63. Sheil AGR, Thompson JF, McCaughan GW, Dorney SFA, McDonald JA, Gallagher ND

(abstract of publications only)

**Speeches and Publications**


11 McWhinnie DL, Taylor HM, Thompson JF, Wood RFM and Morris PJ. Is cellular infiltration a


16 Thompson JF, Bookallil MJ and Sheil AGR. Effects of total hepatectomy in the anaesthetised pig, with relevance to the anhepatic period during liver transplantation in man. Presented to the 4th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand, Adelaide, April 1987.


unrestrained pregnant baboons (p.hamadryas), a model for pre-eclampsia. Presented to the 25th Annual Scientific Meeting ASN, Newcastle 1989.


29 McCaughan GW, Powers B, Hawker F, Herkes R, Rickard K, Thompson J and Sheil AGR. Thrombocytopenia post liver transplantation: correlations and clinical relevance. Presented to the 8th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand, Canberra,

31 Thompson JF. Techniques for transplantation of the liver. Presented to TSANZ Transplantation Course, Sydney, April, 1991


48 Ingvar C, Coates A, Petersen-Schaefer K, Shaw HM, Thompson JF, CJ, Milton GW and McCarthy WH. Role of elective lymph node dissection in primary malignant melanoma 1.5mm or thicker of the trunk and limbs without clinical node metastases. Presented to 3rd International Conference on


(abstract of speeches/lectures only)

Honorary Roles

2015 – Present Honorary Fellow, American Surgical Association

2014 – Present Inaugural Member, Advisory Board, RPA Institute of Academic Surgery

2013 – Present Senior Editor, Melanoma Management Journal

2013 – Present Section Editor, Melanoma, Annals of Surgical Oncology

2013 – Present Member, Editorial Advisory Board (Melanoma section), European Journal of Surgical Oncology

2011 – Present Member, International Faculty, Interdisciplinary Melanoma/Skin Cancer Centres Meeting, Barcelona, November 2012

2011 – Present International Medical Advisory Board Member, Patient Resource Publishing

2011 – Present Member, Asia Pacific Scientific Advisory Board, Annals of Surgical Oncology

2010 – Present Member, International Faculty, Melanoma 2011 Congress, Tampa, Florida

2010 – Present Member, Program Committee, World Congress of Melanoma, Hamburg 2013

2009 – Present Associate Member, Australasian Sarcoma Study Group

2009 – Present Member, International Advisory Board, Schwartz’s Principles of Surgery, Ninth Edition

2008 – Present Melanoma Expert, Editorial Board, Journal of Dermatological Case Reports

2008 – Present Member, Melanoma Institute Australia Research Committee

2008 – Present Member, Organising Committee, Society of Melanoma Research International Melanoma Meeting, Sydney, November 2010
2008 – Present Member, Organising Committee, 4th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres, Sydney, November 2010

2008 – Present Member, Organising Committee, 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres, Berlin, November 2009

2007 – Present Member, Working Party, Stage 3: Surgery Block, Medical Program Curriculum review, The University of Sydney

2007 - Present Member, NSW Melanoma Oncology Group

2007 – Present Scientific Advisory Board, Melanoma Molecular Map Project

2007 – Present Board Member, Melanoma Institute of Australia

2001 - Present Member, Melanoma Staging Task Force, American Joint Committee on Cancer

2005 – Present Chairman, NSW Melanoma Network

2006 – Present Member, The Society of Surgical Oncology International Committee

2006 – Present Member, Editorial Board, *Journal of Clinical Oncology*

6

2006 – Present Section Editor, Melanoma Research

2006 – Present Member, Research Council, Sydney Institutes of Health and Medical Research

2003 – Present Task Force Member, UICC Fellowships – Reviewers Task Force

2003 – Present Task Force Member, UICC TNM Expert Panel (Skin)

2003 – Present Honorary Medical Officer, Royal North Shore Hospital, Sydney

2003 – Present International Liaison Representative, American College of Surgeons Oncology Group Melanoma Working Group

2002 – Present Member, Council Executive, Clinical Oncological Society of Australia

2002 – Present Member, Finance Subcommittee, Cancer Trials (NSW), NSW State Cancer Council

2002 – Present Visiting Surgeon, The Mater Misericordiae Hospital, Sydney

2002 – Present Visiting Surgeon, North Shore Private Hospital, Sydney

2002 – Present Member, Section of Academic Surgery, Royal Australian College of Surgeons

2001 – Present Council member, Clinical Oncological Society of Australia

2001 – Present Member, Executive Committee, Surgical Oncology Group, Royal Australasian College of Surgeons

2000 – Present Member, Executive Committee

Department of Surgery, Faculty of Medicine, University of Sydney
1998 – Present Executive Director, The Sydney Melanoma Unit
1998 – Present Member, Cancer Block Planning Committee, Graduate Medical Programme, Faculty of Medicine, University of Sydney
1997 – Present Member, Patient/Doctor Theme Committee, Graduate Medical Programme, Faculty of Medicine, University of Sydney
1997 – Present Member, Integrated Clinical Attachments Committee, Graduate Medical Programme, Faculty of Medicine, University of Sydney
1996 – Present Member, Court of Examiners, Royal Australasian College of Surgeons
1996 – Present Member, Society of Surgical Oncology
1996 – Present Member, Central Clinical School Management Committee, Faculty of Medicine, University of Sydney
1996 – Present Supervisor of Undergraduate Surgical Teaching, Royal Prince Alfred Hospital, Central Clinical School, University of Sydney
1996 – Present Member, NSW Cooperative Oncology Group
1995 – Present Faculty Adviser for Department of Surgery, Medicine V Option Term, Undergraduate Medical Programme, University of Sydney
1995 – Present Member, Melanoma Expert Working Party, Australian Cancer Network
1992 – Present Visiting Surgeon
Strathfield Private Hospital, Sydney
(A teaching hospital of the University of Sydney)
1992 – Present Member, Final Year Examination Committee
Faculty of Medicine, University of Sydney
1991 – Present Lecturer and Tutor
NSW General Surgical Training Programme
Royal Australasian College of Surgeons
1991 – Present Receiver of Formal Complaints of Misconduct
Department of Surgery, University of Sydney
1985 – Present Consultant Surgeon (Transplantation)
Royal Alexandra Hospital for Children, Camperdown/
New Children’s Hospital, Westmead
1984 – Present Tutor

Final FRACS Examination Candidates

Royal Prince Alfred Hospital

1984 – Present Lecturer in Surgical Oncology

NSW College of Nursing
2. **Professor John Kelly**

**Publications**

- **Holly EA, Kelly JW, Shpall SN, Shu-Hui C.** *Number of melanocytic nevi as a major risk factor for malignant melanoma* J Am Acad Derm, 17, 3, 459-468, 1987
  
  Journal Impact Factor: 5.0
  
  Citations: 247
  
  At the time this study was undertaken there were only anecdotal observations of melanoma occurring in individuals with numerous naevi. As a research fellow Dr Kelly approached Dr Elizabeth Holly, an established epidemiologist, to supervise him in the conduct of this case control study. He conceived the study undertook all aspects with Dr Holly’s supervision. It was one of the first publications to document the association of increased naevus numbers and melanoma risk.

  
  Journal Impact Factor: 39.2
  
  Citations: 45
  
  This letter was the first publication to show that retinoids are useful in the chemoprevention of squamous cell carcinoma in high risk populations. They had previously been avoided in transplant recipients because of a suspected up-regulation of host immunity potentially contributing to graft rejection. It described a small study that was initiated and conducted in all aspects by Dr Kelly and undertaken in collaboration with the renal unit. Retinoids are now standard of care for patients who are developing high numbers of cutaneous squamous cell carcinomas.

  
  Journal Impact Factor: 5.0
  
  Citations: 160
  
  At the time there was no understanding of the extent to which total naevus numbers (a strong melanoma risk factor) was genetically or environmentally determined. Dr Kelly initiated this study to address the question and collaborated with Prof. R MacLennan, a senior epidemiologist with an interest in the area, who supervised the planning and execution. The methodology lead to the development of an international protocol for use in naevus counting studies at the International Organisation for Research on Cancer, World Health Organisation, Report No. 90/002, Nov 1990.
  
  The study counted naevus numbers by 32 body sites in 1100 schoolchildren at ages 6, 9, 12, 15 in Melbourne, Sydney and Townsville, locations of widely varying solar irradiance. Genetic influences were predominant but solar exposure played a role.

  
  Journal Impact Factor: 4.3
  
  Citations: 137
  
  This was the principal paper from the PhD of Wendy Liu, the first PhD student of the VMS, co-supervised by Dr Kelly and Dr McArthur. Little was known of the growth rates of different types of melanoma and the time interval that was available to institute early detection. Different melanoma types showed widely varying rates of growth. This study followed on from the work of the VMS on nodular melanoma and demonstrated that this type showed the highest growth rate.

  
  Journal Impact Factor: 3.79
  
  Citations: 116
Dr Kelly initiated and supervised this cohort study to demonstrate the practical application of naevus associated risk assessment for the early detection of melanoma. The publication received the Medical Journal of Australia’s Wyeth Award for best contribution for 1997.


Dr Kelly initiated and supervised all aspects of this cohort study in a series of patients from his practice to investigate the rates of changes in naevi and development of melanoma in a high risk population and the associations of these changes. The purpose was to aid clinicians in the evaluation of the likelihood of malignancy in the presence of observed change.


This publication was the work of PhD student, Wendy Liu. It was done under the supervision of Drs Kelly and McArthur and was the first publication of the Melbourne Melanoma Project collaboration. The study followed the recognition of the importance of driver mutations in melanoma therapy and demonstrated that driver mutations in melanoma are correlated with clinical features.


This was Dr Kelly’s first study in melanoma and was conducted for his doctorate at University of California San Francisco. He executed all aspects of the study under the supervision of Professor’s Richard Sagebiel and Scott Blois. The study utilised the extensive clinical database in melanoma at UCSF and examined factors that might influence the choice of excision margins to inform surgical practice.


At the time of this study nodular melanoma was little recognised and understood. Dr Kelly supervised Dr Alex Chamberlain in this work and collaborated with Dr Lin Fritschi as epidemiologist. This study has initiated the direction that the VMS subsequently took in addressing aggressive primary melanoma. This work has documented many clinical, epidemiological and laboratory associations of nodular melanoma. Subsequent work showed that nodular melanoma causes more deaths than any other type. The study was aimed at reducing deaths due to failure to recognise it’s very different presenting features. We have since conducted media campaigns to promote these findings.


Dr Kelly joined many collaborators in this study. At the time there was enthusiasm for automated diagnosis with image analysis. Studies have not borne this out.
Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, **Kelly JW.** Nodular type and older age are the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002; 138: 609-614

Dr Kelly supervised Dr Alex Chamberlain in this study, a pair with the study above on nodular melanoma. The study demonstrated that nodular melanoma comprises most of thick, high risk melanoma, underlining the importance of it to clinicians.


Dr Kelly undertook all aspects of this study at UCSF under the supervision of Professors Sagebiel and Blois. It used the melanoma database, at UCSF, to explore the significance of histological evidence of regression as an indicator of poor prognosis. Smaller studies had suggested that it had prognostic significance. This study was more than twice the size of any previous study and had longer follow-up. There was no prognostic significance to the presence of regression.


This was an early study to show an association between the presence of a driver mutation and prognosis. It was part of the Melbourne Melanoma Project collaboration.


A case control study conducted by Dr Kelly under the supervision of Dr Elizabeth Holly had shown that dysplastic naevi were a strong risk factor for melanoma. There was, however, much confusion about the clinical appearances of dysplastic naevi. This photographic study of dysplastic naevi that were confirmed histologically by Dr Sagebiel (one of the pioneers of the concept), using the extensive photographic collection of his colleague, Dr Crutcher. This was the first study to document the clinical features of a large number of dysplastic naevi and aided clinicians in melanoma risk assessment.


Dr Kelly was given responsibility for writing the biopsy chapter of the current national melanoma guidelines and, in the process, it became clear that there was little data on the strengths and weaknesses of different modes of biopsy for melanoma diagnosis. He supervised the Masters project of Jonathan Ng on this subject using the VMS
database. This study remains the benchmark study in this area and aids clinicians in their choice of biopsy method and in interpretation of histologic findings after partial biopsy.


Journal Impact Factor: 7.2
Citations: 47

Level and thickness are both measures of melanoma depth and key prognostic indicators. This study was done by Dr Kelly under the supervision of Professors Sagebiel and Blois and used the UCSF database to demonstrate the survival of patients with discordant level and thickness.


Journal Impact Factor: 5.0
Citations: 46

An important substudy of the large epidemiologic study described in the second reference above.


Journal Impact Factor: 4.3
Citations: 45

Algorithms were developed to aid inexpert clinicians to quickly gain useful diagnostic information from dermoscopy. Dr Kelly initiated the study and supervised Dr Con Dolianitis in executing the study. This study evaluated the strengths and weaknesses of the available algorithms to inform clinicians starting out in dermoscopy. Dr’s Wolfe and Simpson did the statistics.


Journal Impact Factor: 5.0
Citations: 40

Dr Kelly initiated this project and supervised Yan Pan as a medical student for this study. Red, scaly plaques are a common diagnostic challenge in dermatology and this study described new dermoscopic criteria to distinguish different diagnoses. Criteria described in this study are now well accepted and widely used.

Full Publications List

2015


4. The role of BRAF mutations in primary melanoma growth rate and survival. VJ Mar, W Liu, B Devitt, SQ Wong, A Dobrovic, GA McArthur, R Wolfe, JW Kelly British Journal of Dermatology Accepted for publication 24/02/15


7. Luen S et al. Primary tumour thickness is a prognostic factor in stage IV melanoma - A retrospective study of primary tumour characteristics Am J Clin Oncol 2015 Accepted for publication

2014


2013


2011


2010


2009


2. Pan Y, **Kelly JW.** How to Treat Melanoma. Australian Doctor; 20/11/09

2008


2007


2006


2005


2004
1. Upjohn E, Kelly JW. Skin diseases in war and peace keeping. ADF Health 2004; 5: 64-68

2003

2002
1. Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW. Nodular type and older age are the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002; 138: 609-614

2001

(publications since 2000)

Speeches/lectures

National
❖ Australasian College of Dermatologists Annual Scientific Meeting 2014 Co-Chairperson Melanoma Symposia x2, Invited presentation: Rate of Growth in Melanoma
❖ Australian Doctor Education Seminar, annual presentation from 2009
❖ Australasian College of Dermatologists Annual Scientific Meeting 2008. Melanoma Diagnosis and Sequential Dermoscopy
❖ Australasian Dermatopathology Society 29th Annual Conference 2008, Convenor, Melanocytic lesion responder session

College of General Practitioners Annual Scientific Meeting, Melbourne. 2007. Meet the Expert – Melanoma diagnosis with sequential dermoscopy

Annual Scientific Meeting Australasian College of Dermatologists, Adelaide, Monday 14th May 2007. Top publications from the melanoma literature 2006

39th Annual Scientific Meeting, Australasian College of Dermatologists, 2006. Convenor, Melanoma and Dermatoscopy Responder Session


International

3rd International Conference on UV and Skin Cancer Prevention Melbourne, November 2015, Optimal Cancer Care Pathways for People with Skin Cancers.

Melanoma Symposium Chairman, “Melanoma Pathogenesis, Risk Factors and Classification” 23rd World Congress of Dermatology, Vancouver, June 2015


Fourth World Congress of Dermoscopy, Vienna, Austria, April 2015. x2 invited presentations (Declined)


Global Controversies in Skin Cancer, Brisbane, 2013 Merkel Cell Carcinoma Symposium Co-Chair, Invited presentation: Clinical and Dermoscopic Diagnosis of Merkel Cell Carcinoma

The Skin Cancer Conference, Queenstown, New Zealand, 2012 Amelanotic and Nodular Melanoma

3rd World Congress of Dermoscopy, Brisbane, 2012 Dermoscopic diagnosis of the erythematous patch

22nd World Congress of Dermatology, Seoul, South Korea, 2011, Dermato-oncology Symposium, atypical and aggressive presentations of primary melanoma

World Congress of Melanoma Centres, Sydney, November 4th-11th 2010 Melanoma Subtypes: Implications for Diagnosis and Prognosis


7th World Congress on Melanoma, 12-15th May 2009, Vienna, Austria, 4 oral presentations

2nd Congress International Dermoscopy Society, 2009, Barcelona, Spain 2 presentations; Dermoscopy of Nodular Melanoma, Teledermoscopy for Users.

21st World Congress of Dermatology, Buenos Aires, 3rd October 2007, Dermatooncology Course – Melanoma

21st World Congress of Dermatology, Buenos Aires, 1st October 2007, What’s New in Melanoma


International Genes, Environment and Melanoma Symposium, University of Sydney, 15th June 2006. Aggressive Melanoma: What have we learned?

(speeches/lectures since 2006)
3. Professor Georgina Long

Publications

**Key contributions to field bolded**


7. De Sousa SMC, Sheriff N, Tran CH, Menzies AM, Tsang VHM, Guminski AD, Long GV, Tonks KTT. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary 2018. Accepted for publication.


the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology 2016. [Epub ahead of print]. IF 7.644


144. Chien A, Haydu LE, Biechele TL, Kulikajaskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT. Long GV. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/beta-catenin signaling. PlosOne 2014; Apr: 14(9):e94748. IF 3.53


Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after targeted therapy. Cancer 2014; Jun; 1:120(11):1695-1701 IF 5.201

162.Azer MWF, Menzies AM, Haydu LE, Kefferd RF, Long GV. Patterns of Response and Progression in Patients with BRAF-mutant Melanoma Metastatic to the Brain treated with Dabrafenib. Cancer 2014; 120:530-6. IF 5.201


169.Menzies AM, Long GV. Recent advances in melanoma systemic therapy, BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer 2013; 49(15):3229-41. IF 5.54


Speeches/lectures

Invited speaker engagements
1. Neoadjuvant treatment of resectable stage III disease, Current Trens in Immuno-Oncology, Sydney, May 2018
2. ‘Omics in cancer clinical practice, The University of Sydney Cancer Research Networks, Sydney, April 2018
5. Patient selection and biomarkers - Predicating response and resistance in drug therapy for advanced melanoma, COSA ASM, Sydney, November 2017
6. Future Perspectives and Congress Highlights - Highlights in Melanoma from 2017, 9th World Congress of Melanoma, Brisbane, October 2017
7. Melanoma Centre Sessions - Conducting an efficient and effective melanoma tumour board / multidisciplinary meeting, 9th World Congress of Melanoma, Brisbane October 2017
8. A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases’ with a presentation of the interim analysis and trial results (ANZMTG 01.14 ABC trial). ANZMTG Symposium, 9th World Congress of Melanoma, Brisbane October 2017
9. Melanoma: Future Approaches to Therapy and Trials - State of the art treatments for melanoma – what is the current situation? Incyte Biosciences Symposium, 9th World Congress of Melanoma, Brisbane, October 2017
10. The I-O-Approach in Advanced Melanoma – From an Innovation to a Standard Therapy; Clinical factors, biomarkers, guidelines – and how they contribute to an individual therapy decision, 7th European Post-Chicago Melanoma and Skin Cancer, June 2017
11. My Personal Highlights at ASCO 2017 in combined / sequential schedules, 7th European Post-Chicago Melanoma and Skin Cancer, June 2017
15. The evolving therapeutic landscape of advanced melanoma, European Association of Dermato Oncology, Athens, May 2017
16. Choice of immunotherapy versus targeted therapy in first line treatment for BRAF-mutant melanoma, European Association of Dermato Oncology, Athens, May 2017
17. Update on systemic therapies for pathologists, International Melanoma Pathology Course, Paris, Apr 2017
20. Melanoma: Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: Data from KEYNOTE-006, European Cancer Organisation, Amsterdam, Jan 2017
22. Debate: This house believes that high-risk stage III melanoma should NOT be treated with adjuvant ipilimumab after complete resection – Contra, Speaker against, European Cancer Organisation, Amsterdam, Jan 2017
23. Challenge Your Expert session: All patients should receive immune-based therapy for advanced melanoma in the first line, European Society for Medical Oncology Asia Congress, Singapore, Dec 2016
24. Clinical predictors of prolonged response and survival, European Society for Medical Oncology Asia Congress, Singapore, Dec 2016
31. Melanoma Treatment Landscape, European Society for Medical Oncology Congress, Roche Symposium, Copenhagen, Oct 2016
32. Management of Immunotherapy Side Effects, European Society for Medical Oncology Congress, Copenhagen, Oct 2016
33. The Role of Systemic Treatments for Metastatic Melanoma Brain Metastases, Neurosurgical Society of Australasia Annual Scientific Meeting, Sydney, Sept 2016
34. Adjuvant systemic therapy update, Multidisciplinary management of locoregionally advanced melanoma – from surgery to immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Aug 2016.
35. Melanoma drug therapies: Lessons from the clinic and results from the lab, Kinghorn Cancer Centre, Sydney, Aug 2016.
36. Immunotherapies in Melanoma: Results and Lessons from the Clinic, A Workshop on Immunotherapy: from bench to bedside, Centenary Institute, Sydney, Aug 2016.
39. Highlights of the day for Melanoma Oral sessions, ASCO AGM Chicago, June 2016
40. Clinically Approaching Metastatic Melanoma in 2016: Overview of Data and Options, Education Session, ASCO AGM Chicago, June 2016
41. Immunotherapy in Practice: Experiences in Melanoma, ANZGOG Annual Scientific Meeting, Apr 2016
44. Immunotherapy In Melanoma, First International Immunotherapy Conference, Brisbane, Australia, Nov 2015
46. Critical analysis of targeted therapy and immunotherapy outcome, Chair and Speaker, Novartis Oncology Region Europe Investigator Meeting, Marseille, France, Oct 2015
47. New Drug and New Trials; Dabrafenib Plus Trametinib, 11th EADO Congress and the 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, Marseille, France, Oct 2015
49. The evolving therapeutic landscape of advanced melanoma, European Association of Dermato Oncology, Athens, May 2017
50. Choice of immunotherapy versus targeted therapy in first line treatment for BRAF-mutant melanoma, European Association of Dermato Oncology, Athens, May 2017
51. Update on systemic therapies for pathologists, International Melanoma Pathology Course, Paris, Apr 2017
53. Melanoma: BRAF mutated metastatic melanoma: patient-centric management, Harnessing Oncology Targeted Therapies Symposium, Sydney, Mar 2017
54. Melanoma: Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: Data from KEYNOTE-006, European Cancer Organisation, Amsterdam, Jan 2017
55. Neoadjuvant therapy in bulky stage III melanoma: Are we there yet?, European Cancer Organisation, Amsterdam, Jan 2017
56. Debate: This house believes that high-risk stage III melanoma should NOT be treated with adjuvant ipilimumab after complete resection – Contra, Speaker against, European Cancer Organisation, Amsterdam, Jan 2017
57. Challenge Your Expert session: All patients should receive immune-based therapy for advanced melanoma in the first line, European Society for Medical Oncology Asia Congress, Singapore, Dec 2016
58. Clinical predictors of prolonged response and survival, European Society for Medical Oncology Asia Congress, Singapore, Dec 2016
64. Anti-PD1 Therapy in Melanoma, Beijing International Melanoma Congress, Beijing, Oct 2016.
65. Melanoma Treatment Landscape, European Society for Medical Oncology Congress, Roche Symposium, Copenhagen, Oct 2016
66. Management of Immunotherapy Side Effects, European Society for Medical Oncology Congress, Copenhagen, Oct 2016
67. The Role of Systemic Treatments for Metastatic Melanoma Brain Metastases, Neurosurgical Society of Australasia Annual Scientific Meeting, Sydney, Sept 2016
68. Adjuvant systemic therapy update, Multidisciplinary management of locoregionally advanced melanoma – from surgery to immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Aug 2016.
70. Immunotherapies in Melanoma: Results and Lessons from the Clinic, A Workshop on Immunotherapy: from bench to bedside, Centenary Institute, Sydney, Aug 2016.
71. Melanoma: immuno-oncology treatment landscape, BMS Immuno-Oncology Conference, Sydney, July 2016
73. Highlights of the day for Melanoma Oral sessions, ASCO AGM Chicago, June 2016
74. Clinically Approaching Metastatic Melanoma in 2016: Overview of Data and Options, Education Session, ASCO AGM Chicago, June 2016
75. Immunotherapy in Practice: Experiences in Melanoma, ANZGOG Annual Scientific Meeting, Apr 2016
78. Immunotherapy In Melanoma, First International Immunotherapy Conference, Brisbane, Australia, Nov 2015
80. Critical analysis of targeted therapy and immunotherapy outcome, Chair and Speaker, Novartis Oncology Region Europe Investigator Meeting, Marseille, France, Oct 2015
81. New Drug and New Trials; Dabrafenib Plus Trametinib, 11th EADO Congress and the 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, Marseille, France, Oct 2015

59
48. Melanoma Immunology: Long Response and Long Responders, 11th EADO Congress and the 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, Marseille, France, Oct 2015
49. Progress in targeted therapy of Melanoma; Monitoring drug response and therapeutic escape, 11th EADO Congress and the 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, Marseille, France, Oct 2015
50. Melanoma Management Matters: Optimising treatment for BRAF positive Metastatic Melanoma, Chair and Speaker, Novartis Symposium, Sydney Oct 2015
51. Immunotherapy, Melanoma and the Future, BMS Melanoma symposium at ECCO-40th ESOM European Cancer Congress, Vienna, Austria, Sept 2015
52. Mechanisms of Resistance to Targeted Therapies, 18th ECCO-40th ESOM European Cancer Congress, Vienna, Austria, Sept 2015
53. Sequencing and Combining Immunotherapies and Targeted Therapies, 18th ECCO-40th ESOM European Cancer Congress, Vienna, Austria, Sept 2015
54. Immunotherapy and The Treatment Landscape in Melanoma, BMS Immuno-Oncology Symposium, Sweden, Sept 2015
55. Drug Therapies in Melanoma Brain Metastases, Advances in Treatment of Melanoma Brain Metastases, Melanoma Institute Australia, Education Event, Aug 2015
56. Drug Therapies in Melanoma, Faculty of Pharmacy, University of Sydney, Aug 2015
57. Clinical trial results on targeted drugs in metastatic melanoma, and plans for future research Melanoma & Skin Cancer Special Interest Group (MELSIG) Mini-Symposium, University of Sydney, Jul 2015
58. The Melanoma Treatment Landscape, APM Patient Advocate Forum, Munich, Germany, June 2015
59. My personal highlights in ASCO 2015 in targeted therapies, 5th European Post-Chicago Melanoma/Skin Cancer Meeting, Munich, Germany, June 2015
60. New drugs and trials II: An update on targeted agents and combo treatments – Dabrafenib and trametinib, 5th European Post-Chicago Melanoma/Skin Cancer Meeting, Munich, Germany, June 2015
61. Immunotherapies in the modern era of melanoma management 5th European Post-Chicago Melanoma/Skin Cancer Meeting, Munich, Germany, June 2015
62. Targeted therapies in the modern era of melanoma management, 5th European Post-Chicago Melanoma/Skin Cancer Meeting, Munich, Germany, June 2015
63. The Evolving Landscape, Management of Advanced Melanoma, Merck (MSD) Symposium Immuno-Oncology, Chicago, USA, June 2015
64. Emerging Data in Immuno-Oncology in Advanced Melanoma, Merck (MSD) Symposium Immuno-Oncology, Sydney, Australia, June 2015
66. The Molecular Multi-disciplinary Team Meeting, International Melanoma Working Group, Krakow, Poland, Mar 2015
67. Melanoma systemic drug therapies, Skin and Cancer Foundation Scientific Meeting, Leura, Sydney, Australia, Mar 2015
68. Checkpoint Inhibitors in Melanoma, Merck (MSD) Immuno-Oncology Symposium, Hong Kong, Mar 2015
69. Drug Therapies in Melanoma – where to next?, Lorne Cancer Conference, Melbourne, Australia, Feb 2015
70. Melanoma – Australian Epidemiology, Merck (MSD), Melanoma Expert Input Forum, Taipei, Taiwan, Jan 2015
71. Combination Therapies: Where to next?, Society for Melanoma Research Annual Meeting, Zurich, Switzerland, Nov 2014
72. Brain metastases: how to integrate and optimize medical treatments, Italian Melanoma Intergroup Meeting, Venice, Italy, Oct 2014
73. Organising melanoma care, conducting clinical and translational research and monitoring quality of melanoma treatment: the experience of the Melanoma Institute Australia, Italian Melanoma Intergroup Meeting, Venice, Italy, Oct 2014
74. Principles of novel therapeutics in combinations: Combined targeted immune therapy, American Association for Cancer Research, Melanoma Meeting, Philadelphia, USA, Sept 2014
75. Management challenges: brain metastases and progressive disease, GSK Melanoma Masterclass, Melbourne, Australia, July 2014
76. Immune effects MAPK inhibitor treatment, GSK Advisory Board Key Presentation, July 2014
77. Immuno-oncology therapies in melanoma, Paris Symposium, July 2014
79. Optimizing the Use of New Targeted Therapies in the Face of Toxicity, Education Session American Society for Clinical Oncology AGM, Chicago, USA, June 2014
80. Metastatic disease – Is it time to change our approach?, Merck Sharp and Dohme Melanoma Stand Alone Satellite Symposium, American Society for Clinical Oncology AGM, Chicago, USA June 2014
81. GlaxoSmithKline Melanoma Launch of Dabrafenib and Trametinib, Sydney, Australia, April 2014
83. Systemic Therapy in Melanoma. Insights, Perspectives and Future Directions, Cancer Institute NSW, Sydney, Mar 2014
84. Beyond the Target. Why we have to get personal, Haematology and Oncology Targeted Therapies Conference, Melbourne, Australia, Mar 2014
85. The Melanoma Treatment Landscape, Haematology and Oncology Targeted Therapies Conference, Melbourne, Australia, Mar 2014
86. Systemic Therapies in Melanoma, Royal Prince Alfred Hospital Combined Immunology and Rheumatology Department Meeting, Sydney, Feb 2014
88. Kinase Inhibitors in Melanoma, Plenary Session, Society for Melanoma Research, Philadelphia, USA Nov 2013
90. Treatment options of patients with advanced melanoma and the latest research. An interactive seminar for General Practitioners, Northern Sydney General Practice Network, Sydney, Oct 2013
91. Beating Melanoma; Targeting Genes, 21st Century Medicine, The University of Sydney, Sydney, Australia, Oct 2013
93. Combination modality treatment for brain metastases, European Cancer Organisation Conference, Amsterdam, Sept 2013
94. Systemic Treatment of Metastatic Melanoma. Current status and perspectives, Plenary Session German Skin Cancer Meeting, Essen Germany, Sept 2013
95. Systemic Therapy in Melanoma, Melanoma education evening, Australasian Foundation for Plastic Surgery and Melanoma Institute Australia, Sept 2013
96. Melanoma: Beyond the Response to BRAF Inhibitors, Medical Oncology Group of Australia, Melbourne, Australia, Aug 2013
97. Highlights from ASCO 2013: Kinase Inhibitors, 8th World Congress for Melanoma, Hamburg Germany, July 2013
98. New Drugs and Trials: Dabrafenib plus Trametinib, 8th World Congress for Melanoma, Hamburg Germany, July 2013
99. Management of Brain Metastases: Targeted Therapy, 8th World Congress for Melanoma, Hamburg Germany, July 2013
100. Dabrafenib Toxicities, GlaxoSmithKline Dabrafenib Advisory Board Presentation, Chicago, June 2013
101. Management of Melanoma Brain Metastases, American Society for Clinical Oncology, Melanoma Education Session, Chicago, IL USA, June 2013
102. Systemic Therapies for Melanoma: a rapidly changing landscape, and a poster-child for targeted therapies and immunotherapy, Annual Scientific Meeting of the Australasian College of Dermatologist, Sydney, May 2013
103. Melanoma Heterogeneity, Resistance and Implications for Systemic Therapy, Meeting for the Asian Society for Pigment Cell Research (ASPCR) and the Australasian Society for Dermatology Research (ASDR), Sydney, May 2013
104. BRIM3 and BRIM7 update, Skin Cancer Summit, Cancun, Mexico, March 2013
105. The Evolution of Targeted Therapy in Melanoma, Skin Cancer Summit, Cancun, Mexico, March 2013
106. Highlights from the Society for Melanoma Research, ReachMD XM 167, Medical Education Radio Station, USA, Jan 2013
107. New Treatments in Melanoma, Melanoma Institute Australia, Community & Volunteers Seminar, Sydney, Dec 2012
108. Melanoma; Australias Cancer, Australias Progress, Parliamentarians supporting cancer causes breakfast event to mark National Skin Cancer Action Week, Canberra, Nov 2012
111. Randomised Phase II study of BRAF inhibitor dabrafenib vs combination with MEK inhibitor trametinib in BRAF V600 mutant metastatic melanoma, GlaxoSmithKline Combination Dabrafenib and Trametinib Advisory Board Presentation, Vienna, Sept 2012
112. Personalising Therapy in Metastatic Melanoma, Roche Satellite Symposium, European Society for Medical Oncology Conference, Vienna, Sept 2012
113. Update on prognostic significant of tumor BRAF and other mutations, Perspectives in Melanoma XVI, Valencia, Spain, Sept 2012
114. Combination of BRAF and MEK inhibitors for BRAF mutant metastatic melanoma, Perspectives in Melanoma XVI, Valencia, Spain, Sept 2012
115. Targeting Oncogenic Pathways in Melanoma; Progress to Date, Melanoma now & into the future, Symposia, Olivia Newton-John Cancer and Wellness Centre, Melbourne, Aug 2012
116. Adjuvant Therapy in Melanoma, Melanoma Institute Australias World Round-Up Symposium. The latest in melanoma from recent international meetings, Sydney, July 2012
117. Inhibiting mutant-BRAF in metastatic melanoma, Vemurafenib in clinical practice, Vemurafenib Launch Meeting Brazil, Sao Paulo web meeting, June 2012
118. Patient Cases and Discussion, Vemurafenib Launch Meeting Australia, Sydney, June 2012
119. Targeted Therapies in Melanoma, MAP Kinase Pathway Inhibitors, GlaxoSmithKline Investigators Meeting for Phase 3 Studies of dabrafenib combined with trametinib versus single agent BRAF inhibitor, Sydney, April 2012
120. Building translation into clinical practice: Lessons from melanoma and targeted therapies, American Association for Cancer Research, Chicago, USA, April 2012
121. Managing metastatic melanoma, now and in the future, Vemurafenib External Global Launch Meeting, Paris, April 2012
122. Targeted therapies, what lessons have we learnt, Haematology and Oncology Therapeutic Treatments (HOTT) conference, Melbourne, March 2012
123. The BRAF story – from Target to Treatment and Beyond, 7th Annual University of North Carolina Conference on Melanoma, Chapel Hill, North Carolina, Feb 2012
124. The BRAF story – from Target to Treatment and Beyond, Patient Symposium, 7th Annual University of North Carolina Conference on Melanoma, Chapel Hill, North Carolina, Feb 2012
125. The BRAF Story: Managing Metastatic Melanoma, Roche Education Day, Sydney, Dec 2011
127. The BRAF Story-Managing Metastatic Melanoma, Prince of Wales Hospital, Sydney, Oct 2011
129. BRAF in metastatic melanoma, Prognostic significance, age and other associations, Perspectives in Melanoma XV, New York, Sept 2011
130. Management of Melanoma Brain Metastases, Roche Investigators Meeting for Phase 2 Study Vemurafenib in Brain metastases, London, July 2011
132. Systemic Therapies on Melanoma: Immunotherapy, BRAF inhibitors and Beyond, Merck Sharp Dome Educational Evening, Sydney, June 2011
133. BRAF mutant metastatic melanoma - clinical and translational research, University of California, LA, June 2011
134. BRAF mutant metastatic melanoma – clinical and translational research, University of Pennsylvania, Philadelphia, May 2011
135. Advances in the Treatment of Melanoma, Westmead Medical Research Foundation Community Seminars, June 2011
136. Clinical Research in identified targets; The BRAF story in melanoma, Pfizer Oncology Forum Meeting, Melbourne, May 2011
137. GSK2118436 (Dabrafenib) Laboratory Correlates, International Melanoma Working Group, April 2011
139. Management of Patients with Brain Metastases, Roche Melanoma Advisory Board Presentation, Melbourne, Dec 2010
140. Systemic Therapies in Melanoma, Australian & New Zealand Head & Neck Cancer Society, Annual Scientific Meeting, Sydney, Sept 2010
141. Targeted therapies - Trials and the TEAM Study, Melanoma Institute Australia Science Symposium, Sydney, March 2010
142. Targeted Therapies in melanoma, Melanoma Update for Radiation and Medical Oncologists, Sydney, March 2010
143. BRAF Inhibitors and Other Targeted Therapies in melanoma, Sydney Head & Neck Cancer Institute, Sydney, March 2010
144. BRAF Inhibitors and Other Targeted Therapies in melanoma, Radiation Oncology Chapter Meeting, Sydney, March 2010
145. Research and Clinical Trials, Advances in Melanoma Care Symposium, Melanoma Network and Melanoma Institute Australia, Aug 2009

Development of related materials, including guidelines, standards, educational materials or fact sheets

Clinical practice guidelines and patient information resource development
Electronic Clinical Trial Resource Development For Physicians; ClinTrial Refer, Melanoma
From 2014
Lead Clinician - A free downloadable Application for iPhone/Android of clinical trials across Australia for patients with melanoma

Australian Melanoma Management Guidelines Committee, Medical Oncology Section Leader
From 2014
Cancer Institute NSW
Reviewer of Evi-Q – on-line evidence-based guidelines for clinicians using melanoma systemic treatments From 2013
American Society for Clinical Oncology
2013-2016
Editorial board member for Cancer.net patient information website for melanoma.
Responsibilities: regular review of the website and its content.

Melanoma Institute Australia
From 2013
Patient Information Package Design & Review, including patient information for stage 3 and 4 melanoma

4. **A/Professor Susan Neuhaus**

**Research Grants, Publications and Invited presentations**

As an academic researcher and Associate Professor, Susan has been awarded over $500,000 in clinical research grants and collaborates on a number of clinical research projects and trials. She has published over 60 papers in peer reviewed medical and military journals and authored several book chapters. Susan has published two books including ‘Not for Glory: a century of service by medical women to the Australian Army and its Allies’. She has been cited over 1,100 times and has an h-index of 18 (Scopus 2015). Susan has presented at over 30 national and 10 international conferences. She has been invited to speak on themes of Leadership and Ethics, Diversity and Clinical leadership and Governance to varied forums, including community events, professional groups, the Joanna Briggs Institute for Evidence Based Practice and the Centre for Economic Development Australia (CEDA). Susan also leads a developing national research collaborative investigating the gender specific effects of military service and deployment. She was awarded $220,000 as Principal Investigator of a study titled: Mothers in the Middle East Area of Operations (MEAO): The health impacts of maternal deployment to an area of operations.

Susan’s advocacy and health leadership in the area of Defence and Veteran Health is widely recognized and she has been requested to address the House of Representatives, Joint Standing Committee on Foreign Affairs and Trade Inquiry into the Care of ADF Personnel Wounded and Injured on Operations, the ADF Service Women Steering Committee and as Co-Chair South Australian Centre of Excellence for PTSD. She has provided print and radio interviews on areas of strategic military health and was the International Visitor to the Military Families Research Institute, Purdue University, United States of America in 2013.
Dr Annette Pflugfelder

Publications


6. Professor Richard Scolyer

Publications


Speeches/lectures

1. “Genes, Errors and Disease.” to ACT Society of Pharmacists at The Canberra Hospital, Sept 1997.


7. “Can phyllodes tumours of the breast be distinguished from fibroadenomas by fine needle aspiration cytology?” RCPA Annual Scientific Meeting, Canberra ACT, Nov 2000.


10. RCPA Postgraduate Diagnostic Surgical Pathology Course – Soft Tissue Pathology, Sydney, May 2001 (with Dr Andrew Kedziora).

11. RCPA Postgraduate Diagnostic Surgical Pathology Course – Orthopaedic Pathology, Sydney, May 2001 (with Drs Stan McCarthy & Fiona Bonar).


17. RCPA Postgraduate Diagnostic Surgical Pathology Course – Soft Tissue Pathology, Sydney, Februrary 2002 (with Dr Andrew Kedziora).

18. . Royal College of Pathologists of Australasia Pathology Week lecture “Pathology of Tomorrow”. University of New South Wales, March 2002.


30. RCPA Postgraduate Diagnostic Surgical Pathology Course – Soft Tissue and Orthopaedic Pathology, Sydney, April 2003 (with Dr Andrew Kedziora).


32. RCPA Postgraduate Diagnostic Surgical Pathology Course – Melanocytic Pathology, Sydney, May 2003 (with Dr Stan McCarthy & Dr Allan Palmer).

33. “Cellular Neurothekeoma” Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, May 30th 2003

34. “Chordoma Periphericum” Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, May 30th 2003

35. “Polymorphous Low-grade Adenocarcinoma of the Lung” Australasian Division of the International Academy of Pathology Annual Scientific Meeting, Sydney, May 30th 2003


40. “Soft Tissue Pathology- What the Radiation Oncologist Needs to Know”, Royal Australasian College of Radiation Oncologists NSW Training Programme, July 2004

41. “Pathology of Melanocytic Skin Tumours”, Skin Cancer Doctors Symposium 2004, Sydney, September 2004

42. “Deep-penetrating Naevus”, Difficult Problems in Melanocytic Pathology Slide Seminar, 25th International Congress of International Academy of Pathology, Brisbane, October 2004
43. Chairman, Difficult Problems in Melanocytic Pathology Seminar, 25th International World Congress of the International Academy of Pathology, Brisbane, October 2004.

44. "Blue naevus and blue naevus variants", Frontiers in Melanocytic Pathology, Long Course, 25th International Congress of International Academy of Pathology, Brisbane, October 2004


47. Chairman, "A Mistake I Made and What I Learned From It" Soft Tissue Pathology Seminar, 25th International World Congress of the International Academy of Pathology, Brisbane, October 2004


(abstract of speeches/lectures only)
7. Dr Matteo Carlino

Education

PhD:

Thesis: BRAF mutant melanoma prognosis; response and resistance to targeted therapy
2011-2015
The University of Sydney

Fellowship of the Royal Australian College of Physicians
Awarded January 2012

Bachelor of Medicine and Bachelor of Surgery
2000-2003
Flinders University, SA

B. Medical Science
1997-1999
The University of Sydney

Professional Experience

2014- Medical Oncologist Blacktown and Westmead Hospitals

2012-2013 Clinical Superintendent for Medicine, Medical Oncologist, Westmead Hospital

2009 - 2010: Oncology Advanced trainee Westmead Hospital

2006 - 2008: Basic physician trainee Westmed network

Academic Affiliation

2015- Clinical Senior Lecturer University of Sydney

Publications

Peer-Reviewed Manuscripts:


Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016


Carlino MS, Long GV, Kefford RF, Rizos H. Targeting oncogenic BRAF and aberrant MAP kinase activation in the treatment of cutaneous melanoma. Critical reviews in oncology/hematology. 2015

Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Penas P. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA dermatology. 2015


Book Chapters


Selected Presentations to Learned Societies


Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Becker TM et.al. Anti-proliferative effects of continued MAPK pathway inhibition following acquired resistance to dabrafenib and trametinib: Implications for melanoma treatment beyond progression (presented in poster format at the 9th International conference of the Society of Melanoma Research, Los Angeles, 2012)

Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Kefford RF et.al. Anti-proliferative effects of continued MAPK pathway inhibition in acquired resistance to BRAF and/or MEK inhibitors (oral presentation at the 3rd Sydney Cancer Conference, Sydney, 2012)

Carlino MS, Atkins MB, Warneke CL, Roberson F, DeRose ER, Johnson MM,et.al. Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases (plenary presentation Medical Oncology Group of Australia meeting, Adelaide, 2011)

Carlino MS, Saunders CA, Gebski V, Menzies AM, Ma B, Lebowitz PF, et al. Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant (presented in poster format at the American Society of Clinical Oncology Annual Meeting, Chicago, 2011)

Carlino MS, Atkins MB, Warneke CL, Long GV, DeRose ER, Johnson MM et al. Differences between Australia (OZ) and the United States (US) in the Patterns, Prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study. (presented in poster format at the 7th International conference of the Society of Melanoma Research, Sydney, 2010)

Competitive research grants

2016-2018 Cancer Council NSW Project Grant
Title: Co-targeting CD47 and the MAPK pathway in melanoma
Role Chief Investigator
Award $351, 787

2016-2019 National Health and Medical Research Council Project Grant
Title: The combination of CDK4 and MAPK/ERK pathway inhibitor therapy in Melanoma: defining melanoma cell intrinsic and immune mediated responses
Role Associate Investigator
Award $824,288

2015-2017 National Health and Medical Research Council Project Grant
Title: Significance of soluble PD-L1 in melanoma patients
Role Chief Investigator C
Award $542,974.50

2012: Pfizer Australia Cancer Research Grant
Award $50,000

Scholarships and Awards
2011-2013 Australian Rotary Health Gordon Braid Melanoma Research PhD Scholarship
2012: Cancer Institute NSW SW-TCRC Student Award

Leadership/ Professional Committee Representation
2010-2011: Royal Australian College of Physicians - Trainee representative to the Specialist advisory Committee
2010-2011: Medical Oncology Group of Australia - National Trainee representative on the executive
2006-2008: Trainee Representative Westmed Network Governance Committee

Professional Memberships
American society of Clinical Oncology
European Society of medical Oncology
Medical Oncology group of Australia
International Society of Melanoma Research
Australia and New Zealand Melanoma Trials Group (ANZMTG)
8. Dr David Gyorki

Publications


9. Prof Graham Mann

Publications

RESEARCH PUBLICATIONS (2008-PRESENT) AND BIBLIOMETRICS

ORIGINAL RESEARCH


22. Dieng, M., Butow, P.N., Costa, D.S.J., Morton, R.L., Menzies, S.W., Mireskandari, S., Tesson, S., Mann, G.J., Cust, A.E., Kasparian, N.A. Psycho-educational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: Results of a randomised controlled trial. *Journal of Clinical Oncology* 10.1200/JCO.2016.68.2278 (accepted 7 Sep 2016) PMID: 27998215


Kasparian, N.A., Sansom-Daly, U., McDonald, R.P., Meiser, B., Butow, P.N., Mann, G.J. The nature and structure of psychological distress in people at high risk for melanoma: a factor analytic study. *Psycho-Oncology*. May 24, 2011 Epub ahead of print (accepted 16 Mar, 2011) [2.87, 0]


Kasparian, N.A., McLoone, J.K., Meiser, B., Butow, P.N., Simpson, J.M., Mann, G.J. Skin cancer screening behaviours among individuals at high risk of melanoma due to strong risk of melanoma due to highly penetrant gene *Journal of Cancer*. 103(10): 1502-9 (2010). [8.6, 0]


**BOOKS, BOOK CHAPTERS**

10. Dr Victoria Mar

Publications


S Smithson, Y Pan, VJ Mar Differing Trends in Thickness and Survival between Nodular and Non Nodular Primary Cutaneous Melanoma in Victoria, Australia. MJA In press Mar 2015


GP Training Module: Risk Factors for Cutaneous Melanoma. Published as a teaching module for GPs undertaking further education in dermatology, 2007.

**Conference Presentations**

* *VJ Mar*, S Wong, J Li, RA Scolyer, et al. *UV-induced high mutation load melanomas; multiple pathways, multiple targets*. Presented at the Melanoma World Congress, Hamburg July 2013.


* *V Mar*, S Wong, J Li, RA Scolyer, et al. *BRAF/NRAS wild-type melanomas have a high mutation load correlating with histological and molecular signatures of UV damage*. Presented at the Australasian Society for Dermatology Research, Sydney May 2013.


**Invited Presentations and Lectures**

* GPCE Workshop in melanoma and NMSC. November 2015

* The clinical significance of melanoma driver mutations. World Congress of Dermatology, Vancouver 2015
• *Driver mutations: Phenotype and prognosis*. Australasian College of Dermatologists ASM, Melbourne, May 2014


• *Melanoma Update*. Australasian College of Cutaneous Oncology Annual Conference, Melbourne, August 2013.

• *Melanoma Update*. Dermatology in General Practice Workshop. Melbourne, April 2013.


• *Aggressive melanomas*. Skin and Cancer Foundation Update meeting, September 2012.


• *Medical and Surgical management of Lentigo Maligna*. Australasian College of Dermatologists Spring Meeting, Hobart 2011.

**Poster presentations**


• VJ Pearce, L Simpson, A Viros, RA Marsden. *Experiences from an emergency dermatology clinic in the UK: A model to learn from?* St Georges Hospital, London. Presented at the Australasian College of Dermatologists ASM, Broadbeach 2009.
11. Professor Scott Menzies

Employment

- Deputy Director, Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, NSW
- Associate Member of the Australasian College of Dermatologists
- Professor (Sydney Medical School), and Discipline of Dermatology, University of Sydney
- Inducted into the American Dermatological Association

Ownership interests

- Polartechinics Ltd (Sydney). From 1994 to 2007 I was a consultant to Polartechinics Ltd. in regards to the development and commercial release of the automated melanoma diagnostic instrument, SolarScan™.
- Dermtech International (La Jolla, California). From 2008 to 2015 I was on the Melanoma Advisory Board of Dermtech International for the development of a micro-array tape stripping method for the diagnosis of primary melanoma.
- SciBase AB (Stockholm, Sweden.) From 2015 to current I am on the medical advisory board of SciBase for the development and commercial release of the Nevisense™ electrical impedance instrument for the automated diagnosis of melanoma.

Board membership

- US Dermatology
- 12th World Congress on Cancers of the Skin. Tel Aviv, Israel May 2009.
- Secretariat of the 3rd Congress of the International Dermoscopy Society, Brisbane, 2012

Publications


20. Hanrahan PF, D’Este CA, Menzies SW, Plummer T, Hersey P. Skin photography as an aid to management of skin lesions in older males. *J Med Screen* 2002;9:128-32 **No. of citations:** 9


32. Menzies SW. Melanoma is not what it used to look like. Cancer Forum 2005;29;71-72


(Abstract of publications)

Speeches/lectures


23. **Menzies SW.** Sequential digital monitoring for the diagnosis of melanoma. 3rd Congress of the Australian Health and Medical Research Congress Melbourne, Nov-Dec, 2006.

24. **Menzies SW.** Dermoscopy of nodular and hypomelanotic melanoma. 21st World Congress of Dermatology, Buenos Aires, Argentina October 2007.

25. **Menzies SW.** Melanoma and dermoscopy: where we are, where we go. 21st World Congress of Dermatology, Buenos Aires, Argentina October 2007.

26. **Menzies SW.** The role of digital dermoscopy and mole mapping. 21st World Congress of Dermatology, Buenos Aires, Argentina October 2007.

27. **Menzies SW.** In vivo confocal microscopy: discussion. 21st World Congress of Dermatology, Buenos Aires, Argentina October 2007.


32. **Menzies SW.** In vivo confocal microscopy for lentigo maligna and equivocal macules of the face. 3rd meeting of the International Confocal Working Group, San Francisco, USA, March 2009.

33. **Menzies SW.** In vivo confocal microscopy of pigmented macules of the face. 12th World Congress of Cancers of the Skin. Tel Aviv, Israel, May, 2009.

34. **Menzies SW.** Technologic aids for the diagnosis of melanoma. 12th World Congress of Cancers of the Skin. Tel Aviv, Israel, May, 2009.

35. **Menzies SW.** Australian and New Zealand Guidelines for management of melanoma. 12th World Congress of Cancers of the Skin. Tel Aviv, Israel, May, 2009.

36. **Menzies SW.** Diagnosis of non-pigmented and lightly pigmented lesions. 7th World Congress on Melanoma, Vienna, Austria, May 2009.

37. **Menzies SW.** Dermatoscopy of pigmented basal cell carcinoma. 7th World Congress on Melanoma, Vienna, Austria, May 2009.

38. **Menzies SW.** Short and long term follow up strategies for nevi. 7th World Congress on Melanoma, Vienna, Austria, May 2009.

39. **Menzies SW.** What dermoscopy changes induce to remove a lesion. 2nd World Congress of the International Dermoscopy Society, Barcelona Nov 2009.


41. **Menzies SW.** Dermoscopy of nodular melanoma. 3rd World Congress of Dermoscopy, Brisbane May, 2012.

42. **Menzies SW.** Clinical trial of dermoscopy in general practitioners. 3rd World Congress of Dermoscopy, Brisbane May, 2012.

43. **Menzies SW.** Dermoscopy Digital Monitoring. Where are we at? 3rd World Congress of Dermoscopy, Brisbane May, 2012.


47. Menzies SW. Dermoscopy of nodular and amelanotic melanoma. 1st Latin American Congress of Dermoscopy, Sao Paulo, Brazil, Oct 2013.


Development of related materials, including guidelines, standards, educational materials or fact sheets

See publications above.
12. Professor Michael Millward

Publications


**Relationships**

**Colleges and Societies**

- Royal Australasian College of Physicians (RACP)
- European Society for Medical Oncology (ESMO)
- Clinical Oncological Society of Australasia (COSA)
– Medical Oncology Group (Australia) (MOG)
– American Society for Clinical Oncology (ASCO)
– Melanoma Cooperative Group, EORTC
– National Cancer Institute (US) designated investigator (#32613)
– American Association of Cancer Research (AACR)
– Psycho-oncology Cooperative Research Group (PoCoG)
– Australian Melanoma Trials Group (ANZMTG)

Committees
– Western Australian Melanoma Advisory Service (since 2004)
– WA Cancer & Palliative Care Network Research Advisory Committee (since 2007)
– Medical Oncology Group of Australasia Ethics Committee (since 2007)
– WA Melanoma Health Study Management Committee (since 2009, Chairman)
– UWA Translational Cancer Pathology Management Committee (since 2012)
– WA Cancer Care Taskforce (since 2015)
– ANZMTG 01.14 trial, trial management committee (since 2015, Chair)

Consultancies
– Bristol-Myers Squibb Pharmaceuticals Pty Ltd
– Eli-Lilly Australia Pty Ltd
– GlaxoSmithKline Pharmaceuticals Pty Ltd
– Merck Sharp & Dohme Pharmaceuticals Pty Ltd
– Pfizer Pharmaceuticals Pty Ltd
– Provectus Pharmaceuticals
– Roche Pharmaceuticals
13. A/Professor Rachael Morton

Publications

Peer reviewed articles


4. Sellars, M., Morton, RL, Clayton, J. M., Tong, A., Mauren, D., Silvester, W., Power, D., Ma, R., & Detering, K. M. A case-control study of end-of-life treatment preferences and costs following advance care planning for adults with end stage kidney disease. Nephrology. Accepted 27th January 2018

5. Lim WY, Morton RL, Turner RM, Jenkins MC, Gui tera P, Irwig L, Webster AC, Dieng M, Saw RPM, Low D, Low C, Bell KJ. Patient preferences for follow-up after recent excision of a localised melanoma. JAMA Dermatology. Accepted 6th January 2018


7. Caroline Watts, Sally Wortley, Sarah Norris, Scott Menzies Pascale Guitera, Lisa Askie, Graham Mann, Rachael Morton*, Anne Cust*. A national budget impact analysis of a specialised surveillance program for individuals at very high risk of melanoma in Australia. *equal senior authors. Applied Health Economics and Health Policy. Accepted 11th Dec 2017


27. Walker RC, Walker S, Morton RL, Howard K, Tong A, Palmer S, Maori patients’ experiences and perspectives of chronic kidney disease: a New Zealand qualitative interview study, BMJ Open (2017);7:e013829. doi: 10.1136/bmjopen-2016-013829 http://bmjopen.bmj.com/content/7/1/e013829


35. Dieng M, Cust AE, Kasparian NA, Butow P, Costa DSJ, Menzies SW, Mann GJ, Morton RL. Protocol for a within-trial economic evaluation of a psycho-educational intervention tailored to people at high risk


70. Saw RP-M, Armstrong B, Mason RS, Morton RL, Shannon KF, Spillane AJ, Stretch JR, Thompson JF. Adjutant therapy with high dose vitamin D following primary treatment of melanoma at high risk of


Books


Published Abstracts, not listed elsewhere (peer reviewed)


Clinical Practice Guidelines

Speeches/lectures
Conference Presentation (with weblinks to proceedings where available)

1. Robyn PM SAW, Bruce ARMSTRONG, Rebecca S MASON, Rachael L MORTON, Christopher P WHITE, Xuhuang HAN, Elizabeth PATON, Victoria STEEL, Serigne LO, John F THOMPSON. High Dose vitamin D following primary treatment of melanoma at high risk of recurrence: Results of a pilot placebo controlled randomised phase II trial. (ANZMGT 02.09 MEL-D Trial). Abstract number for e-publication: e21624. ASCO Chicago, US, June 2018


3. Antony Mersiades1, Annette Tognela2, Paul Haber3, Martin Stockler1, Nicholas Lintzeris3, John Simes4, Iain McGregor5, Ian Olver6, David J Allsop7, Craig Gedye7, Adrianne Kirby7, Rachael L Morton8, Anh D Tran9, Karen Briscoe8, Peter Fox10, Nicole Wong11, Anna Walsh12, Anjali Bhardwaj4, Carmel Hahn4, Peter Grimison9, PILOT AND DEFINITIVE RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED TRIALS OF EVALUATING AN ORAL CANNABINOID-RICH THC/CBD CANNABIS EXTRACT FOR SECONDARY PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING. ASCO Chicago, US, June 2018

4. Dieng M, Morton RL, Costa DSJ3, Butow PN4, Menzies SW5,6, LoS7, Mann GJ7,8, Cust AE9,7 Sustained long-term benefits of a psycho-educational intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: A randomised controlled trial. ASCO Chicago, US, June 2018
5. Nidhi Sukul, Junhui Zhao, Douglas S. Fuller, Angelo Karaboyas, Brian Bieber, James A. Sloand, Lalita Subramanian, David W. Johnson, Matthew J. Oliver, Kriang Tungsanga, Tadashi Tomo, Rachael L. Morton. Hal Morgenstern, Bruce M. Robinson, Jeffrey Perl, on behalf of the clinical application of PD therapy working group. Patient-Reported Disadvantages of Peritoneal Dialysis: Results from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Accepted 55th ERA-EDTA Congress, Copenhagen, Denmark (May 24-27, 2018).


12. Tran A, Fogarty G, Nowak AK, Espinoza D, Rowbotham N, Stockler M, Morton RL. A systematic review and meta-analysis of preference-based (utility) estimates in melanoma. World Congress of Melanoma, Brisbane, 18-21st October 2017


15. Robyn PM SAW, Bruce ARMSTRONG, Rebecca S MASON, Rachael L MORTON, Christopher P WHITE, Xuhuang HAN, Elizabeth PATON, Victoria STEEL, Serigne LO, John F THOMPSON. High dose vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial assessing feasibility, safety and toxicity (ANZMTG 02.09 MEL-D Trial). World Congress of Melanoma, Brisbane, 18-21st October 2017


45. Dieng M, Butow P, Costa DSJ, Morton RL, Menzies S, Mireskandari S, Tesson S, Mann GJ, Cust AE, Kasprian NA. Psycho-educational intervention reduces fear of cancer recurrence in people at high-risk of developing another primary melanoma: Results of a randomised controlled trial. 18th International Psycho Oncology Society Congress, 17th – 21st October 2016 in Dublin, Ireland. (oral- symposia)


56. Watts C, Cust AE, Menzies S, Mann G, Morton RL. The cost-effectiveness of a specialised clinic for individuals at high risk of melanoma. 11th EADO Congress and 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Center, Marseille, France. October 2015.


60. Morton RL. Demonstrating return on investment in clinical trials. ACTA 2015 International Clinical Trials Symposium, Sydney, October 2015


63. Morton RL. Economic evaluation in end-stage kidney disease. (Invited Plenary). Australia and New Zealand Society of Nephrology (ANZSN), Annual Scientific Meeting, Canberra, September 2015


72. Saw R, Armstrong B, Mason R, Morton R, Thompson T. High dose vitamin D following primary treatment of melanoma at high risk of recurrence: A placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D Trial), Global Controversies and Advances in Skin Cancer, November 2013, Brisbane, Australia


76. Watts C, Dieng M, Morton RL, Mann G, Menzies S, Cust A. A systematic review of different countries’ clinical practice guidelines for screening and follow-up of individuals at high risk of melanoma. World Congress of Melanoma, Hamburg, 17th-20th July 2013


93. Fogarty G, Morton RL, Thompson J. Whole brain radiotherapy following local treatment of 1-3 intracranial metastases of melanoma – A Phase III trial. 7th World Congress on Melanoma/5th Congress of the European Association of Dermato-Oncology (EADO), Vienna, Austria, May 2009.


1. Thompson JF, Saw RPM, Kam PCA, Jones GRD. Elevated macro creatine kinase type 2 in serum reflecting tumour cell breakdown after "stop-flow" aortic chemotherapy. Regional Cancer Treatment 1994;7:75-77.


Speeches/lectures


11. Saw RPM. Skin Cancer and Melanoma (invited speaker). Nursing Course on Surgical Oncology – Royal Prince Alfred Hospital, Sydney, 2005.


41. Saw RPM, Thompson JF. Vitamin D following primary treatment of melanoma at high risk of recurrence (Mel-D). ANZMTG Annual Scientific Research Meeting, 9 October, 2014 (invited speaker).


Development of related materials, including guidelines, standards, educational materials or fact sheets

See publications above.
15. Dr Brindha Shivalingam

Publications


16. A/Professor Michael Sladden

Publications


17. A/Professor Andrew Spillane

Publications

1. Megan Lyle,1,2,3 Lauren E Haydu,1,2 Alexander M Menzies,1,2,4 John F Thompson,1,2,5 Robyn PM Saw,1,2,5 Andrew J Spillane,1,2,4 Richard Kefford,1,6,7 Graham J Mann,1,2,8 Wendy A Cooper,2,5,9 Bing Yu,2,5 Richard A Scolyer,1,2,4 Sandra A O’Toole,1,2,5 Georgina V Long1,2,4, The molecular profile of metastatic melanoma in Australia Pathology Accepted December 2015


5. Spillane AJ. Localising non-palpable breast lesions - the subtleties of selecting the right method. Type: Editorial. ANZ J Surg. 2015; 85;7:8:497-8; DOI: 10.1111/ans.13146


8. Rebecca Read; Sandro Pasquali, MD; Lauren Haydu, BSCHIE MIPH; John F Thompson, MD; Jonathan R Stretch, DPhil; Robyn Saw, MBMS; Michael J Quinn; Kerwin Shannon; Andrew J Spillane, MD. Quality assurance in melanoma surgery: the evolving experience at a large tertiary referral centre. EJSO. Accepted Dec 2014.


11. Rebecca L. Read, MBBS, DPhil1,2, , Lauren Haydu, BSCHIE MIPH1 , Robyn P. M. Saw, MBMS1,2,3 ,Michael J. Quinn, MBBS1,2,3 , Kerwin Shannon, MBBS1,2,3 , Andrew J. Spillane, MD1,2,3 , Jonathan R. Stretch,MBBS, DPhil1,2,3 , Richard A. Scolyer, MD1,2,4 , and John F. Thompson, MD1,2,3. In-transit Melanoma Metastases: Incidence, Prognosis and the Role of Lymphadenectomy. Ann Surg Oncol 2014; DOI 10.1245/s10434-014-4100-0.


15. Robyn P M Saw, Bruce Armstrong, Rebecca Mason, Rachael L Morton Kerwin Shannon, Andrew Spillane, Jonathan Stretch and John F Thompson Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: A placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D) Accepted BMC July 2014.
16. Pasquali S, Spillane AJ. Contemporary controversies and perspectives in the staging and treatment of patients with lymph node metastasis from melanoma, especially with regards positive sentinel lymph node biopsy. Cancer Treatment Reviews. 2014. 40 (8), 893-899.


26. Spillane AJ. (Editorial) Regarding – Why the results of the American College of Surgeons Oncology Group Z0011 Trial are so important. ANZ J Surg 2013; 83(9), 597-598


29. Helena Sung-In Jang, Andrew Spillane, Frances Boyle and Gerald Fogarty. Radiotherapy can cause haemostasis in bleeding skin malignancies. Case Reports in Medicine. 2012; Article ID 168681, 4 pages; http://dx.doi.org/10.1155/2012/168681

30. Sandro Pasquali; Lauren E. Haydu; Richard A. Scolyer; Julie B. Winstanley; Andrew J. Spillane; Michael J. Quinn; Robyn P. M. Saw; Kerwin F. Shannon; Jonathan R. Stretch; John F. Thompson. The


43. Uren RF1,2, Howman-Giles R1,2, Chung DKV1,2, Spillane AJ3,4, Noushi F3,4, Gillett D4,5, Gilch L4,5, Mak C4,6, West R4,8, Briody J and Carmalt H7,8. SPECT/CT Scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. The Breast 2012;21:480-6.


50. Lee NC, Spillane AJ. (Letter) Underpowered conclusions can be potentially misleading with regards to the ratio of number of lymphoscintigraphy identified and surgically excised sentinel nodes in melanoma patients. Eur J Surg Oncol. 2011 May;37(5):454-5; author reply 456-7.

Speeches/lectures


2. Myxoid Liposarcoma - the frequency and natural history of soft tissue metastases. Poster and Short Presentation at European Cancer Conference (ECCO), September 1999.


7. “What Do I Want? Meeting the needs of the multidisciplinary team. The Surgeon’s Perspective” Leura V Darling Harbour Sydney November 2004


20. Spillane A,1, Cheung B,2, Stretch J,1, Scolyer R,1, Thompson J. Lymph node ratio provides prognostic information in addition to AJCC N stage in patients with melanoma, even if quality of surgery is standardized. Sydney Cancer Conference July 2010

22. A Spillane. Quality assurance in melanoma surgery – consensus statements / summary of session. 4th Meeting of Meeting of Interdisciplinary Melanoma / Skin Cancer Centres Sydney 2010 – invited speaker

23. Spillane A., Cheung B., Winstanley J., Thompson J. Lymph node ratio should be recognised as a stratification factor in melanoma surgical trials. 4th Meeting of Meeting of Interdisciplinary Melanoma / Skin Cancer Centres Sydney 2010

24. Spillane A. Sentinel node biopsy in melanoma patients: who, how, when and what next. Melanoma Meeting for Primary Care Physicians. Sydney Nov 2010


27. Are the results of ACOSOG Z11 practice changing? RACS ASM Adelaide May 2011


29. Inguinal versus Ilio-inguinal Dissection for Metastatic Melanoma to Groin Lymph Nodes with Negative PET / CT Pelvic Staging: A multicenter randomised trial supported by ANZMTG. Trial Proposal. ANZMTG ASM Melbourne Nov 2011

30. Peritumoural versus Subareolar Lymphoscintigraphy. RACS ASM Kuala Lumpur May 2012


32. Debate: Internal mammary lymph nodes are more trouble than they are worth: The case against the proposal. RACS ASM Kuala Lumpur May 2012

33. Inguinal versus Ilio-inguinal Dissection for Metastatic Melanoma to Groin Lymph Nodes with Negative PET / CT Pelvic Staging: A multicenter randomised trial supported by ANZMTG. RACS ASM May 2012

34. Implant reconstruction for women who may need post-mastectomy radiotherapy. ANZBCTG ASM July 2012 Hobart


36. The EAGLE FM Study (Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma) update on trial protocol development. ANZMTG ASM Sydney, Dec 2012

37. Internal Mammary SNB in Breast Cancer: Tips, Tricks and Do They Matter. RACS ASM Auckland 2013


39. Training Breast Surgeons in ANZ. RACS ASM Singapore 2014 - invited


43. Adelaide Melanoma Education day 14 February 2014. The role of Sentinel Node Biopsy in Melanoma in 2015.
Development of related materials, including guidelines, standards, educational materials or fact sheets

See publications above.
18. Dr Victoria Atkinson

Publications


5. Atkinson V. Recent advances in malignant melanoma. Internal Medicine Journal October 2017 47 (10) 1114-1121


**Oral Abstracts**


7. Ladwa R, Atkinson V, Andelkovic V. Pembrolizumab from Metastatic Melanoma-Results of the complete responder on the Named Patient Access Presented at Medical Oncology Group of Australia Annual Scientific Meeting, 2016 Gold Coast, Australia.


Posters (Abstract Presentations)


Abstracts

1. Ladwa R and Atkinson V. The changing paradigm of management in melanoma brain metastasis. Journal of Clinical Oncology 35 (15-Supp) e21027

2. Ladwa R and Atkinson V. The management of BRAF mutant melanoma brain metastases upon tyrosine kinase failure. Journal of Clinical Oncology 35 (15-Supp) e21020

19. Dr Trevor W Beer
I have been a pathology assessor for the WA Kirkbride Melanoma Advisory Service (WAKMAS) for more than 10 years, for which I receive payment. This involves assessing the pathology of patients with advanced or complex melanoma. I have been involved with the review of guidelines for the pathology and clinical assessment of patients referred to the service. Within this role I have assisted with the development of educational material and published data derived from WAKMAS (see below).

I have also published on prognostic factors in melanoma and melanocytic lesions in adults and children and lectured on these subjects to WA dermatologists, GPs and Medical Students at Notre Dame University, Fremantle, WA and at the Australasian Dermatopathology Society Annual Scientific meeting.

**Publications & speeches/lectures & development of related materials, including guidelines, standards, educational materials or fact sheets**


20. Dr Svetlana Cherepanoff

Speeches/lectures

Invited Oral Presentations


Oral Presentations (Past 5 years)


3. Cherepanoff S. Eye Companion Meeting. Australasian Division of The International Academy of Pathology Scientific Meeting. June 2 - 4, 2017. Sydney Australia


21. A/Professor Max Conway

Publications


22. Dr Anne Cust

Publications & speeches/lectures

Publications


regulatory factor 4 (IRF4) polymorphism rs12203592 with divergent melanoma pathways. J Natl Cancer Inst 2016 Feb 8;108(7).


Invited editorials and commentaries


Letters


Book chapters


Reports


Invited participation at international, national & local meetings

Keynote speaker (international)


Invited speaker or chair (international)

1. Session Chair, Session 3C – Updates and New Considerations on Sunscreen Use, 4th International Conference on UV and Skin Cancer Prevention, Toronto, 2018.


4. Session Chair, Epidemiology free paper session, 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research, Brisbane, 2017.

5. Reducing fear of cancer recurrence in melanoma survivors: outcomes from a randomised controlled trial of a psycho-educational intervention. 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research, Brisbane, 2017.


7. A pilot study examining the impact of personal genomic risk on motivating preventive behaviours. Visiting Scientist in the Department of Cancer Epidemiology and Prevention Research of Cancer Control Alberta, Alberta Health Services. Invited presentation at the Southern Alberta Cancer Research Institute (SACRI) of the Cumming School of Medicine, University of Calgary, 2015.


Invited speaker, melanoma consortia meetings (international)

1. Melanoma risk factors by anatomical site in Australia and Leeds. GenoMEL consortium collaborator’s meeting, Essen, Germany, 2018

2. Sunscreen use and melanoma risk in young Australian adults. GenoMEL consortium collaborator’s meeting, Essen, Germany, 2018

3. Risk prediction studies in practice. GEM consortium collaborator’s meeting, Old, Australia, 2017

4. Australia-Leeds population-based analyses from the GenoMEL R01. GenoMEL consortium collaborator’s meeting, Camogli, Italy, 2017

5. Update from the Epidemiology R01, and recent results from melanoma studies in NSW. GenoMEL consortium collaborator’s meeting, Leeds, UK, 2016

6. Current Melanoma Research in Australia. GEM consortium collaborator’s meeting, Italy, 2016


8. A pilot study examining the impact of personal genomic risk on motivating preventive behaviours. GEM consortium collaborator’s meeting, Banff, Canada, 2015
10. Update on Australian Melanoma Family Study. GenoMEL consortium collaborator’s meeting, Valencia, Spain, 2014
11. Melanoma Projects in New South Wales. GEM consortium collaborator’s meeting, Italy, 2014
12. Melanoma Risk Prediction Models. GEM consortium collaborator’s meeting, Italy, 2014
13. Update on Australian Melanoma Family Study results and research activities. GenoMEL consortium collaborator’s meeting, Philadelphia, 2013
14. Update on GEM NSW and current and future projects. InterMEL consortium collaborator’s meeting, Los Angeles, 2012
15. Update of results from the Australian Melanoma Family Study. GenoMEL consortium collaborator’s meeting, Tel Aviv, 2011
17. Invited speaker or chair (national and local)
29. Invited speaker. A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours. Screening and Diagnostic Test Evaluation Program (STEP) seminar series, Sydney School of Public Health, May 2016
30. Session Chair, Sydney Catalyst Postgraduate and early-career researcher symposium, 2016
31. Melanoma projects using linked data. University of Sydney Health Data Linkage Special Interest Group annual meeting, 2015
34. Translating genomics to improve skin cancer prevention: motivating preventive behaviours using knowledge of personal genomic risk. Inaugural Melanoma & Skin Cancer Special Interest Group (MELSIG) Mini-Symposium, 2015. (Chair and speaker)
35. Genetic epidemiology of melanoma and translational research. Screening and Diagnostic Test Evaluation Program (STEP) seminar series, Sydney School of Public Health, 2015
37. Genetic and environmental epidemiology of melanoma: findings and research from the Australian Melanoma Family Study. Victorian Comprehensive Cancer Centre Skin Cancer & Melanoma Basic Translational & Clinical Research Workshop, Melbourne, 2013
40. Recruitment of cases and controls in the Australian Melanoma Family Study. NSW & ACT Cancer Epidemiology Network Meeting, Sydney, 2011

42. Sun exposure and sunbed use during childhood and early adulthood and melanoma risk before age 40. Sydney Cancer Conference, University of Sydney, 2010 (Plenary speaker)

43. Introduction to Data Management for Clinical Trials Research. Study Management in Clinical Trials Course, NHMRC Clinical Trials Centre, University of Sydney, 2003

International presentations, proffered abstracts

Oral presentations (international)


2. Cust AE et al. The melanoma genomics Managing Your Risk Study: a randomised controlled trial of an innovative behaviour change intervention to improve melanoma prevention in the Australian general population. 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research, Brisbane, 2017.

3. Cust AE et al. Associations of pigmentedary and nevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure. 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research, Brisbane, 2017.


Deutschen Dermatologischen Gesellschaft 2013; 11 (Suppl.S7):10-11. 8th World Congress of Melanoma, Hamburg, Germany, 2013

17. Watts CG, Cust AE. Mann GJ, Coates E, Menzies SW, Morton RL. Using multiple data sources to determine the cost of managing individuals at high risk of primary melanoma skin cancer in a specialized clinic. 9th World Congress on Health Economics, Sydney, 2013


Poster presentations (international)


National and local presentations, proffered abstracts

Oral presentations (national and local)


32. Cust AE, Tarnow-Mordi W, Hague W, on behalf of the INIS Collaborative Group. INIS: a randomised controlled trial of intravenous immunoglobulin for neonatal sepsis. IMPACT workshop, Clinical Trials subgroup of PSANZ, Christchurch, 2002


34. Cust AE, Darlow BA, Donoghue DA, on behalf of the ANZNN. Caring for New Zealand’s high-risk newborns in 1998-99 Paediatric Society of New Zealand annual scientific meeting, Napier, New Zealand, December 2000; and PSANZ Annual Congress, Canberra, 2001

35. Cust AE, Donovan Tj, Colditz PB. Appropriate pulse oximeter alarm settings to prevent hypoxia and hyperoxia. The 29th Australian & New Zealand Annual Scientific Meeting on Intensive Care, Adelaide, 1998. Awarded Young Investigator’s Award

36. Cust AE, Donovan Tj, Colditz PB. Appropriate pulse oximeter alarm settings to prevent hypoxia and hyperoxia. Royal Women's Hospital 60th Year Anniversary Conference, Brisbane, 1998. Received high commendation, Young Investigator’s Award.

Poster presentations (national and local)


6. Watts CG, Dieng M, Morton RL, Mann GJ, Menzies SW, Cust AE. Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a


16. Donoghue DA and Cust AE, on behalf of the ANZNN. The exclusive use of continuous positive airways pressure to ventilate babies of the ANZNN during 1998. PSANZ Annual Congress, Canberra, 2001

23. Prof Diona Damian

Publications & Speeches/lectures & Development of related materials, including guidelines, standards, educational materials or fact sheets

Publication

69. Australasian Journal of Dermatology
Damian DL. Nicotinamide for skin cancer chemoprevention. 58(3):174-180

68. Pathology

67. British Journal of Dermatology

66. British Journal of Dermatology
Chen AC, Martin AJ, Dalziel RA, Halliday GM, Damian DL. Oral nicotinamide reduces transepidermal water loss: a randomised controlled trial. 175(6):1363-1365

65. New England Journal of Medicine

This paper has been discussed in the following Commentaries:

- Hajdenberg J. (2016) In high-risk patients, oral nicotinamide reduced number of new nonmelanoma skin cancers during treatment. ACP Journal Club, Ann Int Med 164(4) JC18

64. Nutritional Neuroscience
63. PLOS One
Thompson BC, Halliday GM, Damian DL. Nicotinamide enhances repair of arsenic and ultraviolet radiation-induced DNA damage in HaCaT keratinocytes and ex vivo human skin. 10(2) e0117491, 2015

62. Experimental Dermatology

61. Australasian Journal of Dermatology

60. World Journal of Surgical Oncology
Song EJ, Scolyer RA, Damian DL, Thompson JF. Primary oesophageal melanoma – a case report. 12:77, 2014

59. Journal of Surgical Oncology

58. Photodermatology Photoimmunology Photomedicine

57. Carcinogenesis

56. Pathology

55. Lancet

54. Journal of Steroid Biochemistry and Molecular Biology

53. British Journal of Dermatology
Thanos S, Halliday GM, Damian DL. Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans. 167:631-6, 2012. Faculty of 1000 citation as an important article in its field (M Norval, University/Edinburgh; M Chiu UCLA; http://f1000.com/717950044)

52. Medicine Today

51. Journal of Investigative Dermatology

50. Journal of Dermatological Science
Halliday GM, Damian DL, Rana S, Byrne SN. The suppressive effects of ultraviolet radiation on immunity in the skin and internal organs: implications for autoimmunity. 66:176-182, 2012

49. Seminars in Cutaneous Medicine and Surgery

48. American Journal of Clinical Dermatology
Damian DL, Thompson JF. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg. 12:403-4, 2011
47. Journal of Investigative Dermatology
Frost GA, Halliday GM, Damian DL. Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery. 131:962-8, 2011

46. British Journal of Dermatology

45. SKINmed: Dermatology for the Clinician

44. Journal of the American Academy of Dermatology

43. Australasian Journal of Dermatology

42. Journal of Drugs in Dermatology
Martiniuk F, Damian DL, Thompson JF, Scolyer RA, Tchou-Wong, K-M, Levis WR. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. 9:1368-72, 2010

41. Journal of Dermatologic Science

40. Journal of Nucleic Acids
Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. [Invited review] Article ID 157591, 2010

39. American Journal of Medicine
Damian DL, Bertouch JV. A plethora of protein. 123:904-6, 2010

38. Photochemistry and Photobiology
Park J, Halliday GM, Surjana D, Damian DL. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. 86:942-8, 2010

37. Photochemical and Photobiological Sciences
Damian DL. Photoprotective effects of nicotinamide (invited review). 9: 578-85, 2010

36. Journal of Investigative Dermatology
Matthews YJ, Halliday GM, Phan TA, Damian DL. A UVB wavelength dependency for suppression of recall immunity in humans demonstrates a peak at 300nm. 130:1680-4, 2010 Featured on MDLinx.com site 9.3.10 (www.mdlinx.com/dermlinx/news-article.cfm/3069539)

35. Medical Journal of Australia
Christou E, Damian DL, Thompson JF. Regressing metastatic melanoma and vitiligo in an indigenous Australian. 192:171, 2010

34. British Journal of Dermatology
Moloney FJ, Vestergaard ME, Radojkovic BL, Damian DL. Randomised, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. 162:1138-9, 2010

33. Photodermatology, Photoimmunology and Photomedicine
Damian DL, Matthews YJ, Halliday GM. Topical riboflavin attenuates UVB and UVA-induced immunosuppression in humans.26:66-9, 2010

32. British Journal of Dermatology
Matthews YJ, Damian DL. Topical photodynamic therapy is immunosuppressive in humans. 162:637-41, 2010 Cited as an important article by the "Faculty of 1000" (http://1000medicine.com/article/id/2082973/evaluation Robert Knobler: Faculty of 1000 Medicine).

31. Experimental Dermatology
15. Frontiers in Bioscience

14. Photochemistry and Photobiology
Friedmann AC, Halliday GM, Barnetson RStC, Reeve VE, Walker C, Patterson CRS, Damian DL. The topical isoflavonoid NV-07a reduces solar-simulated UV-induced suppression of Mantoux reactions in humans. 80:416-21, 2004

13. International Journal of Dermatology

12. Journal of Photoscience
Halliday GM, Poon TSC, Damian DL, Barnetson RStC. Immune Protection Factor of sunscreens in humans is dependent on protection from UVA and cannot be predicted from the Sun Protection Factor. 9:236-9, 2002

11. Methods
Damian DL, Halliday GM. Measurement of ultraviolet radiation induced suppression of recall contact and delayed type hypersensitivity in humans. 28:34-45, 2002

10. Australasian Journal of Dermatology

9. Australasian Journal of Dermatology

8. Photochemistry and Photobiology

7. British Journal of Dermatology
Damian DL, Halliday GM, Barnetson RStC. Sun protection factor measurement of sunscreens is dependent on minimal erythema dose. 141:502-507, 1999

6. Journal of Investigative Dermatology
Damian DL, Barnetson RStC, Halliday GM. Low-dose UVA and UVB have different time-courses for suppression of contact hypersensitivity to a recall antigen in humans. 112:939-944, 1999

5. Journal of Investigative Dermatology

4. Journal of Investigative Dermatology
Damian DL, Halliday GM, Barnetson RStC. Broad-spectrum sunscreens provide greater protection against ultraviolet radiation-induced suppression of contact hypersensitivity to a recall antigen in humans 109:146-151, 1997

3. British Journal of Dermatology

2. Melanoma Research

1. Lancet

Book chapters and Special Issues


4. Thompson JF and Damian DL. Co-editor, Skin Cancer Themed Issue, Cancer Forum 36(3) 2012

Invited Presentations

Asia and Oceania Conference on Photobiology, 2017 (Seoul)
Keynote invited speaker:  "Nicotinamide for skin cancer chemoprevention"
     "Mechanisms of nicotinamide chemoprevention"

World Congress of Melanoma, 2017 (Brisbane)
Invited speaker:  "Nicotinamide for skin cancer chemoprevention"
     "Nicotinamide for actinic keratoses"

European Society for Photobiology Annual Meeting, 2017 (Pisa)
Invited speaker:  "Nicotinamide for skin cancer chemoprevention"

18th International Society of Ocular Oncology Biennial Conference / NSW RANZCO Annual Scientific Meeting, 2017 (Sydney)
Invited speaker: "Skin cancer prevention"

Combined Meeting of the Australasian Society for Dermatology Research and the Japanese Society for Investigative Dermatology, 2016 (Noosa)
Invited speaker: "Nicotinamide for skin cancer chemoprevention"

Australian Dermatology Nurses Association Meeting, within the Australasian College of Dermatologists 49th Annual Scientific Meeting, 2016 (Perth)
Invited speaker: "Nicotinamide for skin cancer prevention"

Australia and Oceania Society for Photobiology, 2013 (Sydney)
Plenary session invited speaker: "Nicotinamide for cellular energy"

Skin Cancer College Australia New Zealand, 2013 (Gold Coast)
Plenary session invited speaker: "Nicotinamide for skin cancer chemoprevention"

Melanoma Institute Australia Research Retreat, 2012
Invited speaker: "Topical immunotherapy"

American Society for Photobiology, 2012 (Montreal)
Invited speaker: "Photodynamic therapy-induced immunosuppression"

Australasian Society for Dermatology Research Annual Meeting, 2012 (Sydney)
Invited speaker: "Nicotinamide for skin cancer prevention"

Mutagenesis and Experimental Pathology Society of Australasia, 2011 (Brisbane)
Invited speaker: "Photoimmunology"

Joint meeting of the Melanoma Institute Australia and Harvard Melanoma Group, 2011 (Boston)
"Diphencyprone immunotherapy for cutaneous metastatic melanoma"
     "Nicotinamide for skin cancer chemoprevention."

Joint meeting of the Melanoma Institute Australia and Memorial Sloan Kettering Cancer Centre Melanoma Group, 2011 (New York)
"Diphencyprone immunotherapy for cutaneous metastatic melanoma"
     "Nicotinamide for skin cancer chemoprevention."

Joint meeting of the Melanoma Institute Australia and Yale Melanoma Group, 2011 (New Haven)
“Diphencyprone immunotherapy for cutaneous metastatic melanoma”

European Society for Photobiology, 2011 (Geneva)
“Photodynamic therapy-induced immunosuppression”

Skin Cancer College Australia New Zealand, 2011 (Gold Coast)
Plenary session invited speaker: “Skin cancer prevention”

Practice Nurses Continuing Education annual meeting, 2011 (Sydney)
“Common and important skin conditions”

Bosch Institute Annual Scientific Meeting, 2010 (Sydney)
Bosch Senior Speaker: “Targeting cellular energy: nicotinamide for skin cancer chemoprevention.”

4th International Skin Cancer Centres Meeting, 2010 (Sydney)
“Diphencyprone immunotherapy for cutaneous melanoma metastases.”

Melanoma in Practice symposium: Melanoma 2010 (Sydney)
“Skin cancer prevention”

Brisbane Melanoma Unit, 2010
“Diphencyprone immunotherapy” Invited lecture and discussion to facilitate start-up of topical immunotherapy program for melanoma in Brisbane

Australian Practice Nurses Continuing Education National Meeting Sydney, 2010
“Common skin conditions”

The Australasian College of Dermatologists Annual Scientific Meeting, 2010 (Darwin)
“UVA and skin immunity”

Australian Doctor GP Education Forum (Sydney) 2009
“Skin signs of systemic disease”

Melanoma Network Meeting (Sydney) 2009
“Prevention;”(highest audience-rated talk of the meeting) “Management of advanced locoregionally recurrent melanoma;”(second highest highest audience-rated talk of the meeting) “Prevention” (Public Forum)

7th World Congress of Melanoma and 5th Congress of the European Association of Dermato-Oncology Joint Meeting 2009 (Vienna)
“Nicotinamide for photoprotection”

American Society for Photobiology, 2008 (San Francisco)
“Nicotinamide prevents UV immunosuppression in humans”

5th World Congress of the International Academy of Cosmetic Dermatology 2006 (Melbourne)
“Skin cancer prevention: the latest on sunscreen”

Melanoma and Skin Cancer Research Institute, 2005 (Royal Prince Alfred Hospital)
“Effect of topical nicotinamide on UV radiation induced immunosuppression in humans”

Dermatology Update: University Health Service GPs 2005
“Skin cancer prevention and PDT”

Dermatology Update: University Health Service GPs 2004
“Skin cancer management”

Melanoma and Skin Cancer Research Institute, 2003 (Royal Prince Alfred Hospital)
“Photodynamic therapy”

Royal Australian and New Zealand College of Obstetricians and Gynaecologists Revision Course for General practitioners, 2003 (Northern Sydney Education Centre)
“Pregnancy dermatoses”

Dermatology Update for GPs 2003 (Sydney University)
“Non-surgical skin cancer treatments”

The Australasian College of Dermatologists Annual Scientific Meeting, 2000 (Sydney)
“Immune protection factors of sunscreens” (awarded FC Florance-Ewan Murray Will Grant)

North American Clinical Dermatology Society Meeting, 1998 (Sydney)
“Sunscreens, sunlight and immunosuppression”

4th World Conference on Melanoma, 1997 (Sydney)
“Diagnostic quiz” - epiluminescence microscopy workshop

International Federation of Sunscreen and Cosmetic Chemists, 1996 (Sydney)
“Sunscreens and UV induced immunosuppression”

Presentations from submitted abstracts

Australasian College of Dermatologists 49th Annual Scientific Meeting, 2016 (Perth)
Necotinamide for skin cancer chemoprevention: the ONTRAC study and clinical practice
-Awarded F&E Bauer Prize for best presentation of the conference

Australasian College of Dermatologists 49th Annual Scientific Meeting, 2016 (Perth)
Oral nicotinamide reduces transdermal water loss: a randomised controlled trial

Australasian College of Dermatologists 49th Annual Scientific Meeting, 2016 (Perth)
Nicotinamide for skin cancer chemoprevention after renal transplant

European Association for Dermato Oncology and Skin Cancer Centres Meeting, 2015, Marseille
Nicotinamide chemoprevention: the ONTRAC study

15th World Congress on Cancers of the Skin, 2014 (Edinburgh)
Nicotinamide chemoprevention

44th Annual Meeting of the European Society for Dermatology Research, 2014 (Copenhagen)
Nicotinamide enhances DNA repair

World Congress of Melanoma, 2013 (Hamburg)
Nicotinamide for skin cancer chemoprevention

Clinical Oncology Society of Australasia Annual Meeting, 2012 (Brisbane)
“Topical diphencyprone immunotherapy for cutaneous metastatic melanoma”

Clinical Oncology Society of Australasia Annual Meeting, 2012 (Brisbane)
“Skin cancer chemoprevention with nicotinamide” (poster)

The Australasian College of Dermatologists Annual Scientific Meeting, 2012 (Brisbane)
“Topical diphencyprone immunotherapy for melanoma”

International Melanoma and Skin Cancer Centres meeting, 2011 (Tampa)
“Nicotinamide for skin cancer prevention” (poster presentation)

International Melanoma and Skin Cancer Centres meeting, 2011 (Tampa)
“Diphencyprone immunotherapy for recurrent melanoma” (poster presentation)

European Society for Dermatology Research Annual Meeting, 2011 (Barcelona)
“Nicotinamide for skin cancer prevention” Oral presentation and poster: selected by faculty of 1000 as an important article; F1000 Posters 2011, 2: 1491

European Society for Dermatology Research Annual Meeting, 2011 (Barcelona)
“Diphencyprone immunotherapy for recurrent melanoma” (poster presentation)

The Australasian College of Dermatologists Annual Scientific Meeting, 2011 (Perth)
“Photodynamic therapy-induced immune suppression”

Australasian Society for Dermatology Research Annual Meeting, 2011 (Perth)
“Nicotinamide for skin cancer prevention”

The Australasian College of Dermatologists Annual Scientific Meeting, 2010 (Darwin)
“Topical diphencyprone immunotherapy for extensive cutaneous metastatic melanoma.”

The Australasian College of Dermatologists Annual Scientific Meeting, 2010 (Darwin)
“Nicotinamide for photoprotection.” Awarded FC Florance-Ewan Murray Will Grant (best immunology research presentation)

Grand Rounds, Royal Prince Alfred Hospital March 2010
“Nicotinamide for skin cancer chemoprevention”

Grand Rounds, Royal Prince Alfred Hospital November 2010
“Topical immunotherapy for cutaneous melanoma metastases”

7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology, 2009 (Vienna).
Topical diphencyprone immunotherapy for extensive cutaneous metastatic melanoma.

10th International Congress of Dermatology, 2009 (Prague).
Topical diphencyprone immunotherapy for extensive cutaneous metastatic melanoma.

Clinical Oncological Society of Australia Annual Scientific Meeting, 2008 (Sydney)
“Nicotinamide (vitamin B3) protects against the immune effects of UV radiation in humans.”

The Australasian College of Dermatologists Annual Scientific Meeting, 2008 (Sydney)
“Topical immunotherapy for cutaneous metastatic melanoma” Awarded FC Florance-Ewan Murray Will Grant (best immunology research presentation)

The Australasian College of Dermatologists Annual Scientific Meeting, 2008 (Sydney)
“Ultrasound therapy for lipodermatosclerosis”

21st World Congress of Dermatology, 2007 (Buenos Aires).
“Topical and oral nicotinamide (vitamin B3) prevents ultraviolet radiation-induced immunosuppression in humans”.

The Australasian College of Dermatologists Annual Scientific Meeting, 2007 (Adelaide)
Treatment of extensive cutaneous melanoma metastases with topical diphencyprone.” (poster)

European Society for Dermatology Research Annual Meeting 2006 (Paris)
“Effect of topical nicotinamide on UV immunosuppression in humans” (poster presentation) Awarded Best Poster.

The Australasian College of Dermatologists Annual Scientific Meeting, 2005 (Perth)
“Effect of topical nicotinamide on UV immunosuppression in humans” Awarded FC Florance-Ewan Murray Will Grant

The Australasian College of Dermatologists Annual Scientific Meeting, 2004 (Sydney)
“Photodynamic therapy with 5-ALA and a narrow band red light source”

The Australasian College of Dermatologists Annual Scientific Meeting, 2000 (Sydney)
“Sunscreen sun protection factors vary with skin colour and minimal erythema dose”

American Society for Photobiology 27th Annual Meeting, 1999 (Washington DC)
“UVA and UVB have different time-courses for suppression of contact hypersensitivity to a recall antigen in humans”

Liverpool Hospital Grand Rounds presentation, 1999
“Wegener’s granulomatosis”

Annual Meeting of the Australasian Society for Experimental Pathology, 1998 (Sydney)
“Relative contribution of UVB and UVA to UV-induced immunosuppression in humans”

7th World Congress on Cancers of the Skin, 1998 (Rome)
“Relative contribution of UVB and UVA to ultraviolet radiation induced immunosuppression in humans, and implications for Immune Protection Factor determination of sunscreens”

Pharmaceutical and Biotechnology Forum, University of Sydney, 1998
“Immune Protection Factors of sunscreens”
Spring Meeting of the Australasian College of Dermatologists, 1997 (Hobart)
“Relative contribution of UVA and UVB to ultraviolet radiation-induced immunosuppression in humans, and implications for Immune Protection Factor determination of sunscreens”

63rd Annual Meeting of the Royal Prince Alfred Hospital Medical Officers Association 1997
“Effect of ultraviolet radiation on Mantoux reactions in humans” (Winner, best presentation)
“Prediction of minimal erythema dose with a reflectance melanin meter” (poster presentation)

4th World Conference on Melanoma, 1997 (Sydney)
“Effect of ultraviolet radiation on Mantoux reactions in humans” (poster presentation)

Mount Buller Conference on the Health and Environmental Effects of UV Radiation, 1996
“Do sunscreens protect against ultraviolet radiation-induced immunosuppression?”
“Naevi and melanoma: have we clarified the relationship?” (paper presented on behalf of Professor W McCarthy)

Clinical Oncological Society of Australia Annual Scientific Meeting, 1996 (Brisbane)
“Diffuse axial skeleton infiltration as the initial presentation of metastatic melanoma” (poster)

2nd Sydney University Faculty of Medicine Research Conference, 1996 (Wollongong)
“Effect of sunscreens on UV-induced suppression of contact sensitivity to a recall antigen in humans”

12th International Congress of Photobiology, 1996 (Vienna)
“Effect of sunscreens on ultraviolet radiation-induced suppression of contact sensitivity to a recall antigen in humans”

The Australasian College of Dermatologists Annual Scientific Meeting, 1996 (Brisbane)
“Effect of sunscreens on ultraviolet radiation-induced suppression of contact sensitivity to a recall antigen in humans” F & E

Bauer prize for best paper
“Prediction of minimal erythema dose with a reflectance melanin meter” (poster presentation- awarded Best Poster)
“Diffuse infiltration of the axial skeleton as the initial presentation of metastatic melanoma” (poster presentation)

Clinical Oncological Society of Australia Annual Scientific Meeting, 1995 (Canberra)
“Metastatic melanoma: the role of positron emission tomography in staging and management”

The Australasian College of Dermatologists and Japanese Dermatological Association Joint Meeting, 1995 (Cairns)
“Positron emission tomography for the staging and management of metastatic melanoma”

Published abstracts
12. Damian DL. Topical immunotherapy with diphenycpronyle for cutaneous metastatic melanoma. Asia Pacific J Clin Oncol 8(S3): S154, 2012 (received Best of the Best Oral Award)
16. Damian DL. Surjana D, Martin AM, Halliday GM. Oral nicotinamide for skin cancer prevention. Proceedings of the 41st annual meeting of the European Society for Dermatological Research, Barcelona, Sep 7-10 2011. J Invest Dermatol, 131 Supplement 2, pS99 Identified by the Faculty of 1000 (Photobiology; Professor Peter Wolf) as a particularly important development in the field (September 2011)
21. Frost GA, Halliday GM, Damian DL. Photodynamic therapy-induced immunosuppression is prevented by slowing the rate of light delivery. Australas J Dermatol 51 (Suppl), A4, 2010 G Frost received inaugural Eileen Collins Memorial Award for best presentation by a registrar in NSW
36. Damian DL, Barnetson RSIC, Halliday GM. UVA and UVB have different time-courses for suppression of
contact hypersensitivity to a recall antigen in humans. *Photochemistry and Photobiology* 69:96S, 1999


Conference abstracts


15. Surjana D, Halliday GM, Damian DL. Nicotinamide Supplementation Reduces Actinic Keratoses. Presented as oral presentation at Bosch Institute Young Investigators Symposium (as part of Bosch Institute Annual Scientific Meeting). Sydney, 29-30 November 2010 p95
16. Surjana D, Halliday GM, Damian DL. Chemoprevention of Actinic Keratoses by Oral Nicotinamide. Presented as oral presentation at Mutagenesis and Experimental Pathology Society of Australasia Annual Scientific meeting (as part of The Australian Health Medical Research Congress), Melbourne, 14-18 November 2010 p286
17. Surjana D, Halliday GM, Damian DL. Nicotinamide Protects Ultraviolet-induced DNA damage by Enhancing DNA Repair. Presented as oral presentation at Mutagenesis and Experimental Pathology Society of Australasia Annual Scientific Meeting, Sydney, 1-4 December 2009 p55


Presented by Y Renwick; awarded best student presentation


37. Patterson CRS, Halliday GM, Barnetson RSIC, Damian DL. Ultraviolet radiation-induced immunosuppression in humans is prevented by topical nicotinamide (vitamin B3) and is greater in men than women. Proceedings of the 11th congress of the European Society for Photobiology, Aix-Les-Bains, France, September 2005. p84


47. Damian D, Barnetson R, Halliday G. Immune Protection Factors of Sunscreens. Pharmaceutical and Biotechnology Forum, the University of Sydney, March 1998


24. Dr Gerald Fogarty

Publications


Submitted publications


2017 De Moraes LPB, et al. Large solitary distant metastasis of cutaneous squamous cell carcinoma to skin graft site with complete response following definitive radiotherapy. IJB 2017

25. Dr Mark Hanikeri

Publications


Speeches/lectures & Development of related materials, including guidelines, standards, educational materials or fact sheets & Other (e.g. unpaid advisory roles)

Presentations

1997
Annual Scottish-Irish Meeting, Aberdeen, Scotland
The Use of Large Full-Thickness Skin Grafts for Resurfacing Post-burn Contractures on the Face and Neck

2001
Annual Australian and New Zealand Plastic Surgery Registrar Conference, Brisbane
Secretan Disorder, A Differential Diagnosis for Chronic Hand Swelling
Western Australian Hand Surgery Society, Perth
Current Concepts in Management of Neuromas of the Upper Limb

2002
Australian and New Zealand Plastic Surgery Registrar Conference, Perth
Antenatal Diagnosis of Cleft Lip and Palate in Western Australia
Royal Australasian College of Surgeons Annual Scientific Congress, Adelaide
Accuracy of Antenatal Diagnosis of Cleft Lip and Palate in Western Australia 1996-2000; Implications on Management
Royal Australian College of Surgeons, Grand Round, Brisbane
Current Trends in Breast Reconstruction

2003
Annual Australian and New Zealand Plastic Surgery Registrar Conference, Perth
The Use of Anatomical Modelling in Planning Craniofacial Surgery in Western Australia
Biannual Meeting of the Australasian Cleft Lip and Palate Association, Sydney
Antenatal Transabdominal Ultrasound Detection of Cleft Lip and Palate in Western Australia from 1996 to 2003

2005
GP Presentation, Mercy Hospital, Perth
Facial Rejuvenation Surgery
Western Australia Melanoma Advisory Service
Newer Techniques in Melanoma Staging (sentinel node biopsy/PET scanning) -- when should they be done?

2009
Great Southern General Practitioner Network, Albany
Management of Cutaneous Malignancies
Western Australia Melanoma Advisory Service
Overview of Model of Care for Melanoma - implications for GP's and indications for referral.

2010
Cutting Edge Course for Rural GP's
Principals of Skin Flaps
Day Surgery Nurses Association Conference
Principals of Facial Rejuvenation

Inaugural ‘Scott Kirkbride’ Conference on Advances in Management of Cutaneous Malignant Melanoma
Melanoma – Challenges to the Plastic Surgeon

Western Australia Melanoma Advisor Service: Melanoma Update
Chaired Meeting

2011

Western Australia Melanoma Advisory Service
The Great Debates: Two Major Controversies in the Clinical Management of Malignant Melanoma
Moderator and Chair

QBE, St Georges Terrace, Perth
Commonly Missed Hand Injuries

Gorgon Gas Project, Barrow Island
Getting to Grips with Workplace Injuries

St John Ambulance, Belmont
Commonly Missed Hand Injuries

2012

QBE, St Georges Terrace, Perth;
Bunbury Emergency Department and Busselton Emergency Department
Commonly Missed Hand Injuries

2013

Western Australia Melanoma Advisory Service
The Role of WAMAS and Referral Process

WA Melanoma Multidisciplinary Treatment Centre Forum
Chaired Session

Kalgoorlie Emergency Department and Barrick Mining Kalgoorlie;
Newman Emergency Department, Atlas Copco and BHP Area C, Newman
Getting to Grips with Workplace Injuries

2014

Albany Emergency Department
Commonly Missed Hand Injuries

WA Cancer Education Meeting Series
Chaired Session: Sentinel Node Biopsy for Melanoma Patients

2015

Albany Emergency Department
Hand and Wrist Plastering Workshop

Armadale Emergency Department
Commonly Miss Hand Injuries

2nd Global Advances in Controversies in Skin Cancer, Brisbane
Chaired Session: Squamous Cell Carcinoma
Presented: Recurrent Infiltrative Basal Cell Carcinoma, How Would I Like it to be Treated if it was on My Face

Western Australia Melanoma Advisory Service
The Future for Melanoma Treatment in WA

2016

Fiona Stanley Hospital
Suturing Workshop

Allianz Insurance
Hand Education Session

Collie Emergency Department and GP’s
Commonly Missed Hand Injuries and Case Examples

2017
IMA Forum
Functional Recovery After Hand Injury
General Practitioner Education, Bethesda Hospital
Management of Skin Cancers in General Practice
General Practice Conference & Exhibition
Assessment and Management of Melanoma and Non-Melanoma Skin Cancers in General Practice
Western Australian Clinical Oncology Group
Melanoma Clinical Education Update
Notre Dame Association of Surgical Specialties
The Diversity in Surgery Workshop
Sir Charles Gairdner Hospital Interns – 2006 and 2007
Breast Bumps and Botox…and Other Plastic Surgery Challenges

Annual presentations
Breast Bumps and Botox…and Other Plastic Surgery Challenges
Year 6 Medical Students – 2006 to 2015
Plastic Surgery Challenges
Sir Charles Gairdner Hospital Interns – 2008, 2009 and 2010
Plastic Surgery Challenges
A New Model of Care for Management of Cutaneous Malignant Melanoma
26. Dr Craig James

Publications


64. Rajak SN, James C, Selva D. "The clinical, histologic and immunohistochemical characteristics and nomenclature of meibomian gland ductal cysts (intratarsal keratinising cysts) and steatocystoma". Eye (Lond). 2017; 31(5): 736-40.
73. RCPA Skin macroscopic cutup protocols working group 2014.
74. RCPA cutaneous, mucosal melanoma and carcinoma of the salivary gland synoptic structured pathology reporting subcommittee member 2015 and 2018.
75. SA Head and Neck cancer pathway working committee member 2014.

Speeches/lectures

19. James, CL – “Skin Pathology (Lectures 1 and 2)”. Royal Adelaide Hospital Department of Plastic Surgery (2000).
22. James, CL – “Squamous Cell Carcinoma of the upper aerodigestive tract.” College of Surgeons (Ear, Nose and Throat), Education Meeting, Adelaide (December 2001).
28. James, CL – “The Folliculitis histologic pattern and its clinical correlates.” Bimonthly meeting of the South Australian Faculty of the College of Dermatologists, Flinders Medical Centre (October 2003).
31. James, CL – “Squamous neoplasia of the upper aerodigestive tract” and “ENT Quiz” National ENT Registrars meeting, Royal Adelaide Hospital (August 2005).
34. James, CL – “How I approach skin appendage tumours” South Australian Histopathology trainees, Adelaide Pathology (June 2006).
40. James, CL – “What you should expect to find in a pathology report for cutaneous melanoma”. South Australian Chinese Medical Association meeting (June 2007).
27. A/Professor Chris McCormack

Publications


28. Prof Catriona McLean

Publications

- Stephen Luen, Siew Wei Wong, Victoria Mar, John W Kelly, Catriona McLean, Grant A McArthur, Andrew Haydon: Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics. American journal of clinical oncology 08/2015;
29. A/Professor Bernard Mark Smithers

Speeches/lectures (2013-2018)

2017:
Update on Sentinel node biopsy for melanoma: where does it fit in our armamentarium
Annual Scientific Meeting, Australia and New Zealand Society of Plastic Surgeons, Gold Coast, Australia

Update on the role of sentinel node biopsy for cutaneous melanoma
HealthCert 9th Skin Cancer Summit and Masterclasses

2016:
Management of Special Site Primary Melanomas
Sentinel Node Biopsy – when and how it may affect treatment
Panel Discussion
Annual Scientific Meeting, Skin Cancer College of Australia, Gold Coast,

Melanoma in the Adolescent and young Adult - local excision and follow up plans.
Queensland Youth Cancer Service, Brisbane

When should I recommend sentinel lymph node biopsy.
Standards in Skin Cancer Surgery – Primary Cutaneous Melanoma
Annual Skin Cancer Conference, HealthCert, Brisbane

2013:
The surgical management of primary cutaneous melanoma
3rd Skin Cancer Conference, Bali, Indonesia

Sentinel node biopsy in Brisbane
Global Controversies in Skin Cancer, Brisbane, Australia


30. Mr John Spillane

Publications & Speeches/lectures & Development of related materials, including guidelines, standards, educational materials or fact sheets

Book Chapters:
- PET/CT in Melanoma.
  Editors: Hofman MS & Hicks RJ.
  Melanoma: Spillane JB, Henderson MA, McArthur GA

- Textbook of Complex General Surgical Oncology
  Editors: Morita SY, Balch CM, Klimberg VS, Pawlik TM, Posner MC, Tanabe KK.
  Chapter 20: Noncutaneous Melanoma. Henderson MA, Spillane J & Gyorki D.

Publications:

Posters:

4. Surgical management of melanoma in older patients, the impact of increasing age. Matthew J Rees1, Henry Liao1, Imogen Walpole1, Alexandra Sanelli1, John Spillane1, David Gyorki1, David Speakma1, Chris McCormack1, Angela Webb1, Michael A. Henderson1. Poster at the Society of Surgical Oncology Meeting Houston Texas USA 2015.


7. The Desmoplastic melanoma subtype: Clinical behaviour and guidelines for management. Shen S, Rozen WM & Spillane JB. Poster at the Royal Australian College of Surgeons Annual Scientific Meeting- Adelaide 2011


Publications


### Funding

#### Personal Support

<table>
<thead>
<tr>
<th>Year</th>
<th>Fellowship/Grant Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016 – 19</td>
<td>Victorian Cancer Agency Clinical Research Fellowship, AUD$800K</td>
<td></td>
</tr>
<tr>
<td><strong>Past</strong></td>
<td><strong>Current</strong></td>
<td></td>
</tr>
<tr>
<td>2011 – 15</td>
<td>Pfizer Australia Senior Research Fellowship, AUD$1M</td>
<td></td>
</tr>
<tr>
<td>2010 – 12</td>
<td>Innovation Fellowship, veski AUD$150K</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>Career Development Award 1, NHMRC, Australia, AUD$94K (then declined)</td>
<td></td>
</tr>
<tr>
<td>2007 – 10</td>
<td>Long-Term Fellowship, Human Frontier Science Programme, France, USD$78K</td>
<td></td>
</tr>
<tr>
<td>2006 – 10</td>
<td>Neil Hamilton Fairley Training Fellowship, NHMRC, AUD$168K (then declined)</td>
<td></td>
</tr>
<tr>
<td>2005 – 7</td>
<td>Australia Post Fellowship, Royal Australasian College of Physicians, AUD$50K</td>
<td></td>
</tr>
<tr>
<td>2004 – 5</td>
<td>Edith Moffat Scholarship, The Walter &amp; Eliza Hall Institute, Australia, AUD$24K</td>
<td></td>
</tr>
<tr>
<td>2001 – 4</td>
<td>Medical and Dental Post-Graduate Scholarship, NHMRC, Australia, AUD$95K</td>
<td></td>
</tr>
</tbody>
</table>

#### Project Support

<table>
<thead>
<tr>
<th>Year</th>
<th>Grant Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017 – 9</td>
<td>Melanoma Research Alliance Pilot Award, USD$100K (Shackleton) – &quot;Dissecting the significance of pigment heterogeneity in cutaneous melanoma&quot;</td>
<td></td>
</tr>
<tr>
<td>2016 – 9</td>
<td>NHMRC Project Grant ID APP1107126, AUD$1,299K (Dawson, Shackleton) – &quot;Circulating tumour DNA as a noninvasive biomarker in melanoma&quot;</td>
<td></td>
</tr>
<tr>
<td>2015 – 8</td>
<td>NHMRC Project Grant ID APP1080253, AUD$812K (Shackleton) – &quot;Deciphering mechanisms of disease evolution in melanoma&quot;</td>
<td></td>
</tr>
<tr>
<td>2015 – 7</td>
<td>Cancer Council of Victoria Project Grant ID APP1080255, AUD$300K (Shackleton, Harvey) – &quot;Melanoma and the Hippo pathway&quot;</td>
<td></td>
</tr>
<tr>
<td>2015 – 6</td>
<td>Bristol-Myers-Squibb Development Grant AUD$100K (Shackleton)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&quot;Characterization and comparison of spatio-temporally separated tumor-associated immune microenvironments in melanoma patients.&quot;</td>
<td></td>
</tr>
<tr>
<td>2015 – 6</td>
<td>Peter MacCallum Cancer Centre Foundation Grant AUD$50K (Shackleton)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&quot;A phase 1 clinical trial of simvastatin combined with BRAF and MEK inhibition in advanced BRAF mutant melanoma.&quot;</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>Equity Trustees (Shackleton) AUD$30K</td>
<td></td>
</tr>
<tr>
<td>2014 – 6</td>
<td>NHMRC Project Grant ID APP1058897, AUD$640K (Shackleton, Marine)</td>
<td></td>
</tr>
</tbody>
</table>
"Suppressing MDM4 in melanoma"


2013 – 5 NHMRC Project Grant ID APP1042980, AUD$555K (Ferrao, McArthur, Bollag, Shackleton) – “Overcoming Receptor Tyrosine Kinase mediated resistance to BRAF Inhibitors in metastatic melanoma, colorectal and lung cancers”

2013 – 4 Peter MacCallum Cancer Centre Foundation Grant AUD$50K (Shackleton)

“Application of transposon mutagenesis to dissect drug resistance in melanoma”

2012 – 14 NHMRC Project Grant ID APP1022150, AUD$574K (Bonder, Shackleton) – “Functional characterisation of a new surface adhesion molecule on human vascular progenitor cells to combat cancer”

2011 – 2013 NHMRC Project Grant ID APP1008790, AUD$640K (Shackleton)

“The nature and significance of clonal evolution in human melanoma”


2011 Ramaciotti Foundation Establishment Grant, AUD$75K

 Infrastructure Support

2017-9 Melanoma Patients Australia – Melanoma March Project, AUD$585K (Shackleton) ‘AXMAP – the Australian pdX Melanoma Project.’

2017 ACRF Cancer Research Grants, AUD$2M (Dawson SJ, Bowtell, Dawson M, Johnstone, Hicks, Loi, Shackleton, Grimmond, Papenfuss) – ‘The ACRF Tumor Heterogeneity Program’

2013 ACRF Cancer Research Grants, AUD$3.5M (Russell, Boussioutas, Ellis, Fox, Gu, Humbert, Pearson, Ritchie, Rossi, Shackleton, Stacker, Trapani, Zalcberg) – ‘The ACRF Advanced Centre for Cancer Cell Isolation and Imaging at the Peter MacCallum Cancer Centre’

Publications

Publication summary and citation metrics (11 years post-PhD)

- First/senior author papers = 9 (two in Nature, one in Cancer Cell)
- Minor author papers = 29
- Review articles = 10 (one in Cell, one in the N Eng J Med; all invited)
- Book chapters = 2 (invited)
- Total citations = 9087
- H index = 26

Original Research [Citations]


Reviews [Citations]


Book Chapters [Citations]


Miscellaneous


Scientific Presentations – Speaker

1. 2017 COSA (Clinical Oncology Society of Australia) ASM, Sydney Australia, 13 – 15 November 2017 (invited session chair)
2. ‘Cancer heterogeneity: unassailable foe or Achilles’ heel?’ Eastern Health, Melbourne Australia, November 2017 (invited speaker).
3. ‘The role of co-operative trials groups in melanoma research’ 9th World Congress of Melanoma, Brisbane Australia, 18 – 21 October 2017 (invited speaker, session chair, funded).
4. ‘Melanoma heterogeneity – the elephant in the room’ Melanoma Research and Therapy Meeting, Queenstown NZ, September 8 – 10 2017 (invited speaker, fully funded).
5. ‘Melanin pigment and melanoma heterogeneity’ 2017 International Pigment Cell Conference (Breakthroughs in Pigment Cell and Melanoma Research), Denver Colorado, August 26 – 30, 2017 (invited speaker, session chair, funded).
7. ‘Determinants and consequences of melanoma heterogeneity’ Tumour Heterogeneity and Cellular Plasticity Symposium, Melbourne Australia, April 2017 (invited speaker).
9. ‘Large-scale chromosomal changes dominate the genomic landscape of end-stage melanoma’ Society of Melanoma Research Annual Meeting, Boston USA. November 2016 (selected for oral presentation).
12. ‘Cancer heterogeneity – causes and consequences’ Western Hospital, Melbourne Australia, October 2016 (invited speaker).
14. ‘Follow up of patients at high risk of relapse: What is the role of surveillance imaging?’ Locoregional Melanoma Conference, Melbourne Australia, August 2016 (invited speaker).
15. ‘Melanoma and immunotherapy’ Locoregional Melanoma Conference, Melbourne Australia, August 2016 (session chair).
16. ‘Predicting evolutionary change in melanoma’ Melbourne Melanoma Project Annual Scientific Exchange, February 2016 (invited speaker).
18. ‘Causes and consequences of cancer heterogeneity’, Medical Oncology Group of Australia Sciences of Oncology Program, Melbourne, November, 2015 (organizing committee chair, invited speaker)
19. ANZMTG Annual Meeting, Auckland New Zealand, November 2015 (invited session chair, Member of Executive Committee)
20. 2nd Thomas Ashworth CTC Symposium, Melbourne Australia, October 2015, (invited session co-chair)
21. ‘Studies in melanoma evolution’, Peter MacCallum Cancer Centre Research Seminar Series, October 2015 (invited speaker)
22. ‘Causes and consequences of melanoma heterogeneity’, University of Zurich, Switzerland, September 2015 (invited speaker).
24. ‘Advances in melanoma’. MOGA ASM 2015, Tasmania, August 2015 (invited session chair)
27. ‘Convergent de-differentiation during intra-patient evolution in therapy naïve melanoma’
29. ‘Orientation of precision cancer medicine in time, place and person’ Precision Medicine Symposium, Sydney, April 2015. (invited speaker, funded by Peter MacCallum Cancer Centre)
30. ‘Convergent intra-patient evolution in therapy naïve melanoma’. Cancer and Evolution Symposium, University of Sydney Cancer Research Network (CRN), April 2015 (invited speaker, fully funded)
32. ‘Pervasive evolutionary potential among human melanoma cells revealed by clonal tumorigenesis assays’ Karolinska Institute Symposium, Stockholm, Sweden, November 2014 (declined due to illness, invited speaker, fully funded)
33. ‘Cancer and development’ Medical Oncology Group of Australia - Annual ‘Sciences of Oncology’ Meeting, Melbourne, November 2014 (invited speaker, conference organizing committee chair).
34. ‘Convergent de-differentiation during intra-patient evolution in therapy naïve melanoma’ 2nd Australian National Melanoma Conference 2014 Combination therapies: towards a cure (for melanoma), Perth, WA, October 2014 (invited fully funded keynote speaker).
35. 'Studies of melanoma maintenance and progression' WEHI Systems Biology & Personalised Medicine Division Seminar, July 2014 (invited speaker).
36. ‘Research in Medical Practice’ University of Melbourne Doctor of Medicine Student Conference, Melbourne, July 2014 (invited speaker).
37. 'Opportunities for studying disease evolution within individual melanoma patients' Melanoma Genome Project Resource Meeting, Sydney, June 2014 (invited speaker).
38. 'Intra-patient evolution of melanoma', Australian College of Dermatology Annual Scientific Meeting, Melbourne, May 2014 (invited speaker).
39. 'New Age Melanoma.' Australian Dermatology Nurses Association National Conference, Melbourne, May 2014 (invited).
40. 'How do melanomas grow? Biological paradigms of disease heterogeneity and progression’ WAIMR (Western Australian Institute for Medical Research) Seminar Series, Perth (invited fully funded speaker), March 2014.
42. 'Pervasive evolutionary potential among tumourigenic melanoma cells', AMATA 2013 Conference, Surfers Paradise. October 2013 (invited Keynote Speaker – fully funded).
43. Deakin University School of Medicine Research Seminar Series, Melbourne, October 2013 (invited speaker).
44. Australian Dermatology Nurses of Australia (ADNA) Victorian Education Day, Melbourne September 2013 (invited speaker).
45. 'The basis of cellular heterogeneity in melanoma.' Monash Research Seminar Series September 2013 (invited speaker).
46. 'Opportunities and challenges for personalized cancer medicine.' Epsworth Grand Round Seminar Series, September 2013 (invited speaker).
47. 'Out damned spot! Out I say!' Gaining the upper hand against melanoma.“ Fiona Elsey Cancer Research Institute 2013 Seminar Series, Ballarat Cancer Research Centre, September 2013 (invited speaker).
48. 'Opportunities and challenges in personalizing cancer medicine. ISOPP (International Society of Oncology Pharmacy Practitioners) Regional Meeting, Melbourne, August 2013 (invited speaker).
49. 'Out, damned spot!' Gaining the upper hand against Australia's disease, Melbourne University Health Initiative (MUHI) Public Lecture, Melbourne, August 2013 (invited speaker).
50. 'Stem Cells and Differentiation’ Frontiers in Human Disease in the Department of Pathology at the University of Melbourne, August 2013 (invited speaker).
51. 'Limitations of 2-dimensional personalised cancer medicine. "Driving personalised cancer medicine through next generation sequencing”, Adelaide, July 2013. (Invited and funded speaker).
52. 'Systemic therapy for melanoma – vive la revolution! Cancer Nursing Society of Australia, Melbourne, June 2013 (invited speaker).
53. 'The basis of melanoma heterogeneity. – Peter MacCallum Cancer Centre Research Seminar Series, June 2013 (invited speaker).
56. 'The cancer stem cell model: time to raise the bar. ABCAM International Meeting, Stem Cells and Cancer, Melbourne, April 2013. (invited speaker).
57. 'Identifying biological paradigms of melanoma progression. 2013 AACR Annual Meeting, Washington DC, USA, April 2013. (invited and funded speaker).
58. MEPSA (Molecular & Experimental Pathology Society of Australasia) to be held in conjunction with AHMRC (Australian Medical Research Congress), Adelaide, November 2012. (invited and funded plenary speaker).
59. 'Insights into human melanoma biology through in vivo modelling’. Dept of Stem Cell Biology, MRI, Tokyo Medical & Dental University, November 2012 (invited and funded speaker).
61. SMR Meeting, USA. November 2012 (Member of committee organizing scientific program, invited and funded session co-chair and oral abstract presenter).
63. 'Modeling evolutionary change in human melanoma. QIMR Research Seminar, Qld, Sep 2012 (invited, funded).
64. 'Theories of relativity: post-Einsteinian understanding of melanoma progression. ADS Annual Meeting, Melbourne, September 2012. (invited keynote speaker).
65. 'The dynamism of human melanoma, Children's Cancer Institute Australia (CCIA) Seminar Series, Sydney, June 2012. (invited and funded).


69. Evolutionary change in human melanoma. MMRI Annual Stem Cells Symposium 2012, Brisbane. May 2012. (invited and funded)

70. Advances in melanoma. ANZ GOG Scientific Meeting, February 2012. (invited and funded)


72. Dynamic intratumoral evolution of human melanoma. 8th International Melanoma Research Congress, Tampa Bay, November 2011

73. The evolution of human melanoma. LICR Translational Oncology Conference, Melbourne, October 2011 (invited)


77. Melanoma Progression. 7th International Melanoma Research Congress, Sydney, November 2010 (invited, fully funded)

78. Heterogeneity among human melanoma cells that is not hierarchically organized. Lorne Cancer Conference, Melbourne, February 2010 (invited, fully funded)

79. Modeling the evolution of human melanoma. Melbourne Melanoma Project Annual Scientific Meeting, September 2011

80. Melanoma maintenance and propagation. Queensland Diamantina Institute, Brisbane, September 2011

81. Stem Cells and Cancer. University of Melbourne, Melbourne, August 2011

82. Mechanisms of melanoma progression. Centenary Institute, Sydney, August 2011

83. Mechanisms of melanoma progression. Monash University, Melbourne, May 2011

84. Xenografting - achievements and future prospects. Melbourne Melanoma Project Annual Scientific Meeting, November 2010

85. Melanoma Progression. The Hanson Centre for Cancer Research, Adelaide, October 2010.

86. Understanding melanoma progression. St. Vincent’s Research Institute, Melbourne, September 2010.

87. Understanding melanoma progression. Ludwig Institute, Melbourne, September 2010.


93. Melanoma Stem Cells. Department of Dermatology, University of Michigan, Ann Arbor, November 2009.

94. Are cells with tumorigenic potential common or rare in melanoma? Melanoma Research Alliance Conference, Washington DC, February 2009 (invited, fully funded)


98. The hunt for mammmary stem cells. Dept. of Surgery, Royal Melbourne Hospital, Melbourne, April 2006.

99. The hunt for mammmary stem cells. Peter MacCallum Cancer Institute, Melbourne, April 2006.


106. Generation of a functional mammmary gland from a single stem cell. Royal Melbourne Hospital Research Week, Melbourne, June 2005 (invited)
Teaching and Education Presentations

1. *Melanoma and immunotherapy*. North West Regional Hospital, Burnie, June 2017
2. *Immunoncology*. Barwon Health, Geelong, May 2017
3. *Melanoma*. Australian Cancer and Health Sciences Competition (ACHSC), WEHI, Melbourne, October 2016
4. *Immunoncology and melanoma*. Peter MacCallum Cancer Centre BMS Preceptorship, Melbourne, April 2016
5. *Systemic therapy of melanoma*. Peter MacCallum Cancer Institute Melanoma Education Symposium, Melbourne, March 2016
6. *Systemic therapy for melanoma*. Presentation to Peter Mac Radiation Oncology Registrars, Peter MacCallum Cancer Centre, September 2015
7. *Stem cells and differentiation*. University of Melbourne Pathology Department, August 2015.
9. *Systemic treatment of melanoma*. Nursing Staff, Peter MacCallum Cancer Centre, Melbourne, August 2014
10. *Stem cells and differentiation*. University of Melbourne Pathology Department, August 2014.
12. *Stem cells and differentiation*. University of Melbourne Pathology Department, August 2013.
15. *Stem cells and differentiation*. University of Melbourne Pathology Department, August 2012.
17. *HMO tutorial series on career development*. Peter MacCallum Cancer Centre, Melbourne, April 2012.
18. *Systemic therapy of melanoma*. Peter MacCallum Cancer Institute Melanoma Education Symposium, Melbourne, March 2011
19. *The dawning age of effective therapies for melanoma*. Victorian Oncology Pharmacists Special Interest Group, Melbourne, October 2011
20. *Systemic therapy of melanoma*. Peter MacCallum Cancer Institute Nursing Education Seminar, Melbourne, July 2011

Lay Community Presentations - Speaker

1. ‘Cancer care and research at the Alfred in 2017 and beyond’ The Alfred Hospital, Melbourne December 2017 (invited)
2. ‘The Sound of Cancer’ Barking Spider Visual Theatre and La Trobe University Public Event, Melbourne November 2017 (invited)
3. ‘Integrating research and the clinical care of cancer patients’ The Monash Partners Comprehensive Cancer Consortium Public Forum, Melbourne October 2017 (invited)
4. ‘The power of consumers’ Aftershock Launch Event, Melbourne October 2017 (invited)
5. ‘Updates in melanoma treatment and research’ Rotary Australia, Melbourne February 2016 (invited)
6. The Altona Hockey Club Fundraiser Event, August 2015 (invited)
7. ‘The importance of supporting cancer research’ Ride to Conquer Cancer Fundraiser Event, Melbourne, August 2015 (invited speaker).
8. ‘Careers and directions in biomedical science’ The Walter and Eliza Hall Institute, Student Retreat 2015, Lancefield, April 2015 (invited)
10. ‘The importance of supporting cancer research’ Ride to Conquer Cancer Fundraiser Event, Melbourne, August 2014 (invited speaker).
11. veski High School Student Symposium, University High School and The Walter and Eliza Hall Institute, Melbourne, May 2013.
12. ‘Success and challenge in the fight against Australia’s disease’ Village Roadshow Donor Event, Melbourne, September 2013 (invited)
14. Why we need medical research. Peter MacCallum Foundation, Melbourne, September 2011
Publications


**Book Chapters**


iBook


**Speeches/lectures**

**Published Abstracts and Presentations**


13. Stretch J, Thompson J. Evolving the format of a melanoma centre in a changing health care system to maximize patient care, research and training. 7th World Congress on Melanoma/5th Congress of the European Association of Dermato-Oncology (EADO), Vienna, Austria, 12-16 May 2009.


Posters


**Convenor (International & Australian Meetings)**

- Convenor, Melanoma Education Evening, North Sydney, September 2013.
- Member of Organising Committee and Convenor, Society of Melanoma Research, 2010 Annual Congress, Sydney, November 2010.

**Invited Lecturer (to peer groups)**

- XXVIIIth Annual Meeting of the Japanese Skin Cancer Society. Sapporo, Japan. 29th – 30th June, 2012
- Advances in Melanoma Care Symposium, Coogee, Australia. Thompson J, Stretch JR. The Melanoma Institute Australia. 8-9 August 2009.
- XXth International Pigment Cell Conference/Vth International Melanoma Research Congress, Roiyton Sapporo, Japan. May 2008
- An overview of clinical & research practice at the Sydney Melanoma Unit. PLA- Privatiakarakademien (Swedish Academy of Physicians) January, 2007
- Review of SMU NMR Spectroscopy Research. Prince of Wales Multidisciplinary Oncology Group. 6th October 2006
- Melanoma; 2006 Overview. NSW Chapter of Royal Australasian College Surgeons. April 4th, 2006
- Clinical Melanoma Practice & Research at the Sydney Melanoma Unit. Shanghai Hospital, Second Military University. Shanghai, China
- The local dissemination of primary cutaneous melanoma. Danish Melanoma Group, Rigshospital. Copenhagen Denmark, April 2003.

**Conference Session Chairman:**

- Surgical Management Session. 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting, Sydney, Australia, 4-5 November, 2010.
• Melanoma Symposium. World Congress Plastic & Reconstructive Surgery, 2003, Sydney

Presentations

10. Local dispersal of melanoma: serial horizontal section survey of the operative specimen. Stretch JR. Presented at the scientific meeting of the U.K. melanoma study group. 1 June 1990, Leicester.
23. Local dispersal of cutaneous melanoma. Stretch JR. Guest lecturer for the Danish melanoma service. Rigshospitalet, Copenhagen, Denmark. 11 March 2002, Copenhagen.
27. The application of nuclear magnetic resonance spectroscopy to the study of tumour progression and metastasis in cutaneous melanoma. Stretch JR. Presented at Sydney Cancer Centre seminar. Centenary Institute, University of Sydney, 10 February 2003, Sydney.
28. The application of nuclear magnetic resonance spectroscopy to the study of tumour progression and metastasis in cutaneous melanoma. Stretch JR. Presented at the Who Mediterranean melanoma conference. 2 May 2003, Athens.
29. Detection of primary and metastatic melanoma with nuclear magnetic resonance spectroscopy. Stretch JR. Presented at the World Congress on Cancers of the Skin. 8 May 2003, Seville.
43. Fine needle biopsy in melanoma patients: an analysis of 2204 cases with implications for patient management. Murali R, Doubrovsky A, Watson GF, McKenzie PR, Lee CS, McLeod DJ, Uren RF,
Stretch JR, Saw RP, Thompson JF, Scolyer RA. Presentation at the Clinical Oncological Society of Australia Annual Scientific Meeting and Australian Health and Medical Research Congress. 1 December, 2006, Melbourne.


51. Stretch J, Thompson J. Evolving the format of a melanoma centre in a changing healthcare system to maximize patient care, research and training. 7th World Congress on Melanoma/5th Congress of the European Association of Dermato-Oncology (EADO), Vienna, Austria, 12-16 May 2009.


61. Stretch J. Development of informatics at Melanoma Institute Australia. 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting, Sydney, Australia, 4-5 November, 2010.


**Presentations to community based organizations & media**

1. *Melanoma & Skin Cancer*. Glenhaven Lions Club, 10 December, 2002
5. *Cancer Is...* A feature documentary for worldwide television distribution in 2009 highlighting international models of cancer care and research. Sponsored by:
   - International Agency for Research on Cancer
   - UICC: International Union Cancer Control
   - American Cancer Society

Development of related materials, including guidelines, standards, educational materials or fact sheets

Publications & Development of related materials, including guidelines, standards, educational materials or fact sheets

Publications (papers)


Publications (abstracts/letters)


Publications (books)
2016  Melanoma Principles and Practice – A Comprehensive Guide
  Editor  Co-author of 9 chapters
  Published by Melanoma Institute Australia, 2016, ISBN 9780992454838

2015  Melanoma Essentials – A Concise Guide
  Editor  Co-author of 5 chapters
  Published by Melanoma Institute Australia, 2015, ISBN 9780992454807

2010  Landscape Photographer of the Year: Collection 4

2009  Landscape Photographer of the Year: Collection 03

Publications (iPhone and iPad apps)
2015  Picturing-MD
  New iPad and iPhone pictorial learning tool, incorporating content of PicturingMed and PicturingSyndromes Apps, plus new theme of Signs and Symptoms. Now has hyperlinks to enable easy access to more information on topics for users and inbuilt sharing functionality.
  Role: developer

2011  PicturingMed
  Pictorial learning tool for the differential diagnoses of 37 presenting complaints commonly encountered in the medical patients.
~ 900 downloads
Role: developer
**2011**

**Picturing Syndromes**

Pictorial learning tool for the features of 30 syndromes encountered in the clinic.
~ 400 downloads
Role: developer

**2011**

**Leg Fractures**

Summary of BAPRAS/BOA 2009 lower limb trauma guidelines
~ 12000 downloads
Role: developer

**2010**

**PicturingED**

Pictorial learning tool for the differential diagnoses of 11 presenting complaints commonly encountered in the Emergency Department.
~ 12000 downloads
Role: developer

---

**Speeches/lectures**

**Presentations (National and International Meetings)**

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct 2017</td>
<td>Adherence to surgical melanoma guidelines in New South Wales of all newly diagnosed melanomas over a one-year period</td>
<td>9th World Congress of Melanoma, Brisbane, Australia</td>
</tr>
<tr>
<td>Nov 2015</td>
<td>Melanoma ebooks - keeping pace with the rapid progress at an affordable price with added utility</td>
<td>Global Advances and Controversies in Skin Cancer, Brisbane, Australia</td>
</tr>
<tr>
<td>Mar 2015</td>
<td>Risk of Second Primary Malignancies Increases with Melanoma Breslow Thickness</td>
<td>Society of Surgical Oncology Annual Meeting, Houston, Texas, USA</td>
</tr>
<tr>
<td>Mar 2015</td>
<td>Neurotropic Melanomas: Clinical Behaviour and Radiotherapy Responsiveness</td>
<td>Society of Surgical Oncology Annual Meeting, Houston, Texas, USA</td>
</tr>
<tr>
<td>Oct 2014</td>
<td>Neurotropic Melanomas: Clinical Behaviour and Radiotherapy Responsiveness</td>
<td>2nd National SKMRC Melanoma Conference, Perth, Australia</td>
</tr>
<tr>
<td>Apr 2013</td>
<td>Melanoma Lymphatic Assessment Prognostic Index Project (MeLAPIP)</td>
<td>Melanoma Focus Annual Scientific Meeting, Bristol, UK (Invited Speaker)</td>
</tr>
<tr>
<td>Nov 2012</td>
<td>The impact of no longer performing Staging CT scans on stage IIb/C melanoma patients</td>
<td>6th World Meeting of Interdisciplinary Melanoma/ Skin Cancer Centres /EADO, Barcelona, Spain</td>
</tr>
<tr>
<td>Sep 2012</td>
<td>Vitamin D deficiency is widespread in adult burns patients</td>
<td>ISBI Annual meeting, Edinburgh, UK</td>
</tr>
<tr>
<td>Dec 2011</td>
<td>The impact of no longer performing staging CT scans on stage IIb/C melanoma patients</td>
<td>British Association of Plastic Reconstructive and Aesthetic Surgeons Winter Scientific Meeting, London, UK</td>
</tr>
<tr>
<td>Nov 2011</td>
<td>Melanoma Lymphatic Density Prognostic Index Project (MeLyDy PIP) proposal</td>
<td>National Cancer Research Institute Melanoma CSG meeting, London, UK</td>
</tr>
<tr>
<td>Apr 2009</td>
<td>Splicing of RNA-binding protein TIA-1 regulates VEGF expression in colon cancer</td>
<td>British Microcirculation Society Annual Conference, Birmingham, UK</td>
</tr>
<tr>
<td>Mar 2009</td>
<td>Multifocal Extra-abdominal Desmoid Management</td>
<td>British Sarcoma Group Annual Meeting, Glasgow, UK</td>
</tr>
<tr>
<td>Sep 2008</td>
<td>Are complication rates for Breast Reconstruction Surgery affected by Body Mass Index (BMI)?</td>
<td>International meeting of Oncoplastic and Breast Reconstrucive Surgery, Nottingham, UK</td>
</tr>
<tr>
<td>Apr 2008</td>
<td>TIA-1 an RNA binding protein, upregulates the anti-angiogenic isoform of VEGF in colon cancer cells</td>
<td>British Microcirculation Society Annual Conference, London, UK</td>
</tr>
<tr>
<td>Apr 2007</td>
<td>Improving the targeting of bevacizumab therapy for colorectal carcinoma.</td>
<td>American Association for Cancer Research (AACR), San Diego, USA.</td>
</tr>
</tbody>
</table>
Apr 2007  Bevacizumab does not inhibit growth of LS174t tumours over-expressing VEGF165b.
British Microcirculation Society Annual Conference, Belfast, UK.

Oct 2006  Avastin binds VEGF165b (an endogenous anti-angiogenic protein, that inhibits human colon carcinoma tumour growth in vivo) with similar affinity to VEGF165.
National Cancer Research Institute Conference. Birmingham, UK.

July 2006  Anti-angiogenic VEGF-A Isoforms are Endogenous to Normal Colon and Can Inhibit Colorectal Carcinoma Growth In Vivo.
Association of Coloproctologists of Great Britain and Ireland Annual Meeting, Gateshead, UK.

Apr 2006  Avastin binds pro-angiogenic VEGF165 and anti-angiogenic VEGF165b with similar affinities.
British Microcirculation Society Annual conference, Dundee, UK.

Feb 2006  VEGF165b can inhibit colorectal cancer growth in vivo.
Miami Nature Biotechnology Winter Symposium, Miami, USA.

Oct 2005  Simultaneous VEGFxxx and VEGFxxxb splicing variations occur in colorectal carcinoma.
National Cancer Research Institute Conference. Birmingham, UK.

Tripartite Colorectal Meeting, Dublin, Ireland.

May 2005  Inhibitory VEGF isoform expression in colorectal carcinoma shows an alteration in splicing from VEGF165b to VEGF121b.
European Society of Haematology Angiogenesis Conference, Sitges, Spain.

Jan 2005  Evidence of a switch in splicing of VEGF mRNA from anti-angiogenic (VEGFxxxb) to pro-angiogenic (VEGFxxx) isoforms.
European Winter Oncology Conference, Flims, Switzerland.

Apr 2000  The use of mobile phones in the ITU environment.
SCA TA Annual Conference, Bristol, UK.

Presentations (Local and Regional Meetings)

Aug 2014  Neurotropic Melanomas
Melanoma Institute Australia Annual Research Retreat

Oct 2012  The impact of no longer performing Staging CT scans on stage IIIB/C melanoma patients
Severn Deanery School of Surgery Research and Audit Day, Bristol

Oct 2011  Vascular Endothelial Growth Factor predicts response to Bevacizumab in metastatic colorectal carcinoma in both an animal model and the Phase III trial of FOLFOX4 + Bevacizumab v. FOLFOX4 in patients with previously treated patients with advanced colorectal cancer: A trial co-ordinated by the Eastern Co-operative Oncology Group (ECOG-E3200T2)
Severn Deanery School of Surgery Research and Audit Day, Bristol

Nov 2010  Angiomyxoma of the retroperitoneum – case presentation
SouthWest Regional Sarcoma Meeting, Bristol

Nov 2009  Massive Weight Loss Surgery Regional Audit (primary supervisor)
SouthWest Regional Audit Meeting, Bristol

Nov 2009  Paediatric Haemangioma Regional Audit (primary supervisor)
SouthWest Regional Audit Meeting, Bristol
35. A/Prof Alexander Menzies

Publications

Journal Publications

* shared authorship.

Accepted/Online


5. De Sousa SMC, Sheriff N, Tran CH, Menzies AM, Tsang VHM, Guminski AD, Long GV, Tony KTT. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Accepted Pituitary, 2018.


Published


217


**Speeches/lectures**

**Selected National and International Conference Presentations**


37. **Menzies AM.** Immuno-Oncology: Clinical Status Melanoma. **Invited Speaker.** COSA Annual Scientific Meeting, Hobart, Australia, 2015.

38. **Menzies AM.** Clinical Update: Melanoma. **Invited Speaker.** MOGA Immuno-Oncology forum, Melbourne, Australia, 2015.


42. **Menzies AM.** Key advances and developments in melanoma. **Invited Speaker** MOGA Annual Scientific Meeting, Hobart, Australia, 2015.


36. **A/Prof Catriona McNeil**

**Publications**

Citations since 2013 = 5710; H index since 2013 = 24

Citations total = 6409; H index = 27 (metrics per Google Scholar)


18-72


Speeches/lectures


37. Prof Grant McArthur

Grants

Research Support
Past Research Grant Support – National Health and Medical Research Council

2013-2015  National Health and Medical Research Council (#1002698)  “Exploring the Oncogenic Role of E6AP in B Lymphomagenesis”  $603,675.00  
CIA: A/Prof. Y Haupt  
CIB: Prof. G McArthur

CIA: Prof. G McArthur  
CIB: Dr. S Harrison  
CIC: Prof. R Hannan  
CID: Dr. W Rice  
CIE: Dr. D Drygin.

2011-2015  National Health and Medical Research Council Practitioner Fellowship (#1002654)  “Targeting Cancer by Targeting Gene Mutations”  $514,465.00  
CIA: Prof. G McArthur

2013-2015  National Health and Medical Research Council (#1042986)  “Targeting CDK4 in Melanoma”.  $697,472.00  
CIA: Prof. G McArthur  
CIB: Dr. K Sheppard

2013-2015  National Health and Medical Research Council (#1042980)  “Resistance to BRAF Inhibitors Induced by RTKs”.  $555,111.00  
CIA: Dr. P Ferrao  
CIB: Prof. G McArthur  
CIC: Dr G Bollag  
CID: Dr M Shackleton

Current Research Grant Support - National Health and Medical Research Council
2012-2016:  NHMRC Centre for Research Excellence (#1034301)  “Centre for Translational Pathology Research and Training,”  $2,498,410.00  
CIA: Prof. P Waring  
CIB: Prof. D Bowtell  
CIC: Dr. J Desai  
CID: Prof. S Fox  
CIE: A/Prof P Gibbs  
CIF: A/Prof A Landgren  
CIG: Prof. G McArthur  
CIH: Dr. Z Rudzki  
CII: Dr. B Solomon  
CIJ: A/Prof M Southey

2012-2016:  NHMRC Centre for Research Excellence (#1040978)  “Centre of Research Excellence for Translational Breast Cancer Research: From Discovery to Better Health Outcomes”  $2,500,000.00  
CIA: Prof. G Lindeman  
CIB: Prof G Mann  
CIC: Dr. J Desai  
CID: Prof. S Fox  
CIE: Prof D Liew  
CIF: Prof G McArthur
CIG: Prof. J Symes  
CIH: Prof. R Sutherland  
CII: Prof J Visvader

2014-2018  
National Health and Medical Research Council (#1053792)  
“Oncogenic Signaling and Cancer Therapy”  
$7,595,840.00  
**CIA:** Prof. G McArthur  
CIB: A/Prof. R Hannan  
CIC: Prof. R Hicks  
CID: Prof. R Pearson

2016-2020  
National Health and Medical Research Council (#1106576)  
“Therapeutic Targeting of Oncogenes”  
$851,980.00  
**CIA:** Prof G McArthur

2016-2019  
National Health and Medical Research Council (#1100189)  
“The Combination of CDK4 and MAPK/ERK Pathway Inhibitor Therapy in Melanoma: Defining Melanoma Cell Intrinsic and Immune Mediated Responses.”  
$824,288.00  
**CIA:** Prof G McArthur

Support for travel or accommodation

** This is in line with ASCO Guidelines as a Clinical Trial Investigator**

01/04/2015 - World Congress of Melanoma 2017  
- Accommodation

18/04 - 21/04/2015 – AACR Conference  
- Registration

04/05/2015 - The 3rd Lowy Symposium – Drug Discovery to Personalised Medicine.  
- Flights  
- Accommodation  
- Registration

20-21/05/2015 - Cell Signalling and its Therapeutic Implications Meeting  
- Accommodation

28-29/06/2015 - Roche Global Ad Board, Doubletree Suites by Hilton Times Square  
- Accommodation

28-31/10/2015 - EADO Congress / 8th World Meeting of Interdisciplinary Melanoma Skin Cancer Centers  
- Accommodation  
- Travel

31/10-01/11/2015 - International Melanoma Working Group (IMWG), Marseille, France  
- Accommodation

15-17/11/2015 - Cancer Metabolism Conference, Hotel Kabuki, 1625 Post Street, San Francisco  
- Accommodation

18/11 -21/11/2015 - Society for Melanoma Research, San Francisco  
- Accommodation  
- Flights

24-25/11/2015 - First International Immunotherapy@Brisbane 2015 Conference  
- Flights  
- Accommodation  
- Transfers

01/12/2015 - Australian Merkel Cell Carcinoma Study Group Meeting, Melanoma Institute Australia  
- The Poche Centre, Conference Room Level 1, 40 Rocklands Road Crow’s Nest  
- Flight  
- Transfers
- Accommodation

03/12/2015 - Melanoma Conference, Harry Perkins Institute of Medical Research, Perth
  - Organiser: Carolyn Williams

06-09/12/2015 - CTx Retreat, Lancemore Hill, 1030 Kilmore-Lancefield Rd, Lancefield
  - Accommodation

17/12-21/12/2015 - ESMO Asia Congress
  - Accommodation
  - Flights
  - ESMO Presidential Dinner, Gardens by the Bay in Singapore

10/02/2016 - Professor Charles Swanton (CRUK) Dinner

17/02/2016 - Post SMR Dinner Meeting, Novartis & MSD co-ordinating

24/02 - 26/02/2016 - Eighth Annual MRA Scientific Retreat in Washington, DC.
  - MRA Dinner and Retreat Reception, Casa Luca, 1099 New York Ave, NW
  - Accommodation

09/03/2016 - Albury/Wodonga Day - Melanoma Inservice with Border Oncology
  - The Best Western Hovell, Tree Hotel, Albury/Wodonga
  - Dinner Hotel on Olive, Albury

20/03-22/03/2016 - International Melanoma Working Group (IMWG) Meeting, Zagreb, Croatia
  - Accommodation

11/04-15/04/2016 – Roche Canada Tour
  - Accommodation
  - Flights

27/04 – 01/05/2016 - 3rd International Conferences on Regenerative Medicine
  - Transfers
  - Accommodation
  - Flights

24-25/05/2016 CTx MidYear Pipeline Review
  - Accommodation

29/06-03/07/2016 MSD Global Melanoma Advisory Board Meeting and Post-Chicago Melanoma & Skin Cancer Meeting
  - Accommodation

22/07-23/07/2016 - BMS Immuno-Oncology Medical Education Symposium, Sydney
  - Transfers
  - Accommodation

03/08/2016 - MOGA: Immuno-Oncology Forum
  - Transfers

31/08-03/09/2016 - 12th World Congress on Cancers of the Skin/16th EADO Meeting
  - Flight
  - Accommodation

03-04/09/2016 IMWG Meeting – Vienna
  - Accommodation

08-09/09/2016 - Children’s Cancer Institute Scientific Retreat 2016
  - Flights
  - Accommodation

26-27/10/2016 - New Zealand Society of Oncology Meeting
  - Accommodation

06-09/11/2016 - Society for Melanoma Research, Boston, USA
07-09/12/2016 – Cancer Therapeutics (CRC) Retreat
- Accommodation

16-19/12/2016 ESMO Asia Congress, Singapore
- Accommodation
- Transfers

17/01/2017 - Binimetinib-Encorafenib Advisory Board, Pierre-Fabre
- Transfers

13-15/02/2017 MRA Scientific Retreat
- Accommodation

25/03/2017 - HOTT Symposium, Roche Australia
- Accommodation

27/04/2017 - Mindaroo Foundation / Eliminate Cancer Initiative
- Flights
- Accommodation

06-07/05/2017 - International Melanoma Working Group (IMWG) Athens
- Accommodation

15-17/05/2017 - 2nd Australian Cancer and Metabolism Meeting
- Accommodation

02/06-06/06/2017 – ASCO
- Accommodation

07-08/08/2017 Sydney Catalyst Int Translation Cancer Research Symposium
- Accommodation
- Transfers
- Flights

10-11/08/2017 Childhood Cancer Institute Scientific Retreat 2017
- Flights

27-30/08/2017 - International Pigment Cell Conference (IPCC)
- Flights
- Transfers

05/09/2017 - Inaugural Southern Adelaide Local Health Service/Flinders University Research Week
- Accommodation
- Flight

08-10/09/2017 – ESMO Conference
- Flight
- Registration

18-21/10/2017 - 9th World Congress of Melanoma will join with the Society for Melanoma Research
- Accommodation
- Flight
- Registration

01/12/2017 - European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium (EAPS)
- Flights
- Registration

08-11/02/2018 - Lorne Cancer Conference
- Accommodation
- Registration

22-25/02/2018 - Canadian Melanoma Conference
- Flights
- Accommodation
14/03/2018 - Zero Childhood Cancer Scientific Advisory Committee
- Registration
- Flights
- Accommodation

15/03/2018 - Eradicate Cancer 2018
- Registration
- Accommodation
- Flight

Meals and Beverages

27/01/2015 - Paediatrics Collaboration Symposium at Peter MacCallum Cancer Centre.
- Meal

02/02/2015 - BeiGene Investigator Meeting
- Meal

03/02/2015 - Roche Investigators' Dinner with Kandi Shanmugam at Masani Restaurant 313 Drummond Street, Carlton.
- Meal

05/02/2015 - Melanoma March Launch - Melanoma Institute of Australia Event
- Meal

25/02/2015 – Melanoma Research Alliance (MRA)
- Meal

10/03/2015 - Graeme Clark Oration and Dinner, Melbourne Convention & Exhibition Centre
- Meal

11/03/2015 - WEHI Centenary Afternoon Tea, Tapestry Lounge, WEHI
- Meal

12/03/2015 - Aust Grand Prix Welcome Reception
- Meal

16-19/04/2015 - Tucson Symposium, Ventura
- Meal

26-27/04/2018 - Cancer Therapeutics Strategic Program, Peter MacCallum Cancer Centre
- Meal

31/03/2015 - 2015 Australian Cell Cycle Meeting
- Meal

01/04/2015 - World Congress of Melanoma 2017
- Meal

07/04/2015 – Cancer Therapeutics (CRC) Pipeline & Progress Meeting
- Meal

16/04/2015 – Committee for Melbourne Annual Dinner, Margaret Court Arena, Batman Avenue
- Meal, guest of Peter MacCallum Cancer Centre

18/04 - 21/04/2015 – AACR Conference
- Coffee, Dan Von Hoff, Arts Suite, 200 South Broad Street, Philadelphia
- Meal, CRC for Cancer Therapeutics, Ristorante Panorama, 14N Front Street, Philadelphia

04/05/2015 - The 3rd Lowy Symposium – Drug Discovery to Personalised Medicine.
- Meal

19/05/2015 - Amgen Australia, Melanoma Advisory Board, Melbourne Domestic Airport
- Meal

20-21/05/2015 - Cell Signalling and its Therapeutic Implications Meeting
- Meal

29/05-2/06/2015 – ASCO
- Novartis Dinner, Zed451, 739 North Clark Street, Chicago
- Senhwa Dinner, The Capital Grille, 633 North Saint Clair, Chicago

10/06/2015 - Post ASCO Educational Meeting, Amgen, AstraZeneca, Novartis, Jansen, Astellas, MerckSerono, Eisai, and Sanofi
- Meal

16/06/2015 - BMS Immuno-Oncology (I-O) Melanoma Advisory Board Meeting 2015
- Meal

18/06/2015 – CRC for Cancer Therapeutics Pipeline Dinner
- Meal

28-29/06/2015 - Roche Global Ad Board, DoubleTree Suites by Hilton Times Square
- Meal

05/08/2015 - Peter Mac Cup Breakfast guest of Honeywell, Members Dining Room, MCG.
- Meal

25/08/2015 – Cancure Dinner Meeting, Nobu Restaurant, Riverside at Crown Melbourne Australia
- Meal

26/08/2015 – Peter Mac Dinner for Michelle Haber, at Grossi Florentino - The Grill.
- Meal

04/09/2015 - Novartis Ad Board Meeting – London, Renaissance London Heathrow Hotel, Bath Road, Hounslow TW6 2AQ
- Meal

19/09/2015 - ONJ Ball, guest of University of Melbourne, Grand Hyatt Hotel, Melbourne
- Meal

06/10/2015 - Novartis function: Melanoma Management Matters: Optimizing the management of BRAFV600+ Metastatic Melanoma
- Meal

11-17/10/2015 - The Melanoma Focus Meeting, UK
- Meals

20/10/2015 - MSD Melanoma Advisory Board
- Meal

23/10/2015 – Peter MacCallum Cancer Centre Executive Lunch.
- Meal

26/10/2015 – Dinner Meeting: Prof Alexander Eggermont, guest of Peter MacCallum Cancer Centre
- Meal

31/10-01/11/2015 - International Melanoma Working Group (IMWG), Marseille, France
- Meal

13/11/2015 - Standing Subcommittee on Research, Cancer Council Victoria
- Meal

03/12/2015 - Melanoma Conference, Harry Perkins Institute of Medical Research, Perth
- Meal

06-09/12/2015 – Cancer Therapeutics Retreat, Lancemore Hill, 1030 Kilmore-Lancefield Rd, Lancefield
- Meal

17/12-21/21/2015 - ESMO Asia Congress
- ESMO Presidential Dinner, Gardens by the Bay in Singapore

17/02/2016 - Post SMR Dinner Meeting, sponsored by Novartis
  - Meal

24/02 - 26/02/2016 - Eighth Annual MRA Scientific Retreat in Washington, DC.
  - MRA Dinner and Retreat Reception, Casa Luca, 1099 New York Ave, NW

09/03/2016 - Albury/Wodonga Day - Melanoma In-service with Border Oncology
  - Meal

20/03-22/03/2016 - International Melanoma Working Group (IMWG) Meeting, Zagreb, Croatia
  - Meals

11/04-15/04/2016 – Roche Canada Education Tour
  - Meals

27/04 – 01/05/2016 - 3rd International Conferences on Regenerative Medicine
  - Meal

12/05/2016 - VCCC Cancer Genomics and Personalised Medicine Committee Meeting
  - Meal

24-25/05/2016 – CRC for Cancer Therapeutics Midyear Pipeline Review
  - Meal

25/05/2016 - VCCC Research & Education Lead – Melanoma and Skin Cancers
  - Meal

03/06-07/06-2016 - ASCO
  - Pfizer: Avelumab Combination Advisory Board “Checkpoint Inhibitor Combinations Advisory Board.”
    - Meal
  - Biothera Lunch with Dr. Jose Iglesias & Dr. Grant McArthur
  - Meal
  - Senhwa, Gene and Georgetti, 500 N. Franklin, Chicago
  - President’s reception, Morgan Manufacturing 401 North morgan Street, Chicago, IL

15/06/2016 - Post ASCO Dinner Meeting, sponsored by Sanofi, Amgen, Astellas, AstraZeneca, Merck and Novartis
  - Meal

17/06/2016 Peter Mac Research Division Executive farewell Lunch
  - Meal

29/06-03/07/2016 MSD Global Melanoma Advisory Board Meeting and Post-Chicago Melanoma & Skin Cancer Meeting
  - Meal

22/07-23/07/2016 - BMS Immuno-Oncology medical education symposium
  - Meal

03/08/2016 - MOGA: Immuno-Oncology Forum
  - Meal

21/08/2016 - 16th International Congress of Immunology, Melbourne
  - Meal

26/08/2016 - Melanoma Symposium, Melbourne
  - Meal

03-04/09/2016 IMWG Meeting – Vienna
  - Meals

08-09/09/2016 - Children’s Cancer Institute Scientific Retreat 2016
  - Meals

07-11/10/2016 - ESMO 2016, Copenhagen, Denmark,
  - Presidential Dinner Symposium, Copenhagen Room
- Working dinner meeting: Global Merck-Pfizer Alliance Ad Board

19/10/2016 - Post-ESMO Meeting, AstraZeneca, BMS, Pfizer
  - Meal

26-27/10/2016 - New Zealand Society of Oncology Meeting
  - Meal

29/10/2016 - Australasian Melanoma Conference, Melanoma Institute Australia
  - Meal

31/10/2016 - GSK-Peter Mac Dinner, Punch Lane; 43 Little Bourke St, Melbourne
  - Meal

06-09/11/2016 - Society for Melanoma Research, Boston, USA
  - Breakfast Meeting - SMR Steering Committee
  - Breakfast meeting - Array BioPharma Investigator Update Meeting
  - BMS SMR Dinner

07-09/12/2016 – CRC for Cancer Therapeutics Retreat
  - Meal

16-19/12/2016 ESMO Asia Congress, Singapore
  - Meal

17/01/2017 - Binimetinib-Encorafenib Advisory Board, Pierre-Fabre
  - Meal

13-15/02/2017 Melanoma Research Alliance (MRA) Scientific Retreat
  - Meal

25/03/2017 - HOTT Symposium, Roche
  - Meal

11/05/2017 - Committee for Melbourne Annual Dinner, hosted by Peter MacCallum Cancer Centre
  - Meal

17/01/2017 - Binimetinib-Encorafenib Advisory Board, Pierre-Fabre
  - Meal

13-15/02/2017 – Melanoma Research Alliance (MRA) Scientific Retreat
  - Meal

06-07/05/2017 - International Melanoma Working Group (IMWG) Athens
  - Meal

21-22/05/2017 - Minderoo Foundation Philanthropic Announcement
  - Meal

24/05/2017 - Iverson Health Innovation Research Institute Launch, Swinburne University of Technology
  - Meal

30/05-01/06/2017 - MD Anderson, Texas
  - Meal

08/08/2017 - Parker Institute and University of California San Francisco
  - Meal

16/08/2017 - Club Melbourne Ambassador's Welcome Dinner
  - Meal

19/06-20/06/2017 - CRC for Cancer Therapeutics Midyear Pipeline Review
  - Meal

04/08/2017 – Medical Oncology Group of Australia, Annual Scientific Meeting
  - Meal
07-08/08/2017 Sydney Catalyst Int Translation Cancer Research Symposium
  - Meals
23/08/2017 - Wilson Society Dinner, University of Melbourne
  - Meal
10-11/08/2017 Childhood Cancer Institute Scientific Retreat 2017
  - Meal
23/08/2017 - Wilson Society Dinner, University of Melbourne
  - Meal
27-30/08/2017 - International Pigment Cell Conference (IPCC)
  - Meal
05/09/2017 - Inaugural Southern Adelaide Local Health Service/Flinders University Research Week
  - Meal
17-19/09/2017 – Victorian Comprehensive Cancer Centre Research Conference
  - Meal
26/10/2017 - 2017 Victorian Public Health Care Awards, DHHS
  - Meal
27/10/2017 - 2017 Graeme Clark Orator, welcome dinner, Convergence Science Network
  - Meal
31/10/2017 - 2017 Monash Partners Comprehensive Cancer Consortium Forum
  - Meal
04-05/11/2017 – International Melanoma Working Group (IMWG), Florence, Italy
  - Meal
20/11/2017 - Club Melbourne 2017 End of Year Cocktail Celebration
  - Meal
14/03/2018 - Zero Childhood Cancer Scientific Advisory Committee, Children’s Cancer Institute
  - Meal

Other (e.g. registration fees for conferences, institutional interests, etc – see policy)

25/02/2015 – Melanoma Research Associate (MRA)
  - Registration
18/04 - 21/04/2015 – AACR Conference
  - Registration
04/05/2015 - The 3rd Lowy Symposium – Drug Discovery to Personalised Medicine.
  - Registration
ESMO 25/09 – 30/09/2015
  - Registration
18/11 -21/11/2015 - Society for Melanoma Research, San Francisco
  - Registration
24-25/11/2015 - First International Immunotherapy@Brisbane 2015 Conference
  - Registration
17/12-21/21/2015 - ESMO Asia Congress
  - Registration
03/06-07/06-2016 ASCO
  - Registration
21/08/2016 - 16th International Congress of Immunology, Melbourne
26/08/2016 – Inaugural Locoregional Melanoma 2016, Multidisciplinary Management of Locoregionally Advanced Melanoma – from Surgery to Immunotherapy, Peter MacCallum Cancer Centre, the Victorian Comprehensive Cancer Centre, and the Australian and New Zealand Melanoma Trials Group
- Registration

31/08-03/09/2016 - 12th World Congress on Cancers of the Skin/16th EADO Meeting
- Registration

07-11/10/2016 - ESMO 2016, Copenhagen, Denmark,
- Registration

26-27/10/2016 - New Zealand Society of Oncology Meeting
- Registration

02/06-06/06/2017 – ASCO
- Registration

08-10/09/2017 – ESMO Conference
- Registration

18-21/10/2017 - 9th World Congress of Melanoma will join with the Society for Melanoma Research
- Registration

01/12/2017 - European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium (EAPS)
- Registration

08-11/02/2018 - Lorne Cancer Conference
- Registration

22-25/02/2018 - Canadian Melanoma Conference
- Registration

15/03/2018 - Eradicate Cancer 2018
- Registration

Membership of Scientific Advisory Boards (Current) (unpaid roles)
- Novartis. BRAF (International)
- Roche Vemurafenib and Cobimetinib (International chair, National chair)
- GSK MAGE-A3 (International)
- GSK Dabrafenib & Trametinib (National)
- BMS Immuno-oncology Melanoma (International)
- BMS Immuno-oncology Melanoma (National Chair)
- Merck Immuno-oncology Melanoma (National Chair)
- Provectus Melanoma (National Chair)
- Amgen Melanoma (National Chair)

Membership of Scientific Advisory Boards (Previous) (unpaid roles)
- Schering-Plough, Malignant melanoma (Chair)
- Pfizer, SU011248/sunitinib (International)
- BMS Early Drug Development (International)
- Pfizer, Gastrointestinal stromal tumors (National)
- Novartis, Gastrointestinal stromal tumours (National)

Commercial Management Roles
- Chair Scientific Advisory Board Cooperative Research Centre for Cancer Therapeutics (current)
- Member Portfolio Management Group Cooperative Research Centre for Cancer Therapeutics (previous)

Publications
5 most significant publications (excepts from Prof McArthur’s CV)


**Speeches/lectures**

**CV-CP: Conference Participation**

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2018</td>
</tr>
</tbody>
</table>

**Conference title**: Lorne Cancer Conference

**Presentation summary**: Overcoming Early Adaptation to Inhibition of BRAF in Melanoma

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
</tbody>
</table>

**Conference title**: 2nd Australian Cancer and Metabolism Meeting

**Presentation summary**: "Is Metabolism a valid target for cancer therapeutics?"

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United States</td>
<td>Plenary Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
</tbody>
</table>

**Conference title**: International Pigment Cell Conference (IPCC)

**Presentation summary**: Breakthroughs in Melanoma Research
<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
<tr>
<td>Conference title</td>
<td>The Victorian Comprehensive Cancer Centre Inaugural Research Conference</td>
<td>Presentation summary</td>
<td>Cancer Genome Stability and Mutation</td>
<td></td>
</tr>
<tr>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
<tr>
<td>Conference title</td>
<td>Medical Oncology Group of Australia (MOGA) Mid Year Meeting</td>
<td>Presentation summary</td>
<td>Immuno-Oncology Forum, Insights and Advances: Current Clinical Data Melanoma</td>
<td></td>
</tr>
<tr>
<td>National</td>
<td>Australia</td>
<td>Plenary Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
<tr>
<td>Conference title</td>
<td>European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium (EAPS)</td>
<td>Presentation summary</td>
<td>Overcoming Chaos – Understanding Big Data and Complex Problems</td>
<td></td>
</tr>
<tr>
<td>International</td>
<td>Australia</td>
<td>Conference Committee</td>
<td>No</td>
<td>2017</td>
</tr>
<tr>
<td>Conference title</td>
<td>9th World Congress of Melanoma (WCM) and Society for Melanoma Research (SMR)</td>
<td>Presentation summary</td>
<td>Genetic/Mutational Testing for Skin Cancer in 2017 and Beyond</td>
<td></td>
</tr>
<tr>
<td>National</td>
<td>Australia</td>
<td>Panel Chair</td>
<td>No</td>
<td>2017</td>
</tr>
<tr>
<td>Conference title</td>
<td>Victorian Comprehensive Cancer Centre Leadership Program</td>
<td>Presentation summary</td>
<td>Leadership Program Panel Member and Participant</td>
<td></td>
</tr>
<tr>
<td>International</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
<tr>
<td>Conference title</td>
<td>18th Asia-Pacific Prostate Cancer Conference</td>
<td>Presentation summary</td>
<td>Checkpoint Inhibitors in Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
<tr>
<td>Conference title</td>
<td>Sydney Catalyst International Translational Cancer Research Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer with Poor Outcomes: Lessons from Advanced Melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Spain</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conference title</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Society for Medical Oncology (ESMO) Congress</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanisms of Intrinsic and Resistance to Immune Checkpoint Inhibitors - Lessons from Melanoma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Greece</td>
<td>Panel Member</td>
<td>No</td>
<td>2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conference title</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Melanoma Working Group (IMWG)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma International Collaboration for Adaptive Trials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Italy</td>
<td>Panel Member</td>
<td>No</td>
<td>2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conference title</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Melanoma Working Group (IMWG)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma International Collaboration for Adaptive Trials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United States</td>
<td>Panel Member</td>
<td>No</td>
<td>2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conference title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9th Melanoma Research Association (MRA) Scientific Retreat</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Committee Meeting - Grant Review Committee</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conference title</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Society of Clinical Oncology (ASCO) Annual Scientific Meeting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma and Skin Cancer Discussant</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conference title</th>
</tr>
</thead>
<tbody>
<tr>
<td>15th Annual HOTT Symposium</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimising Treatment for Patients with a BCC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Austria</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2016</td>
</tr>
<tr>
<td>Conference title</td>
<td>Presentation summary</td>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------</td>
<td>-------</td>
<td>---------</td>
<td>------</td>
</tr>
<tr>
<td>16th World Congress on Cancers of the Skin</td>
<td>Presented: “Genetic testing in skin cancer - from specific to abundant” and “Acquired mutations in melanoma, B-raf and beyond”</td>
<td>International</td>
<td>Vatican City State (Holy See)</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>3rd International Conference on the Progress of Regenerative Medicine and its Cultural Impact</td>
<td>Cellular and Technological Breakthroughs in Cancer: Combination Therapies</td>
<td>International</td>
<td>Vatican City State (Holy See)</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>Medical Oncology Group of Australia (MOGA)</td>
<td>Immuno-Oncology Forum: Implementation and Innovation</td>
<td>National</td>
<td>Australia</td>
<td>Conference Convenor</td>
</tr>
<tr>
<td>The Locoregional Melanoma Conference</td>
<td>Accessing Clinical Trials - How do I get onto a Melanoma Clinical Trial</td>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>Retranslate Symposia in Translational Science</td>
<td>Presented: “Sequencing the genome of a cancer to direct therapy”</td>
<td>International</td>
<td>China</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>3rd Beijing International Melanoma Congress</td>
<td>New Therapeutic Candidate Targets</td>
<td>International</td>
<td>Germany</td>
<td>Keynote Speaker</td>
</tr>
<tr>
<td>6th European Post-Chicago Melanoma/Skin Cancer Meeting</td>
<td>Presented: “Mutational testing in melanoma”</td>
<td>International</td>
<td>Germany</td>
<td>Keynote Speaker</td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>------</td>
</tr>
<tr>
<td>International</td>
<td>Denmark</td>
<td>Session Chair</td>
<td>No</td>
<td>2016</td>
</tr>
<tr>
<td>Conference title</td>
<td>European Society for Medical Oncology (ESMO) Congress</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Making the Right Choices for your Melanoma Patients in the Era of Combination Therapies: An Interactive Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Denmark</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2016</td>
</tr>
<tr>
<td>Conference title</td>
<td>European Society for Medical Oncology (ESMO) Congress</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Looking Beyond the Curve in BRAF Mutant Metastatic Melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Croatia</td>
<td>Panel Member</td>
<td>No</td>
<td>2016</td>
</tr>
<tr>
<td>Conference title</td>
<td>International Melanoma Working Group (IMWG)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Melanoma International Collaboration for Adaptive Trials</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>New Zealand</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2016</td>
</tr>
<tr>
<td>Conference title</td>
<td>New Zealand Society of Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>The Future of Targeting BRAF in Melanoma in the Era of Immune Checkpoint Inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Singapore</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2016</td>
</tr>
<tr>
<td>Conference title</td>
<td>European Society for Medical Oncology (ESMO) Asia Congress</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>The Role of Circulating Tumour DNA and Functional Imaging in Monitoring Patients Receiving Treatment for Melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Singapore</td>
<td>Session Chair</td>
<td>No</td>
<td>2016</td>
</tr>
<tr>
<td>Conference title</td>
<td>European Society for Medical Oncology (ESMO) Asia Congress</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Management and Perspectives of Melanoma in Asia Monitoring Response and Resistance in Melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2016</td>
</tr>
<tr>
<td>Conference title</td>
<td>Presentation summary</td>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>---------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>American Society of Clinical Oncology (ASCO) Annual Scientific Meeting</td>
<td>Challenges with Immunotherapy over the next 5 years - Would This Change the Narrative for Treating Cancer? Melanoma (and Skin Cancers)</td>
<td>International</td>
<td>United States</td>
<td>Panel Member</td>
</tr>
<tr>
<td>8th Annual Melanoma Research Alliance (MRA) Scientific Retreat</td>
<td>Committee Meeting - Grant Review Committee</td>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>Society for Melanoma Research (SMR) Annual Congress</td>
<td>Precision Medicine in Melanoma: Advances in Knowledge of Biomarkers and Targeted Therapies</td>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>How to be a Principal Investigator</td>
<td>Presented: “Why do it? How to decide which trial to do”</td>
<td>International</td>
<td>Austria</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>European Society for Medical Oncology (ESMO) Congress</td>
<td>Impact of Baseline Genetic Heterogeneities on Progression-free survival (PFS) in Patients (pts) with Advanced BRAFV600-Mutated Melanoma Treated with Cobimetinib (COBI) + Vemurafenib (VEM) in the Phase 3 coBRIM Study</td>
<td>International</td>
<td>Austria</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>3rd International Conference on UV and Skin Cancer Prevention</td>
<td>The Value of Skin Cancer Prevention: An Oncology Perspective The Interface Between Oncogene Targeting and Immunology in Melanoma</td>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
</tr>
<tr>
<td>Conference title</td>
<td>Presentation summary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kirkbride Melanoma Symposium</td>
<td>Towards Long Term Survival from Inhibiting BRAF through Combination Therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First International Immunotherapy Conference</td>
<td>Training the Immune System to Fight Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>International Melanoma Working Group (IMWG)</td>
<td>Melanoma International Collaboration for Adaptive Trials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11th European Association of Dermato Oncology (EADO) Congress and 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Center</td>
<td>Impact of Baseline (BL) Allelic Frequencies of BRAFV600 Mutation and Coexisting Oncogenic Mutations on Progression-Free Survival (PFS) From the coBRIM Phase 3 Study Evaluating Cobimetinib (COBI) + Vemurafenib (VEM) in Advanced BRAFV600-Mutated Melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World Cutaneous Malignancies Congress (WCMC)</td>
<td>Genetic Testing for Melanoma: BRAF, NRAS, c-KIT and Beyond</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>International Melanoma Working Group (IMWG)</td>
<td>Melanoma International Collaboration for Adaptive Trials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Society Medical Oncology (ESMO) Asia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
<tr>
<td>International</td>
<td>France</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
<tr>
<td>International</td>
<td>France</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
<tr>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
<tr>
<td>International</td>
<td>Poland</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
<tr>
<td>International</td>
<td>Singapore</td>
<td>Conference Committee</td>
<td>No</td>
<td>2015</td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
</tr>
<tr>
<td>-------</td>
<td>---------------</td>
<td>------------</td>
<td>----------------------</td>
<td>------</td>
</tr>
<tr>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
</tbody>
</table>
| **Scope Committee Immunology and Melanoma Track ESMO Asia**

**Conference title**
Tucson Symposium

**Presentation summary**
Cancer Metabolism, an Emerging Therapeutic Target in Oncology

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
</tbody>
</table>
| **Conference title**
American Association for Cancer Research (AACR) Annual Scientific Meeting

**Presentation summary**
Educational Session: Bench to Bedside and Back Again: Biology and Therapy of ALK and BRAF Cancers. Title: BRAF inhibitors: Clinical activity across different cancers, innate and acquired resistance

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
</tbody>
</table>
| **Conference title**
Fred Hutchinson Cancer Research Center

**Presentation summary**
Targeting Networks Regulating Metabolism and Protein Synthesis in Melanoma

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United Kingdom</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2015</td>
</tr>
</tbody>
</table>
| **Conference title**
Melanoma Focus

**Presentation summary**
How to Individualise Treatment in Advanced Melanoma

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Brazil</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
</tr>
</tbody>
</table>
| **Conference title**
International Melanoma Symposium

**Presentation summary**
Melanoma Molecular Classification: When, How To, and Who Should Test for Melanoma Mutation?

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
</tr>
</tbody>
</table>
| **Conference title**
HemOnc Today

**Presentation summary**
BRAF and MEK Inhibition in Melanoma
<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
<th>Conference title</th>
<th>Presentation summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Switzerland</td>
<td>Session Chair</td>
<td>No</td>
<td>2014</td>
<td>Society for Melanoma Research (SMR) Annual Congress</td>
<td>Late Breaking Clinical Data</td>
</tr>
<tr>
<td>International</td>
<td>Germany</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
<td>European Post-Chicago Melanoma Meeting</td>
<td>Resistance to Kinase Inhibitors: Mechanisms - What’s New?</td>
</tr>
<tr>
<td>International</td>
<td>Spain</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
<td>European Society for Medical Oncology (ESMO) Congress</td>
<td>Phase III, Double-blind, Placebo-controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated BRAFV600 Mutation? Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma</td>
</tr>
<tr>
<td>International</td>
<td>Ireland</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
<td>Perspectives in Melanoma</td>
<td>Combination Therapies for Melanoma</td>
</tr>
<tr>
<td>International</td>
<td>Ireland</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
<td>International Melanoma Working Group (IMWG)</td>
<td>Melanoma International Collaboration for Adaptive Trials</td>
</tr>
<tr>
<td>International</td>
<td>Italy</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference title</td>
<td>Presentation summary</td>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------</td>
<td>-------</td>
<td>---------</td>
<td>------</td>
<td>----------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Melanoma Bridge</td>
<td>Novel Combination Therapies for BRAF-Mutant Melanoma</td>
<td>International</td>
<td>Korea, Republic Of</td>
<td>Session Chair</td>
<td>No</td>
<td>2014</td>
</tr>
<tr>
<td>MD Anderson Cancer Center Global Academic Program (GAP)</td>
<td></td>
<td>International</td>
<td>Korea, Republic Of</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
</tr>
<tr>
<td>Global Academic Program (GAP)</td>
<td>Clinical and Molecular Biology of Cutaneous Melanoma Arising in Chronic Sun Damaged Skin in Caucasians</td>
<td>International</td>
<td>Singapore</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
</tr>
<tr>
<td>Royal Australasian College of Surgeons (RACS) Annual Scientific Meeting</td>
<td>Targeted Therapy in Melanoma The Search for Targeted Therapy in Cancer</td>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
</tr>
<tr>
<td>Tucson Symposium</td>
<td>Immune Program Focus Group Presenter</td>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
</tr>
<tr>
<td>American Society of Clinical Oncology (ASCO) Annual Scientific Meeting</td>
<td>Poster Discussant - Melanoma</td>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
</tr>
<tr>
<td>American Association for Cancer Research (AACR) Annual Scientific Meeting</td>
<td>Profiling and Monitoring Cancer Genomics for Diagnostics and Therapy</td>
<td>International</td>
<td>United States</td>
<td>Session Chair</td>
<td>No</td>
<td>2014</td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------------</td>
<td>-----------------</td>
<td>-----------------------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>International</td>
<td>United States</td>
<td>Session Chair</td>
<td>No</td>
<td>2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference title</td>
<td>HemOnc Today</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Metastatic Melanoma: Targeting the Pathway</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>International</td>
<td>Switzerland</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference title</td>
<td>Society for Melanoma Research (SMR) Annual Congress</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Satellite Symposium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference title</td>
<td>Children's Cancer Institute</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Opportunities in Research Translation: BRAF Inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>International</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference title</td>
<td>American Society of Clinical Oncology (ASCO) Annual Scientific Meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Clinical Efficacy and Safety of Lambrolizumab (MK-3475, Anti-PD-1 Monoclonal Antibody) in Patients With Advanced Melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National</td>
<td>Australia</td>
<td>Session Chair</td>
<td>No</td>
<td>2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference title</td>
<td>Medical Oncology Group of Australia (MOGA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Clinical Oncology Research in Australia– Opportunities in Research Translation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National</td>
<td>Australia</td>
<td>Session Chair</td>
<td>No</td>
<td>2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference title</td>
<td>11th Annual Haematology and Oncology Targeted Therapies Symposium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Skin Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National</td>
<td>Australia</td>
<td>Plenary Speaker</td>
<td>No</td>
<td>2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference title</td>
<td>Presentation summary</td>
<td>Scope</td>
<td>Country</td>
<td>Role</td>
<td>Related NHMRC Grants</td>
<td>Year</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>-----------------------------------------------------------</td>
<td>-------</td>
<td>---------</td>
<td>------------</td>
<td>----------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Translational Research Conference</td>
<td>Practical Lessons in Research Translation: BRAF Inhibitors</td>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Australian and New Zealand Head and Neck Society Annual Meeting</td>
<td>New Therapies for Melanoma</td>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>La Trobe University Institute for Molecular Science</td>
<td>Targeting Oncogenes for the Treatment of Cancer - The Challenge of Drug Resistance</td>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Inaugural Sydney Catalyst Cancer Conference</td>
<td>Targeting Oncogenes- Bench to Bedside Success in Translational Research Local Perspective</td>
<td>National</td>
<td>Australia</td>
<td>Plenary Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Haematology and Oncology Targeted Therapies (HOTT)</td>
<td>Future of Targeting the RAF Pathway In Cutaneous Malignancy</td>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Centre for Personalised Cancer Medicine</td>
<td></td>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
</tbody>
</table>
Using Sequencing Data to Inform Clinical Management in Cancer: Successes and Challenges

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
</tbody>
</table>

Conference title
Lorne Cancer Conference

Presentation summary
RNA polymerase I: A Novel Target for the Treatment of Cancer

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Brazil</td>
<td>Keynote Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
</tbody>
</table>

Conference title
The Future of Personalized Therapy in Advanced Melanoma

Presentation summary
The Future of Personalized Therapy in Melanoma

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Czech Republic</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
</tbody>
</table>

Conference title
International Melanoma Working Group (IMWG)

Presentation summary
Melanoma International Collaboration for Adaptive Trials

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Germany</td>
<td>Conference Committee</td>
<td>No</td>
<td>2013</td>
</tr>
</tbody>
</table>

Conference title
World Melanoma Congress

Presentation summary
Melanoma Therapeutics

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Germany</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
</tbody>
</table>

Conference title
World Melanoma Congress

Presentation summary
The Use of Mutational Testing in the Treatment of Metastatic Melanoma
Mechanisms of Inhibition of Metabolism by BRAF Inhibitors in BRAF-mutant Melanoma
Oncology Drug Reimbursement Issues in Australia

<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>Germany</td>
<td>Session Chair</td>
<td>No</td>
<td>2013</td>
</tr>
</tbody>
</table>

Conference title
World Melanoma Congress

Presentation summary
Targeting the BRAF Pathway
<table>
<thead>
<tr>
<th>Scope</th>
<th>Country</th>
<th>Role</th>
<th>Related NHMRC Grants</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>International</td>
<td>United Kingdom</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Conference title</td>
<td>UK Metastatic Melanoma Summit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Novel Opportunities in Combination Therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Netherlands</td>
<td>Speaker selected from abstract</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Conference title</td>
<td>European Cancer Congress / European Society for Medical Oncology (ECC and ESMO) Annual Meeting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Vemurafenib &amp; Cobimetinib in Advanced BRAFV600- Mutated Melanoma (BRIM7): Dose-Escalation &amp; Expansion Results of a Phase IB Study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Singapore</td>
<td>Session Chair</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Conference title</td>
<td>Novartis Regional Melanoma Forum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Singapore</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Conference title</td>
<td>Novartis Regional Melanoma Forum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>The Emerging Melanoma Landscape</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Conference title</td>
<td>Tucson Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Molecular Targets in Melanoma: Novel Strategies for Addressing BRAF Resistance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>United States</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
<tr>
<td>Conference title</td>
<td>International Melanoma Working Group (IMWG)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation summary</td>
<td>Melanoma International Collaboration for Adaptive Trials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scope</td>
<td>Australia</td>
<td>Invited Speaker</td>
<td>No</td>
<td>2013</td>
</tr>
</tbody>
</table>
**Development of related materials, including guidelines, standards, educational materials or fact sheets**


**Other (eg unpaid advisory roles)**

**Other Current Appointments**

- Founding Member International Melanoma Working Group
- Founding Chair Melbourne Melanoma Project
- Member Cancer Trials Australia Melanoma Group
- Member Cancer Council of Victoria Standing Research Committee and Member Standing Research Sub-Committee
- Member Portfolio Management Group of the Cooperative Research Centre for Cancer Therapeutics
- Member Cancer Trials Australia Phase I Trials Group
- Member Victorian Cooperative Oncology Group on Skin Cancer
- Member of the BioGrid Australia Cancer Scientific Advisory Committee
- Honorary Visiting Medical Officer to Oncology, St.Vincent’s Hospital, Fitzroy, Melbourne
- Chair Cancer Council NSW Program Grants Committee
- Member Scientific Advisory Board Children’s Cancer Institute of Australia
- Member Scientific Advisory Board Scott Kirkbride Melanoma Research Centre
- Co-chair Microarray In Node-negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy (MINDACT) Independent Review Committee
- Member Victorian Cancer Agency Consultative Council
- Member Skin Cancer Prevention Framework Steering Committee – Department of Health
- Member Melanoma Research Alliance Grant Review Committee
- AJCC – Melanoma Expert Panel Member
- Board Member Cancer Drugs Alliance
- Vice-President Melanoma World Society
- Member Society for Melanoma Research Steering Committee
- Chair Scientific Advisory Board Cooperative Research Centre for Cancer Therapeutics
- Chair Cancer Genomics and Personalised Medicine Steering Committee Victorian Comprehensive Cancer Centre
- Chair Victorian Comprehensive Cancer Centre Molecular Tumour Board
- Chair of the Scientific Advisory Board for the National Paediatric Personalised Medicine Initiative
- Member of Australian Brain Cancer Mission Strategic Advisory Group. Cancer Australia
- Member of Beat Cancer Project Joint Advisory Group, South Australian Health and Medical Research Institute
Board membership

Membership and Functions

- Committee Member of the Australasian College of Dermatology Expert Advisory Committee (EAC) (Oct 2017 onwards)
- Australian Skin and Skin Cancer (ASSC) Research Centre Co-leader (July 2016 onwards)
- Brisbane Diamantina Health Partners (BDHP) Skin and Skin Cancer Theme Leader (July 2016 onwards)
- Committee Member of the Translational Research Institute (TRI) Education Talent Management Committee (Jan 2016 onwards)
- Fellow of the Australian Academy of Health and Medical Sciences Limited (Oct 2015 onwards)
- Board member of the Queensland Skin & Cancer Foundation (2012 onwards)
- Key Opinion Co-leader of the Technique Working Group, 1 of 5 Working Groups making up the International Skin Imaging Collaboration (ISIC) Melanoma Project (May 2013 onwards)
- Specialist in Dermatology on the Health Expert Standing Panel (HESP) for Department of Health and Ageing, Australian Government (June 2013 until Dec 2016)
- Nominated for Member of the NHMRC Research Translation Faculty (2012-2015) and member of the NHMRC Career Development Fellowship Peer Review Panel (2015)
- International Dermoscopy Society (Past President & Co-founder) – see also www.dermoscopy-ids.org
- International Society of Teledermatology (Past President & Co-founder) – see also www.teledermatology-society.org
- Committee Member of the Australasian College of Dermatology Continuing Professional Development Committee (2010-2015)
- National Societies: Australasian College of Dermatology (Academic Committee, Editorial Committee, E-Health Committee (2017-), Teledermatology Task Force Committee (until 2017), GP Dermoscopy Task Force Committee, Scientific Research Committee, Scientific Meetings Steering Committee & IMG Assessment Committee), Australasian Society for Dermatology Research (Board Member, Director of Membership 2017), Australia and New Zealand Melanoma Trials Group (ANZMTG), Australasian Dermatopathology Society, Australasian Telehealth Society, Australian Medical Council (Assessment Team Member in 2008)

Grants

Fund Raising – Competitive and Philanthropic

<table>
<thead>
<tr>
<th>Year</th>
<th>Grant Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>PA Research Foundation Translational Research Innovation Award, Skin Cancer, 1 year ($100,000)</td>
</tr>
<tr>
<td>2018</td>
<td>NHMRC Project Grant (CIB), 4 years ($1,149,373.20)</td>
</tr>
<tr>
<td>2018</td>
<td>Practitioner Fellowship – MRFF Next Generation Clinical Researchers Program, 5 years, 2018-2022 ($577,188.50)</td>
</tr>
<tr>
<td>2018</td>
<td>Advance Queensland Innovation Partnership (CID), 3 years ($240,000)</td>
</tr>
<tr>
<td>2017</td>
<td>Queensland Genomics Health Alliance (QGHA) Demonstration Project (CIA), 18 months ($600,000)</td>
</tr>
<tr>
<td>2017</td>
<td>Health Outcome Program, Faculty of Medicine, The University of Queensland – 3D QMelanoma - flagship program of the Faculty, Lead Investigator, 3 years of funding for Project Coordinator (~$365,000)</td>
</tr>
<tr>
<td>2017</td>
<td>Cancer Council Queensland (CIF), 2 years ($220,000)</td>
</tr>
<tr>
<td>2016</td>
<td>Brisbane Diamantina Health Partners (BDHP) Skin and Skin Cancer Theme Funding, 1 year ($75,000)</td>
</tr>
<tr>
<td>2016</td>
<td>Australasian College of Dermatologist Scientific Research Fund (CIB), 1 year ($25,000)</td>
</tr>
</tbody>
</table>
2015  Philanthropic Funding for Melanoma Research, Engineering/DRC collaboration, 5 years ($600,000)
2015  NHMRC CRE for the Study of Naevi (CIA), 5 years ($2,496,835)
2015  NHMRC Partnership Grant (CIB), 3 years ($581,319)
2015  Australian Research Council (CID), 3 years ($390,000)
2015  Funding for the Australian Skin and Skin Cancer Research Centre (ASSC), a joint collaborative venture between UQ and QIMR Berghofer to commence July 2016, equal UQ and QIMRB funding, 3 years ($900,000)

Publications

Book

Book Chapters

Conference Abstracts


Referred Journal Articles

2018


2017


Read T, Webber S, Thomas J, Wagels M, Schaider H, Soyer HP, Smithers BM. (2017) Protocol for the TiDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of


2016


2015


**Speeches/lectures**

**Yearly**
- Speaker at the American Academy of Dermatology Annual Meeting
- Speaker and prac demonstrations at the ISCD International Short Course on Dermoscopy, Medical University of Graz, Austria.
- Nov 2017: Speaker, Annual Meeting of Chinese Medical Society, Suzhou, China
- Oct 2017: Congress President, Speaker, 9th World Congress of Melanoma, Brisbane, Australia
- Sept 2017: Speaker, 26th EADV Congress, Geneva, Switzerland
- Aug 2017: Speaker and Session Chair, International Pigment Cell Conference (IPCC), Denver, Colorado, USA
- June 2017: Speaker, Rotorua General Practice Conference and Medical Exhibition, Rotorua, New Zealand
- Nov 2016: Speaker, Joint Meeting of Australasian Wound and Tissue Repair Society & Molecular and Experimental Pathology Society of Australasia meeting, Sydney, Australia.
- Nov 2016: Multiple presentations, 39th Philippine Dermatological Society Convention, Manila, Philippines.
- Oct 2016: Co-Chair Melanoma Prevention session at The Australasian Melanoma Conference, Sydney, Australia.
- Oct 2016: Speaker (via video conference), 6th World Congress of Teledermatology, Royal College of Physicians London, UK.
- Oct 2016: Multiple presentations, 26th European Academy of Dermatology and Venereology Congress (EADV), Vienna, Austria.
- Sept 2016: Chair and multiple presentations, 22nd Regional Conference of Dermatology Asian-Australasian, Singapore.
- June 2016: Multiple presentations, Hong Kong Society of Dermatology and Venereology Annual Scientific Meeting, Hong Kong.
- May 2016: Speaker, Australasian Skin Cancer Congress, Skin Cancer College Australasia, Gold Coast, Australia.
- May 2016: Multiple presentations, The Australasian College of Dermatologists 49th Annual Scientific Meeting, Perth, Australia.
- April 2016: Keynote Lecture (via video conference), Annual Congress AIDNID, Rome, Italy.
- June 2015: Multiple presentations, 23rd World Congress of Dermatology, Vancouver, Canada.
April 2015  Multiple presentations, 4th World Congress of Dermoscopy, Vienna, Austria.

Development of related materials, including guidelines, standards, educational materials or fact sheets


Other (e.g. unpaid advisory roles)

2017  Community Skin Checks, Queensland University of Technology (QUT) (Sept)
Consumer forum (Cancer Council QLD and Melanoma Patients Australia) related to the NHMRC CRE for the Study of Naevi (Oct).

2016  Skin checks for Energex field staff (April).
Consumer forums (Cancer Council QLD and Melanoma Patients Australia) related to the NHMRC CRE for the Study of Naevi (April, Sept).

2015  PA Research Foundation & Triple M Men’s Health Breakfast Skin Checks (May).
Skin cancer presentation to Port of Brisbane staff (May).
Secondary Prevention of Melanoma lunchtime presentation for Ramsay Medical Services, Greenslopes Private Hospital (Nov).
Skin checks for Marine Diesel (Dec).
39. Dr Frank Bruscino-Raiola

Speeches/lectures

**Human bite in Victoria: An injury with dirty consequences**
PSC 2015

**Oct 2013. International TMR (Targeted Muscle Reinnervation) Symposium, AKH Hospital, Vienna, Austria**
Invited speaker: Review of upper limb osseointegration cases with a focus to utilizing TMR - implantable myoelectric electrode systems combined with osseointegration – direct Skeletal attachment system reconstruction and possibility of applying future technologies such as neuroprosthetic control devices using - wireless interface.
Steven Gray; A/Prof M. Leung; P. Slattery; A/Prof E Edwards; F. Bruscino-raiola; R. Branemark; E.J.Anstee

**Oct 2013 FORUM 2013 International Facial and Body Prosthetics Conference**
*The Park Inn Hotel, Southend-on-Sea, Essex ENGLAND*
Invited speaker: The Alfred Experience Upper & Lower Limb Osseointegration
Steven Gray; A/Prof M. Leung; P. Slattery; A/Prof E Edwards; F. Bruscino-raiola; R. Branemark; E.J.Anstee.

**Nov 2013 Osseointegration in Upper & Lower Limb Inaugural Meeting Hunan Society of Plastic Surgeons, Changsha Province, Republic of China**
A/Prof M. Leung; S. Gray; P. Bruscino-raiola; A/Prof E Edwards; E.J.Anstee.

**September 2014 AKH Hospital, Vienna, Austria**
TMR & Direct Nerve reconstructions in Osseointegration Upper Limb Amputees TMR or advanced prosthetic control in transhumeral amputees using osseointegration and bidirectional neuromuscular interfaces- Human-machine gateway for long-term sensory feedback and motor control of artificial limbs.
Steven Gray; A/Prof M. Leung; P. Slattery; A/Prof E Edwards; F. Bruscino-raiola; R. Branemark; E.J.Anstee.

**Contemporary incidence and associations of painful neuroma in a mixed traumatic and non-traumatic cohort of lower-limb amputees**
Dr Anthony PENNA Dr Francesco Bruscino-Raiola , Dr Alex Konstantatos, Dr William Cranwell, Mr Eidho Paul, Ms Dana Boyd.
RACS Annual Scientific Congress 2016

**Lower limb trauma experience : distal lower limb free flap survival in the setting of proximal limb injury**
N.. Yalcin; F. Bruscino-Raiola
RACS Annual Scientific Congress 2016

**Impact of Neck lymphadenectomy on head and neck cutaneous melanoma recurrence and survival: a 10 year retrospective study.**
Flora Poon.
50th Australasian College of Dermatology Scientific Meeting Sydney May 2017
Awarded the best paper prize

**Targeted Muscle re-innervation for the Upper Extremity Client**
David Lee Gow.
*Australian Orthotic and Prosthetic Association Congress 2017, Melbourne. Friday 6th October 2017*

**Osseointegration**
F. Bruscino-Raiola
*Alfred Health Department of Surgery Research Forum. November 2, 2017*

**Abutment Fractures in Transfemoral Osseointegration**
Sreedharan S, Penna, A, Pak, K, Gray, S and Bruscino-Raiola F
*Rehab Medicine Society of ANZ Canberra Sept 2017*

**Brief introduction OI / TMR program – Service development.**
S. Gray, A. Hutchison, D. Lee-Gow, T. Hale & F. Bruscino-Raiola
*Rehab Medicine Society of ANZ Canberra Sept 2017*

**TMR Surgical perspective**
F. Bruscino-Raiola; A. Hutchison; D. Lee-Gow; T. Hale; S. Gray
*Rehab Medicine Society of ANZ Canberra Sept 2017*
TMR Serratus anterior the ideal muscle replacement
F. Bruscino-Raiola; A. Hutchison; D. Lee-Gow; T. Hale; S. Gray
Rehab Medicine Society of ANZ Canberra Sept 2017

MRI and Dynamic Ultrasound Assessment of Transhumeral Osseointegration and Targeted Muscle
Reinnervation:
Rehab Medicine Society of ANZ Canberra Sept 2017

Upper Limb Loss:
T. Hale, S. Gray, A. Hutchison, D. Lee-Gow, T. Barber & F. Bruscino-Raiola.
Rehab Medicine Society of ANZ Canberra Sept 2017

Occupational Therapy following Osseointegration (OI) / Targeted Muscle Reinnervation (TMR):
Rehab Medicine Society of ANZ Canberra Sept 2017

Rehabilitation - Prosthetics:
D. Lee-Gow, T. Hale, A. Hutchison, J. Keeves, S. Gray & F. Bruscino-Raiola
Rehab Medicine Society of ANZ Canberra Sept 2017

Patient reported outcomes post Transfemoral osseointegration:
A. Penna, P. Zotov, S. Gray & F. Bruscino-Raiola
Rehab Medicine Society of ANZ Canberra Sept 2017

Second Tier Nodal Recurrence Rates Following Superficial Groin Dissection For Invasive Melanoma of
the Lower Limb: A Retrospective Study.
J. Wiseman, R. Shayan, H. Li, S. Ferris & F. Bruscino-Raiola (Poster)
Society for Melanoma Research Meeting Boston, USA November 2016

Complications in Transhumeral Osseointegration.
Sreedharan S, Pak K, Gray S and Bruscino-Raiola F
Rehab Medicine Society of ANZ Canberra, September 2017(Poster)

Patient Reported Mobility Outcomes Post Transfemoral Osseointegration
Penna A, Zotov P, Gray S and Bruscino-Raiola F
Rehab Medicine Society of ANZ Canberra, September 2017(Poster)

Transfemoral Osseointegration: Retrospective Assessment of Pain
Penna A, Zotov P, Gray S and Bruscino-Raiola F
Rehab Medicine Society of ANZ Canberra, September 2017(Poster)

Quality of Life After Transfemoral Osseointegration
Penna A, Zotov P, Gray S and Bruscino-Raiola F
Rehab Medicine Society of ANZ Canberra, September 2017(Poster)

Transhumeral Osseointegration: Preliminary Patient Reported Outcomes
Penna A, Zotov P, Gray S and Bruscino-Raiola F
Rehab Medicine Society of ANZ Canberra, September 2017(Poster)

Anatomic Symmetry of Anterolateral Thigh Flap Perforators- A Computed Tomography Angiographic Study
Lu DY, Chan P, Ferris S, Shayan R, Angliss M & Bruscino-Raiola F
Alfred Week Research Poster Display October 2017(Poster)
40. Dr Saxon Smith

Publications

PUBLISHED PEER REVIEW ARTICLES


● Forward E, Chee S-N and Smith SD. A Case of Shiitake Mushroom Dermatitis. Australasian Journal of Dermatology DOI10.1111/ajd.12791 Published Online February 2018

● Forward E, Harris V and Smith SD. A novel case of a brush with discomfort: Allergic contact dermatitis caused by mercaptobenzothiazole in rubber components of toothbrush. Contact Dermatitis DOI:10.1111/cod.12967 Published Online February 2018


● Abbott LM and Smith SD. Smartphone "apps" for skin cancer diagnosis: what are the implications for patients and practitioners?. Australasian Journal of Dermatology DOI: 10.1111/ajd.12758 Published Online January 2018


● Scott A, Harris V, Lee A and Smith SD. Assessing the attitudes to skin cancer and sun protection in medical students in Australia. Journal of the European Academy of Dermatology and Venereology DOI: 10.1111/jdv.14298 Published Online April 2017


PUBLISHED ABSTRACTS


• Tong E, Harris V and Smith SD. “Perils and pearls of purchasing sun protection on the internet”. Australasian Journal of Dermatology 58(supp1):96-97, 2017


• Carter S, Smith SD, Lee A, Farrugia L, Smith G. “Measuring patients’ and caregivers’ beliefs about the necessity for and harmfulness of topical corticosteroids for chronic inflammatory skin conditions”. International Journal of Pharmacy Practice 24:37, 2016


• Harris V, Kapila S, Smith SD, Cooper A, Ryman W. “An audit and review of the operation of Australia’s first and only pubic Moh’s surgery clinic within a tertiary referral centre”. Australasian Journal of Dermatology 57(supp1):10, 2016


OTHER PUBLISHED ARTICLES/OPINION EDITORIALS

● S Smith. “The beauty of gluten free”. The Australian Coeliac Magazine June issue p25, 2018

● S Smith. Hidradenitis Suppurativa Research Review issue 1, April, 2018

● S Smith. Dermatology Research Review issue 44, February, 2018

● S Smith. Melanoma Research Review issue 14, February, 2017


● S Smith. “President’s word: Goodbye (but not ‘dead, buried and cremated’)” The NSW Doctor (The Journal of Australian Medical Association NSW Ltd) May/June 2016 issue p2, 2016


● S Smith. “President’s word: Who is going to control the profession?” The NSW Doctor (The Journal of Australian Medical Association NSW Ltd) November/December 2015 issue p2, 2015


● S Smith. “President’s word: Striving for improvement”. The NSW Doctor (The Journal of Australian Medical Association NSW Ltd) July/August 2015 issue p2, 2015

● S Smith. Editorial: “Medicinal promise of cannabis needs exhaustive testing” Sydney Morning Herald 22nd June 2015


● S Smith. “Coeliac disease and your skin”. The Australian Coeliac Magazine March issue p15-17, 2015


ACCEPTED FOR PUBLICATION
● Dickison P, Roger S, Howard V and Smith SD. Beware what lies beneath - a case of a gigantic cutaneous squamous cell carcinoma. Clinical and Experimental Dermatology Accepted June 2018

● Tong E, Fischer G and Smith SD. Cosmetic vs. Medicine: How Does Your Country Define Sunscreen? Journal of Drugs in Dermatology Accepted June 2018

● Charlton O and Smith SD. Balanitis Xerotica Obliterans; A Review of Diagnosis and Management. International Journal of Dermatology Accepted June 2018

● Dickison P and Smith SD. Facing up to contact dermatitis in a dental chair: Lignocaine allergy. Australasian Journal of Dermatology Accepted April 2018

SUBMITTED FOR PUBLICATION
● Anthony E, Lun K and Smith SD. Field therapy for actinic keratosis of the face: Australian experience with ingenol 0.015% gel. Journal of Drugs in Dermatology

● Curchin D, Harris V, McCormack C and SD Smith. Recent trends in the incidence of cutaneous melanoma insitu from Victoria, Australia. Australasian Journal of Dermatology 2018

ARTICLES IN PREPARATION


Speeches/lectures

CONFERENCE/MEETING PRESENTATIONS/POSTERS/PANELS

● Presentation – Australasian College of Dermatology Annual Scientific Meeting May 2018 Future of Dermatology Symposium: Technology in dermatology – are there any caveats? SD Smith

● **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2018 Contact Dermatitis session: Biting down on the truth. **P Dickison** and SD Smith.

● **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2018 Psoriasis session: A prospective study looking at the diagnosis and management of paediatric psoriasis. **E. Forward, G Fischer** and SD Smith.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Comparison of ixekizumab with ustekinumab in patients with baseline PASI>15 and/or at least 3 previous non-biologic therapies treatment failures: 24-week post-hoc analysis from a randomized trial (IXORA-S; NCT02561806). N Burkhardt, S Wilhelm, E Riedl, K Kelin, C Henneges, SD Smith and S Shumack.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Sunscreen active ingredients: An international comparison of the what and where. E Tong, V Harris, G Fischer and SD Smith

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Dermatologists guide to cultural competency and the GLBTIQ patient. SJ MacDonald and SD Smith.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Hidradenitis suppurativa related arthritis – an update for the dermatologist. G Winkler, K Gebauer and SD Smith

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Food for thought – A case of shiitake mushroom dermatitis. E Forward, S-N Chee and SD Smith


● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Melanoma in situ incidence is now higher than invasive melanoma incidence – Trends from Victoria, Australia, 1985-2015. D Curchin, P Dickison, E Forward, V Harris, C McCormack and SD Smith.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Alopecia areata following treatment with adalimumab. E Forward, S Preston and SD Smith

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Don’t be rash: Considerations to be made when creating eLearning resources. P Dickison, SD Smith and G Fischer.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Take the (Blood) pressure down: Increased cardiovascular risk in psoriasis patients. P Dickison, J Peek, G Swain, V Harris and SD Smith.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Wetsuit penetrations: unique cases of mycobacterium abscessus. P Dickison, V Howard, G O’Kane and SD Smith.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: What lies beneath: Immunosuppression, atypical infection and a massive SCC. P Dickison, S Roger, V Howard and SD Smith.


● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: A hedgehog opportunity: Management of multiple basal cell carcinomas in a patient treated for acne with facial radiation therapy. O Charlton and SD Smith.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: Ultrasound in the diagnosis and staging of hidradenitis suppurativa. O Charlton and SD Smith.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: The use of ultrasound in skin cancer. O Charlton and SD Smith.

● **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2018: The cutaneous endocannabinoid system. K Garbutcheon-Singh and SD Smith.
• **Presentation** – Australian Pharmacy Professional (APP) Conference 5th May 2018: Considering the patient journey – maintaining adherence to biologic patients. SD Smith

• **Presentation** – Modern management of psoriatic arthropathy, psoriasis, and spondyloarthropathies: a combined Dermatology/Rheumatology Registrar Preceptorship 10th March 2018: Psoriasis state of the art diagnosis and management. SD Smith

• **Presentation** – Modern management of psoriatic arthropathy, psoriasis, and spondyloarthropathies: a combined Dermatology/Rheumatology Registrar Preceptorship 10th March 2018: Interesting cases and conundrums. SD Smith


• **Presentation and Poster** – American Academy of Dermatology Annual Meeting Poster Presentation Session 17th February 2018: Cosmetic versus Medical Therapy – A comparison of international sunscreen standards. E Tong, V Harris, G Fischer and SD Smith.

• **Poster** – American Academy of Dermatology Annual Meeting 17th February 2018: Diagnosis and management of paediatric psoriasis: A prospective study. E Forward, SD Smith and G Fischer.

• **Poster** World Congress of Melanoma October 2017: Diverging in situ and invasive melanoma incidences – Trends from Victoria, Australia, 1985-2015. DJ Curchin, V Harris, C McCormack and SD Smith.

• **Poster** World Congress of Melanoma October 2017: Diagnostic melanoma smartphone applications - what are the legal implications for dermatologists, patients and regulators? L Abbott and SD Smith.

• **Presentation** – Directions in Dermatology Clinical Meeting 24th June 2017: American Academy of Dermatology Annual Meeting Highlight. SD Smith.

• **Workshop Panelist** – Directions in Dermatology Clinical Meeting 24th June 2017: Oncology and Dermatology. SD Smith and M Khashaw


• **Presentation** – Australasian College of Dermatologists Annual Scientific Meeting Presentation session May 2017: Surveillance by smartphone: can a patient record a consultation without your consent? L Abbott and SD Smith.

• **Presentation** – Australasian College of Dermatologists Annual Scientific Meeting Presentation session May 2017: SkinDeep: Serious Games and Innovative Technology for Dermatology Education. P Dickison, SD Smith and G Fischer.

• **Presentation** – Australasian College of Dermatologists Annual Scientific Meeting Presentation session May 2017: Scratching the surface: Characteristics of itch in psoriasis. P Dickison, J Peek, G Swain, L Dan, A Lee and SD Smith

• **Presentation** – Australasian College of Dermatologists Annual Scientific Meeting Presentation session May 2017: Itching for Nail Fashion. P Dickison and SD Smith

• **Presentation** – Australasian College of Dermatologists Annual Scientific Meeting Presentation session May 2017: Nickel allergy: A bigger headache for patients with chest pain. V Harris, B Gunalingam and SD Smith

• **Presentation** – Australasian College of Dermatologists Annual Scientific Meeting Presentation session May 2017: Development and validation of Vulval Disease Quality of Life Index (VDQLI). V Harris, SD Smith and G Fischer
• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Assessment of sun-protective attitudes and behaviours of parents and the impact on their children. Harris V, Adamthwaite L, Evans G, Lee A and Smith SD.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Life on the beach: The Knowledge, Behaviours and Attitudes of Australian Surf Lifesavers Towards Sun Protection. J Davey, G Evans, A Lee and SD Smith.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Evaluation of the influence of family and friends, and the Internet on patient perceptions of long-term topical corticosteroid use. L Farrugia, V Harris, A Lee, A Blascyznski, G Fischer and SD Smith.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Management of Cutaneous Adverse Events Associated with Daclizumab Treatment in Multiple Sclerosis Patients. J Shen, V Harris, J Parrett and SD Smith.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: First case report of Ustekinumab and botulinum toxin A injections in a patient. V Harris and SD Smith.


• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Comparison between parent versus clinician assessment of disease severity in childhood atopic dermatitis. J Stone, V Harris, S Dixit, G Fischer and SD Smith.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Case study of patient with hypophysitis, pneumonitis, colitis, vitiligo. V Harris, A Giminski and SD Smith.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Psoriasis patients’ knowledge of comorbidities. P Dickison, G Swain, J Peek, L Dan, A Lee and SD Smith.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Cardiovascular risk in psoriasis patients. P Dickison, J Peek, G Swain, L Dan, A Lee and SD Smith.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Medical Student Perceptions of Dermatology Teaching: A Focus Group Study. P Dickison, SD Smith and G Fischer.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Doctors Perceptions of Dermatology Teaching: A Focus Group Study. P Dickison, SD Smith and G Fischer.

• **Poster** – Australasian College of Dermatologists Annual Scientific Meeting Poster presentation session May 2017: Perils and Pearls of Purchasing Sun Protection on the Internet. E Tong, V Harris and SD Smith.


• **Presentation** – American Academy of Dermatology Annual Meeting Late Breaking Research Cutaneous Oncology session 4th March 2017: Assessment of sun protection attitudes and behaviours of parents and the impact on their children. V Harris, L Adamsthwaite, A Lee and SD Smith.

• **Poster and Presentation** – American Academy of Dermatology Annual Meeting Dermatitis, contact, allergic and irritant poster session 4th March 2017: Don’t brush off contact allergies in cheilitis - Modern toothbrush contact dermatitis. V Harris and SD Smith.

• **Poster and Presentation** – American Academy of Dermatology Annual Meeting Dermatitis, contact, allergic and irritant poster session 4th March 2017: Itching for nail fashion. P Dickison and SD Smith.

• **Poster and Presentation** – American Academy of Dermatology Annual Meeting Non-melanoma skin cancer poster session 4th March 2017: Apathy in a sunburnt country - Understanding the skin cancer and sun protection knowledge and practices of Australian Doctors. P Dickison, A Lee, C McCormack and SD Smith.

• **Poster and Presentation** – American Academy of Dermatology Annual Meeting Clinical dermatology and other cutaneous disorders poster session 3rd March 2017: Development and validation of Vulvar Disease Quality of Life Index (VDQLI). V Harris, SD Smith and G Fischer.

• **Presentation** – Asia Pacific Combined Dermatology Research Conference August 2016. Australian Doctor’s Sun Protection. P Dickison, A Lee, C McCormack, SD Smith.


• **Presentation** Australian Medical Association (NSW) Continuing Professional Education Conference 25th July 2016: Influence of advice from General Practitioners and Pharmacists on patient/parents knowledge of safety and efficacy of topical corticosteroids in paediatric atopic dermatitis. SD Smith.

• **Presentation** – Central Coast General Practitioners Education Meeting: How to manage atopic dermatitis and psoriasis 21st June 2016, SD Smith.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Generation Why – Sun-protective behaviour of Australian medical students. A Scott, A Lee and SD Smith.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: An assessment of Australian General Practitioners’ knowledge about use of topical corticosteroids in atopic dermatitis. SD Smith, A Lee, A Blaszczynski and G Fischer.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Psoriasis patients’ knowledge of comorbidities. P Dickison, J Peek, G Swain, L Dan, A Lee and SD Smith.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: The Smartphone Consult - evolving legal responsibilities & vulnerabilities for Dermatologists in the digital age. L Abbott and SD Smith.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Consumer convenience or community confusion: Technology and lesion directed examination skin cancer programs in pharmacies. L Abbott and SD Smith.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: A clinical experience in the early arthritis for psoriatic patients (EARP) screening tool: Screening for psoriatic arthritis in dermatology clinic. F Shepherd, A Lee, A Cooper and SD Smith.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: An audit and review of the operation of Australia’s first and only public Moh’s surgery clinic within a tertiary referral centre. V Harris, S Kapila, SD Smith and W Ryman.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Paediatric psoriasis is associated with increased waist to height ratio in the absence of obesity: a multi-centre Australian study. A Lee, SD Smith, E Hong, S Garnett and G Fischer.

• **Presentation** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Evaluation of the influence of pharmacists on patient perceptions of long-term topical corticosteroid use in Sydney, Australia. SD Smith, L Farrugia, A Lee, S Carter, A Blaszczynski and G Fischer.

• **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Scratching the surface: Characteristics of itch in psoriasis. P Dickison, G Swain, J Peek, L Dan, A Lee and SD Smith.

• **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2016: The operation of a tertiary referral combined Chronic Lymphocytic Leukaemia / Dermatology clinic. V Harris, S Kapila, C Tang, SD Smith, S Mulligan, S Shumack.
• **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Shooting star sarcoid. P Dickison, A Fischer and SD Smith.

• **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Axillae Milia-en-plaque: An atypical presentation for primary systemic amyloidosis. P Dickison, V Howard and SD Smith.

• **Poster** – Australasian College of Dermatology Annual Scientific Meeting May 2016: Peristomal Intestinal Metaplasia – A case report. J Davey, V Howard and SD Smith

• **Presentation** – Australian Dermatology Nurses’ Association 13th National Conference May 2016: Atopic Dermatitis and Topical Corticosteroids Phobia. SD Smith.

• **Keynote Speaker** New South Wales Medical Students’ Council Leadership in Medicine Symposium 23rd April 2016: Medicine Outside the Hospital. SD Smith

• **Presentation** – American Academy of Dermatology Annual Meeting 5th March 2016 Late Breaking Research Symposium: Is sun safety public health messaging a success or fail in Generation Y? A survey of sun protection behaviours of Australian Medical Students. SD Smith, A Scott and A Lee


• **Symposium Co-Chair** The Raising Expectations in Dermatology Sydney Symposium 13th February 2016. SD Smith and P Penas.

• **Presentation** – 3rd International Conference on UV and Skin Cancer Prevention, Melbourne 9th December 2015: From new research to targeted public health advocacy – Closing the gaps in sun-protection behaviour. SD Smith.

• **Presentation** – 2nd Global Advances and Controversies in Skin Cancer Conference 31st October 2015: Covering the costs of skin cancer – Trends, treatments, and priorities. SD Smith

• **Presentation** – 2nd Global Advances and Controversies in Skin Cancer Conference 31st October 2015 Breakfast session: Optimising Patient Outcomes With Picato Gel – How far can it go?. SD Smith, E Anthony and K Lun

• **Session Chair** The UPDATE Meeting: Understanding Psoriasis, Dermatology and Treatment Evolution 24th October 2015 Session 1.


• **Poster and Presentation** British Association of Dermatologists 95th Annual Meeting 7th July 2015: An assessment and comparison of pharmacists’ and dermatologist’s knowledge about the safety and efficacy of topical corticosteroids in paediatric atopic dermatitis: a source of topical corticosteroid phobia. SD Smith, A Lee, A Blaszczynski and G Fischer.

• **Presentation** General Practitioner Conference and Exhibition (GPCE) Sydney 24th May 2015: Rethinking management of atopic dermatitis – topical corticosteroid phobia. SD Smith.

• **Presentation** Australasian College of Dermatologists Annual Scientific Meeting: Novartis Symposium 18th May 2015: The role of IL-17a antagonist in management of moderate to severe psoriasis. SD Smith.

• **Session Chair, presentation and panellist** Australasian College of Dermatologists Annual Scientific Meeting 18th May 2015: Leo Pharma Breakfast session Field therapy for actinic keratosis SD Smith, K Lun, I Coutts, S Barker.

• **Presentation** Australasian College of Dermatologists Annual Scientific Meeting May 2015: An assessment pharmacists’ knowledge about the safety and efficacy of topical corticosteroids in paediatric atopic dermatitis: before and after education intervention. SD Smith, A Lee, A Blaszczynski and G Fischer.

• **Poster** Australasian College of Dermatologists Annual Scientific Meeting May 2015: An assessment of dermatologist’s attitude to the safety and efficacy of topical corticosteroids in paediatric atopic dermatitis. SD Smith, A Lee, A Blaszczynski and G Fischer.

• **Keynote Speaker** New South Wales Medical Students’ Council Leadership in Medicine Symposium 9th May 2015: Clinical Leadership. **SD Smith**

• **Presentation** Malaysian Society of Dermatology Mid-Term Meeting 25th April 2015: The role and safety of Biologics in the management of moderate to severe psoriasis. **SD Smith**